[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_6842a8c5-a6f3-42ab-802f-d3de037bd8a4":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:6842a8c5-a6f3-42ab-802f-d3de037bd8a4,\"}":752},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":669,"manageAffiliations":686,"indexDatabases":706,"url":746,"thumbnailPath":26,"statistic":747,"gsStatistic":26,"type":175,"analyzePriority":26},"6842a8c5-a6f3-42ab-802f-d3de037bd8a4","2024-04-11T05:33:30.990+00:00","2025-11-21T10:01:51.610+00:00",[],"Breast-Cancer-Research",{"issn":665,"title":667},{"VOID":666},"1465-542X",{"EN":668},"Breast Cancer Research",[670,678],{"id":671,"createTime":672,"updateTime":673,"relativeEntities":674,"label":675,"description":677,"parentId":26,"standard":26,"scholarHubFieldId":26},"740fbbd4-0204-4499-bc5d-be3ba61fc9be","2023-05-29T10:24:05.032+00:00","2023-11-21T05:08:37.653+00:00",[],{"EN":676},"Cancer Research",{},{"id":679,"createTime":680,"updateTime":681,"relativeEntities":682,"label":683,"description":685,"parentId":26,"standard":26,"scholarHubFieldId":26},"d9687dc3-fd83-46ff-aef4-1925044c24eb","2023-05-29T10:24:05.052+00:00","2023-11-21T05:08:37.643+00:00",[],{"EN":684},"Oncology",{},[687,696],{"id":688,"createTime":689,"updateTime":690,"relativeEntities":691,"slug":692,"properties":693,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":52,"url":26,"parentIds":695,"statistic":26},"67883518-0c98-470e-b6b0-160ab49bb03d","2023-05-29T12:06:59.969+00:00","2024-02-19T18:45:45.100+00:00",[],"BMC",{"title":694},{"EN":692},[],{"id":697,"createTime":698,"updateTime":699,"relativeEntities":700,"slug":701,"properties":702,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":116,"url":26,"parentIds":705,"statistic":26},"c5894808-4e99-4047-bbce-594f58821845","2023-05-29T10:24:08.212+00:00","2025-11-21T10:07:05.787+00:00",[],"BioMed-Central-Ltd-",{"title":703},{"EN":704},"BioMed Central Ltd.",[],[707,726],{"id":708,"indexDatabase":709,"url":723,"indexYears":26,"academicFieldIds":724,"indexDatabaseRanking":26},"d3898774-2362-4d0c-a179-139e45fc7e4e",{"id":710,"createTime":711,"updateTime":712,"relativeEntities":713,"label":714,"description":716,"key":719,"publicationTags":720,"standard":26},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":715,"VI":715},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":717,"EN":718},"Cơ sở dữ liệu SCIE","SCIE database","scie",[721,722],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1465-5411",[725],"248e54de-c562-4c06-8a10-d7f8a37c06fe",{"id":727,"indexDatabase":728,"url":740,"indexYears":741,"academicFieldIds":742,"indexDatabaseRanking":745},"0ec58fbd-36bf-4293-8fc0-315136f1717f",{"id":729,"createTime":730,"updateTime":731,"relativeEntities":732,"label":733,"description":735,"key":737,"publicationTags":738,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":734,"VI":734},"Scopus - Elsevier",{"EN":734,"VI":736},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[739],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F28764","1999-2025",[743,744],"ee505398-b96f-423d-82ed-9f73f07d49d4","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","SCOPUS__Q1","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F13058",{"impactFactor":36,"impactFactorByYear":748,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":749,"totalCitation":36,"totalCitationByYear":750,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":751,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},{"meta":753,"data":755},{"total":754},"3560",[756,1212,1643,1984,2360,2578,2942,3242,3633,4121],{"id":757,"createTime":758,"updateTime":759,"relativeEntities":760,"slug":761,"properties":762,"entityType":778,"verifyStatus":25,"verifyTime":759,"verifyNote":779,"syncStatus":28,"languages":780,"translateLanguages":26,"viewCount":36,"primaryUrl":781,"fullTextUrl":26,"authors":782,"publicationType":849,"publisherRelationship":850,"citationCount":878,"citationInfo":879,"publishDate":884,"publishYear":885,"citationAnalyzeStatus":886,"lastCitationAnalyze":887,"indexDatabases":26,"openAccess":26,"references":888,"isForceReanalyzing":1211},"bed3d07e-635d-47f5-a4a6-d331a2a79be9","2024-04-14T04:11:40.664+00:00","2025-01-30T05:37:44.089+00:00",[],"Triple-negative-breast-cancer-molecular-subtyping-and-treatment-progress",{"mag":763,"keywords":765,"pmc":766,"openalex":768,"abstract":770,"title":772,"pm":774,"doi":776},{"VOID":764},"3033869790",{},{"VOID":767},"7285581",{"VOID":769},"W3033869790",{"EN":771},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\u003Cjats:p>Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.\u003C\u002Fjats:p>",{"EN":773},"Triple-negative breast cancer molecular subtyping and treatment progress",{"VOID":775},"32517735",{"VOID":777},"10.1186\u002Fs13058-020-01296-5","PUBLICATION","Auto Verify",[102],"https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13058-020-01296-5",[783,802,816,833],{"id":784,"sortIndex":115,"researcher":26,"roles":785,"affiliations":786,"properties":795},"692ece69-a379-4358-a7a9-ff72a750a641",[],[787],{"id":26,"sortIndex":36,"affiliation":788,"properties":26},{"id":789,"createTime":790,"updateTime":790,"relativeEntities":791,"slug":26,"properties":792,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"258d070f-4592-4ccf-a315-a2f80be3c9a8","2024-01-25T16:23:00.007+00:00",[],{"title":793},{"VI":794},"Department of Stem Cell and Regenerative Medicine, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China",{"openalex":796,"orcid":798,"title":800},{"VOID":797},"A5089396023",{"VOID":799},"https:\u002F\u002Forcid.org\u002F0000-0002-1455-4202",{"EN":801},"Duan Jiang",{"id":803,"sortIndex":59,"researcher":26,"roles":804,"affiliations":805,"properties":811},"5a20a9d9-959c-4858-b394-22ef81914ff2",[],[806],{"id":26,"sortIndex":36,"affiliation":807,"properties":26},{"id":789,"createTime":790,"updateTime":790,"relativeEntities":808,"slug":26,"properties":809,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":810},{"VI":794},{"openalex":812,"title":814},{"VOID":813},"A5053882402",{"EN":815},"Shi Cang Yu",{"id":817,"sortIndex":114,"researcher":26,"roles":818,"affiliations":819,"properties":828},"61b17608-9ea1-48ce-b54a-e174689f7088",[],[820],{"id":26,"sortIndex":36,"affiliation":821,"properties":26},{"id":822,"createTime":823,"updateTime":823,"relativeEntities":824,"slug":26,"properties":825,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"8fa0e08a-5b3b-4093-8646-9f2928f6a1b1","2024-01-25T16:23:00.078+00:00",[],{"title":826},{"VI":827},"Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China",{"openalex":829,"title":831},{"VOID":830},"A5022362832",{"EN":832},"Xiu Wu Bian",{"id":834,"sortIndex":36,"researcher":26,"roles":835,"affiliations":836,"properties":842},"afd0f999-db11-484e-a2e1-b12960512e54",[],[837],{"id":26,"sortIndex":36,"affiliation":838,"properties":26},{"id":789,"createTime":790,"updateTime":790,"relativeEntities":839,"slug":26,"properties":840,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":841},{"VI":794},{"openalex":843,"orcid":845,"title":847},{"VOID":844},"A5010320756",{"VOID":846},"https:\u002F\u002Forcid.org\u002F0000-0001-9596-3325",{"EN":848},"Li Yin","ARTICLE",{"url":26,"publisher":851,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":852,"slug":663,"properties":853,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":856,"manageAffiliations":857,"indexDatabases":858,"url":746,"thumbnailPath":26,"statistic":873,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":854,"title":855},{"VOID":666},{"EN":668},[],[],[859,866],{"id":727,"indexDatabase":860,"url":740,"indexYears":741,"academicFieldIds":865,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":861,"label":862,"description":863,"key":737,"publicationTags":864,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":867,"url":723,"indexYears":26,"academicFieldIds":872,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":868,"label":869,"description":870,"key":719,"publicationTags":871,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":874,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":875,"totalCitation":36,"totalCitationByYear":876,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":877,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},1072,{"total":878,"publishYear":26,"statisticByYear":880},{"2020":135,"2021":881,"2022":882,"2023":883,"2024":633},127,312,477,"2020-12-01",2020,"ERROR_IN_ANALYZE_CITATION","2024-04-14T15:04:56.515+00:00",[889,893,897,901,905,909,913,917,921,924,928,932,935,939,943,947,951,955,959,963,967,971,974,978,982,986,990,994,998,1002,1006,1010,1014,1018,1022,1025,1029,1033,1037,1041,1045,1049,1053,1057,1061,1065,1069,1073,1077,1081,1085,1089,1093,1097,1101,1105,1109,1113,1117,1121,1125,1129,1133,1137,1141,1145,1149,1153,1157,1161,1165,1168,1172,1176,1180,1184,1188,1192,1196,1200,1204,1208],{"id":26,"text":890,"url":26,"identifiers":891},"Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.",{"doi":892},"10.3322\u002Fcaac.21262",{"id":26,"text":894,"url":26,"identifiers":895},"Goldhirsch A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.",{"doi":896},"10.1093\u002Fannonc\u002Fmdt303",{"id":26,"text":898,"url":26,"identifiers":899},"Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\u002FCollege of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.",{"doi":900},"10.1200\u002FJCO.2013.50.9984",{"id":26,"text":902,"url":26,"identifiers":903},"Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.",{"doi":904},"10.1038\u002F35021093",{"id":26,"text":906,"url":26,"identifiers":907},"Prat A, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35.",{"doi":908},"10.1016\u002Fj.breast.2015.07.008",{"id":26,"text":910,"url":26,"identifiers":911},"Morris GJ, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–84.",{"doi":912},"10.1002\u002Fcncr.22836",{"id":26,"text":914,"url":26,"identifiers":915},"Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.",{"doi":916},"10.1158\u002F1078-0432.CCR-06-3045",{"id":26,"text":918,"url":26,"identifiers":919},"Lin NU, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.",{"doi":920},"10.1002\u002Fcncr.23930",{"id":26,"text":922,"url":26,"identifiers":923},"Zhang L, et al. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int. 2015;2015:357485.",{},{"id":26,"text":925,"url":26,"identifiers":926},"Gluz O, et al. Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009;20(12):1913–27.",{"doi":927},"10.1093\u002Fannonc\u002Fmdp492",{"id":26,"text":929,"url":26,"identifiers":930},"Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am. 2018;27(1):141–53.",{"doi":931},"10.1016\u002Fj.soc.2017.08.004",{"id":26,"text":933,"url":26,"identifiers":934},"Collignon J, et al. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016;8:93–107.",{},{"id":26,"text":936,"url":26,"identifiers":937},"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.",{"doi":938},"10.1172\u002FJCI45014",{"id":26,"text":940,"url":26,"identifiers":941},"Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142–50.",{"doi":942},"10.1002\u002Fpath.4280",{"id":26,"text":944,"url":26,"identifiers":945},"Gibson GR, et al. Metaplastic breast cancer: clinical features and outcomes. Am Surg. 2005;71(9):725–30.",{"doi":946},"10.1177\u002F000313480507100906",{"id":26,"text":948,"url":26,"identifiers":949},"Bertucci F, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66(9):4636–44.",{"doi":950},"10.1158\u002F0008-5472.CAN-06-0031",{"id":26,"text":952,"url":26,"identifiers":953},"Hayes MJ, et al. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008;14(13):4038–44.",{"doi":954},"10.1158\u002F1078-0432.CCR-07-4379",{"id":26,"text":956,"url":26,"identifiers":957},"Masuda H, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–40.",{"doi":958},"10.1158\u002F1078-0432.CCR-13-0799",{"id":26,"text":960,"url":26,"identifiers":961},"Burstein MD, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.",{"doi":962},"10.1158\u002F1078-0432.CCR-14-0432",{"id":26,"text":964,"url":26,"identifiers":965},"Hines LM, et al. Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women. J Women’s Health (Larchmt). 2011;20(10):1543–50.",{"doi":966},"10.1089\u002Fjwh.2010.2558",{"id":26,"text":968,"url":26,"identifiers":969},"Ding YC, et al. Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity. Oncotarget. 2019;10(2):198–208.",{"doi":970},"10.18632\u002Foncotarget.26559",{"id":26,"text":972,"url":26,"identifiers":973},"Breast Cancer Facts and Figures 2013–2014. Am Cancer Soc, 2013.",{},{"id":26,"text":975,"url":26,"identifiers":976},"Liu YR, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18(1):33.",{"doi":977},"10.1186\u002Fs13058-016-0690-8",{"id":26,"text":979,"url":26,"identifiers":980},"Weiss RB, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–8.",{"doi":981},"10.1200\u002FJCO.1990.8.7.1263",{"id":26,"text":983,"url":26,"identifiers":984},"Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015;9:3767–77.",{"doi":985},"10.2147\u002FDDDT.S88023",{"id":26,"text":987,"url":26,"identifiers":988},"Bauer JA, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010;16(2):681–90.",{"doi":989},"10.1158\u002F1078-0432.CCR-09-1091",{"id":26,"text":991,"url":26,"identifiers":992},"Juul N, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010;11(4):358–65.",{"doi":993},"10.1016\u002FS1470-2045(10)70018-8",{"id":26,"text":995,"url":26,"identifiers":996},"Edwardson DW, et al. Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines. Curr Drug Metab. 2015;16(6):412–26.",{"doi":997},"10.2174\u002F1389200216888150915112039",{"id":26,"text":999,"url":26,"identifiers":1000},"Trudeau M, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005;6(11):886–98.",{"doi":1001},"10.1016\u002FS1470-2045(05)70424-1",{"id":26,"text":1003,"url":26,"identifiers":1004},"Henderson IC, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–83.",{"doi":1005},"10.1200\u002FJCO.2003.02.063",{"id":26,"text":1007,"url":26,"identifiers":1008},"Levine MN, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada clinical trials group trial MA5. J Clin Oncol. 2005;23(22):5166–70.",{"doi":1009},"10.1200\u002FJCO.2005.09.423",{"id":26,"text":1011,"url":26,"identifiers":1012},"Bonneterre J, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French adjuvant study group 05 randomized trial. J Clin Oncol. 2005;23(12):2686–93.",{"doi":1013},"10.1200\u002FJCO.2005.05.059",{"id":26,"text":1015,"url":26,"identifiers":1016},"(EBCTCG)., E.B.C.T.C.G., Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005. 365(9472): p. 1687–717.",{"doi":1017},"10.1016\u002FS0140-6736(05)66544-0",{"id":26,"text":1019,"url":26,"identifiers":1020},"Nakatsukasa K, et al. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Breast Cancer. 2017;24(1):63–8.",{"doi":1021},"10.1007\u002Fs12282-016-0666-7",{"id":26,"text":1023,"url":26,"identifiers":1024},"Wu CE, et al. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy. Anticancer Res. 2014;34(3):1301–6.",{},{"id":26,"text":1026,"url":26,"identifiers":1027},"Trimmer EE, Essigmann JM. Cisplatin. Essays Biochem. 1999;34:191–211.",{"doi":1028},"10.1042\u002Fbse0340191",{"id":26,"text":1030,"url":26,"identifiers":1031},"Zhang J, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer. 2015;136(1):204–11.",{"doi":1032},"10.1002\u002Fijc.28966",{"id":26,"text":1034,"url":26,"identifiers":1035},"von Minckwitz G, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56.",{"doi":1036},"10.1016\u002FS1470-2045(14)70160-3",{"id":26,"text":1038,"url":26,"identifiers":1039},"Jovanovic B, et al. A randomized phase II Neoadjuvant study of Cisplatin, paclitaxel with or without Everolimus in patients with stage II\u002FIII triple-negative breast Cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res. 2017;23(15):4035–45.",{"doi":1040},"10.1158\u002F1078-0432.CCR-16-3055",{"id":26,"text":1042,"url":26,"identifiers":1043},"Li Q, et al. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. Cancer Biol Ther. 2015;16(12):1746–53.",{"doi":1044},"10.1080\u002F15384047.2015.1095400",{"id":26,"text":1046,"url":26,"identifiers":1047},"Nielsen TO, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.",{"doi":1048},"10.1158\u002F1078-0432.CCR-04-0220",{"id":26,"text":1050,"url":26,"identifiers":1051},"Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71.",{"doi":1052},"10.1038\u002Fmodpathol.3800528",{"id":26,"text":1054,"url":26,"identifiers":1055},"Carey LA, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–23.",{"doi":1056},"10.1200\u002FJCO.2010.34.5579",{"id":26,"text":1058,"url":26,"identifiers":1059},"Cho SY. Identification of ERBB pathway-activated cells in triple-negative breast cancer. Genomics Inform. 2019;17(1):e3.",{"doi":1060},"10.5808\u002FGI.2019.17.1.e3",{"id":26,"text":1062,"url":26,"identifiers":1063},"Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005;52(1):25–33.",{"doi":1064},"10.1016\u002Fj.phrs.2005.02.010",{"id":26,"text":1066,"url":26,"identifiers":1067},"De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84(2):137–46.",{"doi":1068},"10.1016\u002Fj.bcp.2012.03.018",{"id":26,"text":1070,"url":26,"identifiers":1071},"Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.",{"doi":1072},"10.1038\u002Fnature03445",{"id":26,"text":1074,"url":26,"identifiers":1075},"Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.",{"doi":1076},"10.1001\u002Fjama.295.21.2492",{"id":26,"text":1078,"url":26,"identifiers":1079},"Gonzalez-Angulo AM, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9.",{"doi":1080},"10.1158\u002F1078-0432.CCR-10-2560",{"id":26,"text":1082,"url":26,"identifiers":1083},"Gelmon KA, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61.",{"doi":1084},"10.1016\u002FS1470-2045(11)70214-5",{"id":26,"text":1086,"url":26,"identifiers":1087},"Ibrahim YH, et al. PI3K inhibition impairs BRCA1\u002F2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–47.",{"doi":1088},"10.1158\u002F2159-8290.CD-11-0348",{"id":26,"text":1090,"url":26,"identifiers":1091},"Abramson VG, et al. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121(1):8–16.",{"doi":1092},"10.1002\u002Fcncr.28914",{"id":26,"text":1094,"url":26,"identifiers":1095},"Barton VN, et al. Androgen receptor biology in triple negative breast cancer: a case for classification as AR+ or quadruple negative disease. Horm Cancer. 2015;6(5–6):206–13.",{"doi":1096},"10.1007\u002Fs12672-015-0232-3",{"id":26,"text":1098,"url":26,"identifiers":1099},"Farmer P, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660–71.",{"doi":1100},"10.1038\u002Fsj.onc.1208561",{"id":26,"text":1102,"url":26,"identifiers":1103},"Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25(28):3994–4008.",{"doi":1104},"10.1038\u002Fsj.onc.1209415",{"id":26,"text":1106,"url":26,"identifiers":1107},"Gucalp A, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505–12.",{"doi":1108},"10.1158\u002F1078-0432.CCR-12-3327",{"id":26,"text":1110,"url":26,"identifiers":1111},"Traina TA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884–90.",{"doi":1112},"10.1200\u002FJCO.2016.71.3495",{"id":26,"text":1114,"url":26,"identifiers":1115},"Gonzalez-Angulo AM, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15(7):2472–8.",{"doi":1116},"10.1158\u002F1078-0432.CCR-08-1763",{"id":26,"text":1118,"url":26,"identifiers":1119},"Stemke-Hale K, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084–91.",{"doi":1120},"10.1158\u002F0008-5472.CAN-07-6854",{"id":26,"text":1122,"url":26,"identifiers":1123},"Wang Z, et al. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005;336(4):1023–7.",{"doi":1124},"10.1016\u002Fj.bbrc.2005.08.226",{"id":26,"text":1126,"url":26,"identifiers":1127},"Wang Z, et al. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A. 2006;103(24):9063–8.",{"doi":1128},"10.1073\u002Fpnas.0603339103",{"id":26,"text":1130,"url":26,"identifiers":1131},"Zhang XT, et al. A positive feedback loop of ER-alpha36\u002FEGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 2011;30(7):770–80.",{"doi":1132},"10.1038\u002Fonc.2010.458",{"id":26,"text":1134,"url":26,"identifiers":1135},"Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.",{"doi":1136},"10.1002\u002Fj.1460-2075.1992.tb05481.x",{"id":26,"text":1138,"url":26,"identifiers":1139},"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.",{"doi":1140},"10.1038\u002Fnrc3239",{"id":26,"text":1142,"url":26,"identifiers":1143},"Khosravi-Shahi P, Cabezon-Gutierrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2017;14(1):32-9.",{"doi":1144},"10.1111\u002Fajco.12748",{"id":26,"text":1146,"url":26,"identifiers":1147},"Gatalica Z, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomark Prev. 2014;23(12):2965–70.",{"doi":1148},"10.1158\u002F1055-9965.EPI-14-0654",{"id":26,"text":1150,"url":26,"identifiers":1151},"Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med. 2016;14(1):173.",{"doi":1152},"10.1186\u002Fs12967-016-0925-6",{"id":26,"text":1154,"url":26,"identifiers":1155},"Nanda R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7.",{"doi":1156},"10.1200\u002FJCO.2015.64.8931",{"id":26,"text":1158,"url":26,"identifiers":1159},"Atezolizumab Extends Survival for Breast Cancer. Cancer Discov, 2017. 7(6): p. OF10.",{"doi":1160},"10.1158\u002F2159-8290.CD-NB2017-053",{"id":26,"text":1162,"url":26,"identifiers":1163},"Tolba MF, Omar HA. Immunotherapy, an evolving approach for the management of triple negative breast cancer: converting non-responders to responders. Crit Rev Oncol Hematol. 2018;122:202–7.",{"doi":1164},"10.1016\u002Fj.critrevonc.2018.01.005",{"id":26,"text":1166,"url":26,"identifiers":1167},"Giltnane JM, Balko JM. Rationale for targeting the Ras\u002FMAPK pathway in triple-negative breast cancer. Discov Med. 2014;17(95):275–83.",{},{"id":26,"text":1169,"url":26,"identifiers":1170},"Mao H, et al. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 2010;10(7):728–36.",{"doi":1171},"10.2174\u002F156800910793605811",{"id":26,"text":1173,"url":26,"identifiers":1174},"Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.",{"doi":1175},"10.1189\u002Fjlb.1212621",{"id":26,"text":1177,"url":26,"identifiers":1178},"Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.",{"doi":1179},"10.1056\u002FNEJMoa1414428",{"id":26,"text":1181,"url":26,"identifiers":1182},"Hodi FS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68.",{"doi":1183},"10.1016\u002FS1470-2045(16)30366-7",{"id":26,"text":1185,"url":26,"identifiers":1186},"Liu L, et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther. 2018;26(1):45–55.",{"doi":1187},"10.1016\u002Fj.ymthe.2017.10.020",{"id":26,"text":1189,"url":26,"identifiers":1190},"Bernier C, et al. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anti-Cancer Drugs. 2018;29(8):774–85.",{"doi":1191},"10.1097\u002FCAD.0000000000000653",{"id":26,"text":1193,"url":26,"identifiers":1194},"Song DG, et al. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 2016;9(1):56.",{"doi":1195},"10.1186\u002Fs13045-016-0285-y",{"id":26,"text":1197,"url":26,"identifiers":1198},"Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014;74(11):2907–12.",{"doi":1199},"10.1158\u002F0008-5472.CAN-14-0337",{"id":26,"text":1201,"url":26,"identifiers":1202},"Wei J, et al. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Cell Immunol. 2018;331:49–58.",{"doi":1203},"10.1016\u002Fj.cellimm.2018.05.004",{"id":26,"text":1205,"url":26,"identifiers":1206},"Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5(3):169–81.",{"doi":1207},"10.1177\u002F1758834012475152",{"id":26,"text":1209,"url":26,"identifiers":1210},"Santoni M, et al. Triple negative breast cancer: key role of tumor-associated macrophages in regulating the activity of anti-PD-1\u002FPD-L1 agents. Biochim Biophys Acta. 2018;1869(1):78–84.",{},false,{"id":1213,"createTime":1214,"updateTime":1215,"relativeEntities":1216,"slug":1217,"properties":1218,"entityType":778,"verifyStatus":25,"verifyTime":1215,"verifyNote":779,"syncStatus":28,"languages":1233,"translateLanguages":26,"viewCount":36,"primaryUrl":1234,"fullTextUrl":26,"authors":1235,"publicationType":849,"publisherRelationship":1405,"citationCount":1433,"citationInfo":1434,"publishDate":1438,"publishYear":1439,"citationAnalyzeStatus":886,"lastCitationAnalyze":1440,"indexDatabases":26,"openAccess":26,"references":1441,"isForceReanalyzing":1211},"b5f534cc-f498-4607-8858-a0c928d72d11","2024-04-11T19:49:21.548+00:00","2024-12-14T07:05:19.443+00:00",[],"CD44-CD24-breast-cancer-cells-exhibit-enhanced-invasive-properties-an-early-step-necessary-for-metastasis",{"mag":1219,"keywords":1221,"pmc":1222,"openalex":1224,"abstract":1226,"title":1227,"pm":1229,"doi":1231},{"VOID":1220},"2139151018",{},{"VOID":1223},"1779499",{"VOID":1225},"W2139151018",{},{"EN":1228},"CD44+\u002FCD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis",{"VOID":1230},"17062128",{"VOID":1232},"10.1186\u002Fbcr1610",[102],"https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr1610",[1236,1265,1284,1303,1317,1335,1354,1375,1391],{"id":1237,"sortIndex":50,"researcher":26,"roles":1238,"affiliations":1239,"properties":1258},"0f5fc457-0341-4917-9474-b25bb50675bd",[],[1240,1249],{"id":26,"sortIndex":36,"affiliation":1241,"properties":26},{"id":1242,"createTime":1243,"updateTime":1243,"relativeEntities":1244,"slug":1245,"properties":1246,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9a9a2372-9b2d-4f1b-8b58-a34421a694b1","2024-04-11T19:49:21.613+00:00",[],"Walther-Cancer-Institute-Indianapolis-USA",{"title":1247},{"EN":1248},"Walther Cancer Institute, Indianapolis, USA",{"id":26,"sortIndex":36,"affiliation":1250,"properties":26},{"id":1251,"createTime":1252,"updateTime":1252,"relativeEntities":1253,"slug":1254,"properties":1255,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"88f26958-bd94-4914-b9c1-4c9678f2783c","2023-11-24T11:55:09.098+00:00",[],"Walther-Oncology-Center-Indiana-University-School-of-Medicine-Indianapolis-USA",{"title":1256},{"VI":1257},"Walther Oncology Center, Indiana University School of Medicine, Indianapolis, USA",{"openalex":1259,"orcid":1261,"title":1263},{"VOID":1260},"A5077837457",{"VOID":1262},"https:\u002F\u002Forcid.org\u002F0000-0001-8876-0052",{"EN":1264},"Harikrishna Nakshatri",{"id":1266,"sortIndex":36,"researcher":26,"roles":1267,"affiliations":1268,"properties":1279},"75bbd3db-c9fc-443b-8832-016c7f9e76de",[],[1269],{"id":26,"sortIndex":36,"affiliation":1270,"properties":26},{"id":1271,"createTime":1272,"updateTime":1273,"relativeEntities":1274,"slug":1275,"properties":1276,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"48104fa7-d80f-462a-aa05-27625c718fb1","2023-12-05T23:16:03.688+00:00","2024-10-01T01:56:53.164+00:00",[],"Department-of-Surgery-Indiana-University-School-of-Medicine-Indianapolis-USA",{"title":1277},{"VI":1278},"Department of Surgery, Indiana University School of Medicine, Indianapolis, USA",{"openalex":1280,"title":1282},{"VOID":1281},"A5010925671",{"EN":1283},"Carol Sheridan",{"id":1285,"sortIndex":59,"researcher":26,"roles":1286,"affiliations":1287,"properties":1298},"2101de57-f298-4945-ab6c-34e1aafe06c2",[],[1288],{"id":26,"sortIndex":36,"affiliation":1289,"properties":26},{"id":1290,"createTime":1291,"updateTime":1292,"relativeEntities":1293,"slug":1294,"properties":1295,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5ff958ac-3ebd-4725-a621-62b9a75b09b7","2023-12-12T00:06:20.247+00:00","2024-09-23T09:57:27.206+00:00",[],"Department-of-Pathology-Indiana-University-School-of-Medicine-Indianapolis-USA",{"title":1296},{"VI":1297},"Department of Pathology, Indiana University School of Medicine, Indianapolis, USA",{"openalex":1299,"title":1301},{"VOID":1300},"A5077200492",{"EN":1302},"Sanjana Mehrotra",{"id":1304,"sortIndex":135,"researcher":26,"roles":1305,"affiliations":1306,"properties":1312},"1ed8d66d-81ad-4e92-a191-f50de65a229c",[],[1307],{"id":26,"sortIndex":36,"affiliation":1308,"properties":26},{"id":1271,"createTime":1272,"updateTime":1273,"relativeEntities":1309,"slug":1275,"properties":1310,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1311},{"VI":1278},{"openalex":1313,"title":1315},{"VOID":1314},"A5060652372",{"EN":1316},"Robert J. Goulet",{"id":1318,"sortIndex":162,"researcher":26,"roles":1319,"affiliations":1320,"properties":1330},"da8545c5-95cf-42e1-a5db-80dc73c1b6dd",[],[1321],{"id":26,"sortIndex":36,"affiliation":1322,"properties":26},{"id":1323,"createTime":1324,"updateTime":1324,"relativeEntities":1325,"slug":1326,"properties":1327,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"c723b2f0-2c2d-4d49-928a-c37c124b045d","2024-04-11T19:49:21.633+00:00",[],"Orthopedics-Research-Labs-Indiana-University-School-of-Medicine-Indianapolis-USA",{"title":1328},{"EN":1329},"Orthopedics Research Labs, Indiana University School of Medicine, Indianapolis, USA",{"openalex":1331,"title":1333},{"VOID":1332},"A5041978225",{"EN":1334},"Charles H. Turner",{"id":1336,"sortIndex":114,"researcher":26,"roles":1337,"affiliations":1338,"properties":1347},"0ace48e3-df4d-4f2b-bba7-ab6375765521",[],[1339],{"id":26,"sortIndex":36,"affiliation":1340,"properties":26},{"id":1341,"createTime":1342,"updateTime":1342,"relativeEntities":1343,"slug":26,"properties":1344,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"11b1c40d-558f-4a80-a836-87d1ceaed459","2023-12-28T17:21:51.824+00:00",[],{"title":1345},{"VI":1346},"Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, USA",{"openalex":1348,"orcid":1350,"title":1352},{"VOID":1349},"A5004366421",{"VOID":1351},"https:\u002F\u002Forcid.org\u002F0000-0001-6227-729X",{"EN":1353},"Robyn K. Fuchs",{"id":1355,"sortIndex":111,"researcher":26,"roles":1356,"affiliations":1357,"properties":1368},"f3e9cae2-4894-42b3-b6c2-c2407b130490",[],[1358,1363],{"id":26,"sortIndex":36,"affiliation":1359,"properties":26},{"id":1251,"createTime":1252,"updateTime":1252,"relativeEntities":1360,"slug":1254,"properties":1361,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1362},{"VI":1257},{"id":26,"sortIndex":36,"affiliation":1364,"properties":26},{"id":1242,"createTime":1243,"updateTime":1243,"relativeEntities":1365,"slug":1245,"properties":1366,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1367},{"EN":1248},{"openalex":1369,"orcid":1371,"title":1373},{"VOID":1370},"A5016741414",{"VOID":1372},"https:\u002F\u002Forcid.org\u002F0000-0002-6539-8537",{"EN":1374},"Poornima Bhat‐Nakshatri",{"id":1376,"sortIndex":158,"researcher":26,"roles":1377,"affiliations":1378,"properties":1384},"70f326bf-1b69-46f7-b9bc-f4aebc0d70c4",[],[1379],{"id":26,"sortIndex":36,"affiliation":1380,"properties":26},{"id":1290,"createTime":1291,"updateTime":1292,"relativeEntities":1381,"slug":1294,"properties":1382,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1383},{"VI":1297},{"openalex":1385,"orcid":1387,"title":1389},{"VOID":1386},"A5006346528",{"VOID":1388},"https:\u002F\u002Forcid.org\u002F0000-0001-8861-9980",{"EN":1390},"Sunil Badve",{"id":1392,"sortIndex":115,"researcher":26,"roles":1393,"affiliations":1394,"properties":1400},"71e7f4ff-205a-46fd-a4d4-2ad0e5ed80a6",[],[1395],{"id":26,"sortIndex":36,"affiliation":1396,"properties":26},{"id":1271,"createTime":1272,"updateTime":1273,"relativeEntities":1397,"slug":1275,"properties":1398,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1399},{"VI":1278},{"openalex":1401,"title":1403},{"VOID":1402},"A5035456514",{"EN":1404},"Hiroyuki Kishimoto",{"url":26,"publisher":1406,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1407,"slug":663,"properties":1408,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1411,"manageAffiliations":1412,"indexDatabases":1413,"url":746,"thumbnailPath":26,"statistic":1428,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1409,"title":1410},{"VOID":666},{"EN":668},[],[],[1414,1421],{"id":727,"indexDatabase":1415,"url":740,"indexYears":741,"academicFieldIds":1420,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":1416,"label":1417,"description":1418,"key":737,"publicationTags":1419,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":1422,"url":723,"indexYears":26,"academicFieldIds":1427,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":1423,"label":1424,"description":1425,"key":719,"publicationTags":1426,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":1429,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":1430,"totalCitation":36,"totalCitationByYear":1431,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1432,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},895,{"total":1433,"publishYear":26,"statisticByYear":1435},{"2012":245,"2013":43,"2014":1436,"2015":1437,"2016":254,"2017":282,"2018":286,"2019":539,"2020":48,"2021":257,"2022":48,"2023":252,"2024":50},62,85,"2006-10-01",2006,"2024-04-11T23:42:43.417+00:00",[1442,1446,1450,1454,1458,1462,1466,1470,1474,1478,1482,1486,1490,1494,1498,1502,1506,1510,1514,1518,1522,1525,1528,1532,1536,1540,1544,1548,1552,1555,1559,1563,1566,1570,1574,1578,1582,1586,1590,1594,1598,1601,1605,1609,1613,1617,1621,1625,1629,1633,1636,1640],{"id":26,"text":1443,"url":26,"identifiers":1444},"Smalley M, Ashworth A: Stem cells and breast cancer: a field in transit. Nat Rev Cancer. 2003, 3: 832-844. 10.1038\u002Fnrc1212.",{"doi":1445},"10.1038\u002Fnrc1212",{"id":26,"text":1447,"url":26,"identifiers":1448},"Dontu G, El-Ashry D, Wicha MS: Breast cancer, stem\u002Fprogenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004, 15: 193-197. 10.1016\u002Fj.tem.2004.05.011.",{"doi":1449},"10.1016\u002Fj.tem.2004.05.011",{"id":26,"text":1451,"url":26,"identifiers":1452},"Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038\u002F35102167.",{"doi":1453},"10.1038\u002F35102167",{"id":26,"text":1455,"url":26,"identifiers":1456},"Behbod F, Rosen JM: Will cancer stem cells provide new therapeutic targets?. Carcinogenesis. 2005, 26: 703-711. 10.1093\u002Fcarcin\u002Fbgh293.",{"doi":1457},"10.1093\u002Fcarcin\u002Fbgh293",{"id":26,"text":1459,"url":26,"identifiers":1460},"Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5: 275-284. 10.1038\u002Fnrc1590.",{"doi":1461},"10.1038\u002Fnrc1590",{"id":26,"text":1463,"url":26,"identifiers":1464},"Jordan CT, Guzman ML: Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004, 23: 7178-7187. 10.1038\u002Fsj.onc.1207935.",{"doi":1465},"10.1038\u002Fsj.onc.1207935",{"id":26,"text":1467,"url":26,"identifiers":1468},"Singh SK, Clarke ID, Hide T, Dirks PB: Cancer stem cells in nervous system tumors. Oncogene. 2004, 23: 7267-7273. 10.1038\u002Fsj.onc.1207946.",{"doi":1469},"10.1038\u002Fsj.onc.1207946",{"id":26,"text":1471,"url":26,"identifiers":1472},"Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell. 2004, 118: 409-418. 10.1016\u002Fj.cell.2004.08.005.",{"doi":1473},"10.1016\u002Fj.cell.2004.08.005",{"id":26,"text":1475,"url":26,"identifiers":1476},"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073\u002Fpnas.0530291100.",{"doi":1477},"10.1073\u002Fpnas.0530291100",{"id":26,"text":1479,"url":26,"identifiers":1480},"Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\u002Fprogenitor cell properties. Cancer Res. 2005, 65: 5506-5511. 10.1158\u002F0008-5472.CAN-05-0626.",{"doi":1481},"10.1158\u002F0008-5472.CAN-05-0626",{"id":26,"text":1483,"url":26,"identifiers":1484},"Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093\u002Fjnci\u002F89.17.1260.",{"doi":1485},"10.1093\u002Fjnci\u002F89.17.1260",{"id":26,"text":1487,"url":26,"identifiers":1488},"Edwards DR, Murphy G: Cancer. Proteases: invasion and more [news]. Nature. 1998, 394: 527-528. 10.1038\u002F28961.",{"doi":1489},"10.1038\u002F28961",{"id":26,"text":1491,"url":26,"identifiers":1492},"Dumont N, Arteaga CL: Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 2003, 3: 531-536. 10.1016\u002FS1535-6108(03)00135-1.",{"doi":1493},"10.1016\u002FS1535-6108(03)00135-1",{"id":26,"text":1495,"url":26,"identifiers":1496},"Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003, 3: 537-549. 10.1016\u002FS1535-6108(03)00132-6.",{"doi":1497},"10.1016\u002FS1535-6108(03)00132-6",{"id":26,"text":1499,"url":26,"identifiers":1500},"Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005, 115: 44-55. 10.1172\u002FJCI200522320.",{"doi":1501},"10.1172\u002FJCI22320",{"id":26,"text":1503,"url":26,"identifiers":1504},"Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006, 440: 692-696. 10.1038\u002Fnature04524.",{"doi":1505},"10.1038\u002Fnature04524",{"id":26,"text":1507,"url":26,"identifiers":1508},"Bernards R, Weinberg RA: A progression puzzle. Nature. 2002, 418: 823-10.1038\u002F418823a.",{"doi":1509},"10.1038\u002F418823a",{"id":26,"text":1511,"url":26,"identifiers":1512},"van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038\u002F415530a.",{"doi":1513},"10.1038\u002F415530a",{"id":26,"text":1515,"url":26,"identifiers":1516},"Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 2004, 4: 448-456. 10.1038\u002Fnrc1370.",{"doi":1517},"10.1038\u002Fnrc1370",{"id":26,"text":1519,"url":26,"identifiers":1520},"Bhat-Nakshatri P, Newton TR, Goulet R, Nakshatri H: NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. Proc Natl Acad Sci USA. 1998, 95: 6971-6976. 10.1073\u002Fpnas.95.12.6971.",{"doi":1521},"10.1073\u002Fpnas.95.12.6971",{"id":26,"text":1523,"url":26,"identifiers":1524},"Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ: Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 2002, 62: 5571-5579.",{},{"id":26,"text":1526,"url":26,"identifiers":1527},"Graphpad software. [ http:\u002F\u002Fwww.graphpad.com ]",{},{"id":26,"text":1529,"url":26,"identifiers":1530},"Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H: NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003, 278: 21631-21638. 10.1074\u002Fjbc.M300609200.",{"doi":1531},"10.1074\u002Fjbc.M300609200",{"id":26,"text":1533,"url":26,"identifiers":1534},"Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992, 150: 534-544. 10.1002\u002Fjcp.1041500314.",{"doi":1535},"10.1002\u002Fjcp.1041500314",{"id":26,"text":1537,"url":26,"identifiers":1538},"Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, et al: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006, 25: 2273-2284. 10.1038\u002Fsj.onc.1209254.",{"doi":1539},"10.1038\u002Fsj.onc.1209254",{"id":26,"text":1541,"url":26,"identifiers":1542},"Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M: BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 2006, 66: 41-45. 10.1158\u002F0008-5472.CAN-05-2853.",{"doi":1543},"10.1158\u002F0008-5472.CAN-05-2853",{"id":26,"text":1545,"url":26,"identifiers":1546},"Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL: Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer. 2003, 106: 8-16. 10.1002\u002Fijc.11172.",{"doi":1547},"10.1002\u002Fijc.11172",{"id":26,"text":1549,"url":26,"identifiers":1550},"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073\u002Fpnas.191367098.",{"doi":1551},"10.1073\u002Fpnas.191367098",{"id":26,"text":1553,"url":26,"identifiers":1554},"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038\u002F35021093.",{"doi":904},{"id":26,"text":1556,"url":26,"identifiers":1557},"Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature. 2005, 436: 518-524. 10.1038\u002Fnature03799.",{"doi":1558},"10.1038\u002Fnature03799",{"id":26,"text":1560,"url":26,"identifiers":1561},"Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002, 2: 584-593. 10.1038\u002Fnrc867.",{"doi":1562},"10.1038\u002Fnrc867",{"id":26,"text":1564,"url":26,"identifiers":1565},"Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T: Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 2002, 62: 917-923.",{},{"id":26,"text":1567,"url":26,"identifiers":1568},"Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999, 17: 343-359. 10.1023\u002FA:1006326203858.",{"doi":1569},"10.1023\u002FA:1006326203858",{"id":26,"text":1571,"url":26,"identifiers":1572},"Edwards PA: Metastasis: the role of chance in malignancy. Nature. 2002, 419: 559-560. 10.1038\u002F419559b.",{"doi":1573},"10.1038\u002F419559b",{"id":26,"text":1575,"url":26,"identifiers":1576},"Bourguignon LY: CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia. 2001, 6: 287-297. 10.1023\u002FA:1011371523994.",{"doi":1577},"10.1023\u002FA:1011371523994",{"id":26,"text":1579,"url":26,"identifiers":1580},"Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, et al: Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene. 2006, 25: 6079-6091. 10.1038\u002Fsj.onc.1209628.",{"doi":1581},"10.1038\u002Fsj.onc.1209628",{"id":26,"text":1583,"url":26,"identifiers":1584},"Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA: CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res. 2005, 65: 6755-6763. 10.1158\u002F0008-5472.CAN-05-0863.",{"doi":1585},"10.1158\u002F0008-5472.CAN-05-0863",{"id":26,"text":1587,"url":26,"identifiers":1588},"Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP: CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005, 65: 10783-10793. 10.1158\u002F0008-5472.CAN-05-0619.",{"doi":1589},"10.1158\u002F0008-5472.CAN-05-0619",{"id":26,"text":1591,"url":26,"identifiers":1592},"Schabath H, Runz S, Joumaa S, Altevogt P: CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci. 2006, 119: 314-325. 10.1242\u002Fjcs.02741.",{"doi":1593},"10.1242\u002Fjcs.02741",{"id":26,"text":1595,"url":26,"identifiers":1596},"Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, Birembaut P: Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999, 112: 4615-4625.",{"doi":1597},"10.1242\u002Fjcs.112.24.4615",{"id":26,"text":1599,"url":26,"identifiers":1600},"Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW: SPARC\u002Fosteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998, 58: 5529-5536.",{},{"id":26,"text":1602,"url":26,"identifiers":1603},"Price JE: Metastasis from human breast cancer cell lines. Breast Cancer Res Treat. 1996, 39: 93-102. 10.1007\u002FBF01806081.",{"doi":1604},"10.1007\u002FBF01806081",{"id":26,"text":1606,"url":26,"identifiers":1607},"Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M: A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005, 65: 6130-6138. 10.1158\u002F0008-5472.CAN-04-1408.",{"doi":1608},"10.1158\u002F0008-5472.CAN-04-1408",{"id":26,"text":1610,"url":26,"identifiers":1611},"Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H: Prevalence of CD44+\u002FCD24-\u002Flow cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005, 11: 1154-1159.",{"doi":1612},"10.1158\u002F1078-0432.1154.11.3",{"id":26,"text":1614,"url":26,"identifiers":1615},"Cowin P, Rowlands TM, Hatsell SJ: Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005, 17: 499-508. 10.1016\u002Fj.ceb.2005.08.014.",{"doi":1616},"10.1016\u002Fj.ceb.2005.08.014",{"id":26,"text":1618,"url":26,"identifiers":1619},"Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004, 101: 14228-14233. 10.1073\u002Fpnas.0400067101.",{"doi":1620},"10.1073\u002Fpnas.0400067101",{"id":26,"text":1622,"url":26,"identifiers":1623},"Locke M, Heywood M, Fawell S, Mackenzie IC: Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res. 2005, 65: 8944-8950. 10.1158\u002F0008-5472.CAN-05-0931.",{"doi":1624},"10.1158\u002F0008-5472.CAN-05-0931",{"id":26,"text":1626,"url":26,"identifiers":1627},"Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ: CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial\u002Fbasal and non-epithelial cells. Breast Cancer Res. 2006, 8: R7-10.1186\u002Fbcr1371.",{"doi":1628},"10.1186\u002Fbcr1371",{"id":26,"text":1630,"url":26,"identifiers":1631},"Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE: Generation of a functional mammary gland from a single stem cell. Nature. 2006, 439: 84-88. 10.1038\u002Fnature04372.",{"doi":1632},"10.1038\u002Fnature04372",{"id":26,"text":1634,"url":26,"identifiers":1635},"Langlois AJ, Holder WD, Iglehart JD, Nelson-Rees WA, Wells SA, Bolognesi DP: Morphological and biochemical properties of a new human breast cancer cell line. Cancer Res. 1979, 39: 2604-2613.",{},{"id":26,"text":1637,"url":26,"identifiers":1638},"Gaffney EV: A cell line (HBL-100) established from human breast milk. Cell Tissue Res. 1982, 227: 563-568. 10.1007\u002FBF00204786.",{"doi":1639},"10.1007\u002FBF00204786",{"id":26,"text":1641,"url":26,"identifiers":1642},"Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50: 6075-6086.",{},{"id":1644,"createTime":1645,"updateTime":1646,"relativeEntities":1647,"slug":1648,"properties":1649,"entityType":778,"verifyStatus":25,"verifyTime":1646,"verifyNote":779,"syncStatus":28,"languages":1664,"translateLanguages":26,"viewCount":36,"primaryUrl":1665,"fullTextUrl":26,"authors":1666,"publicationType":849,"publisherRelationship":1741,"citationCount":1774,"citationInfo":1775,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1777,"isForceReanalyzing":1211},"6b35071a-0b8e-4015-a17e-6e9df515de8e","2024-04-20T12:18:55.937+00:00","2025-01-24T21:35:27.044+00:00",[],"Infiltrating-lobular-carcinoma-of-the-breast-tumor-characteristics-and-clinical-outcome",{"mag":1650,"keywords":1652,"pmc":1653,"openalex":1655,"abstract":1657,"title":1658,"pm":1660,"doi":1662},{"VOID":1651},"1886195314",{},{"VOID":1654},"400666",{"VOID":1656},"W1886195314",{},{"EN":1659},"Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome",{"VOID":1661},"15084238",{"VOID":1663},"10.1186\u002Fbcr767",[102],"https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr767",[1667,1687,1704,1721],{"id":1668,"sortIndex":59,"researcher":26,"roles":1669,"affiliations":1670,"properties":1682},"1f796578-c635-4497-895c-b22f9bf9fcf8",[],[1671],{"id":1672,"sortIndex":36,"affiliation":1673,"properties":26},"0d1f12c8-a341-46b2-80f4-da962f033fc6",{"id":1674,"createTime":1675,"updateTime":1676,"relativeEntities":1677,"slug":1678,"properties":1679,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"de65a619-1cc0-4d1f-94d0-33c3a9757469","2024-04-20T12:18:55.960+00:00","2024-09-25T07:17:49.157+00:00",[],"Breast-Center-at-Baylor-College-of-Medicine-and-The-Methodist-Hospital-6550-Fannin-St-Suite-701-Houston-Texas-77030-USA",{"title":1680},{"EN":1681},"Breast Center at Baylor College of Medicine and The Methodist Hospital, 6550 Fannin St., Suite 701, Houston, Texas, 77030, USA",{"openalex":1683,"title":1685},{"VOID":1684},"A5035522047",{"EN":1686},"Richard M. Elledge",{"id":1688,"sortIndex":114,"researcher":26,"roles":1689,"affiliations":1690,"properties":1697},"5a8e537a-3cae-4c5d-ae1a-fd05028b95cc",[],[1691],{"id":1692,"sortIndex":36,"affiliation":1693,"properties":26},"8c93c317-a1d3-4bb8-a686-6fda0a6bff0f",{"id":1674,"createTime":1675,"updateTime":1676,"relativeEntities":1694,"slug":1678,"properties":1695,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1696},{"EN":1681},{"openalex":1698,"orcid":1700,"title":1702},{"VOID":1699},"A5004386291",{"VOID":1701},"https:\u002F\u002Forcid.org\u002F0000-0002-2265-6743",{"EN":1703},"Gary M. Clark",{"id":1705,"sortIndex":36,"researcher":26,"roles":1706,"affiliations":1707,"properties":1714},"3b087c45-148c-4909-987a-894c1c3680b3",[],[1708],{"id":1709,"sortIndex":36,"affiliation":1710,"properties":26},"721d0637-cd8d-4ae2-8cbe-70413f42228a",{"id":1674,"createTime":1675,"updateTime":1676,"relativeEntities":1711,"slug":1678,"properties":1712,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1713},{"EN":1681},{"openalex":1715,"orcid":1717,"title":1719},{"VOID":1716},"A5034676299",{"VOID":1718},"https:\u002F\u002Forcid.org\u002F0000-0002-4074-2530",{"EN":1720},"Grazia Arpino",{"id":1722,"sortIndex":115,"researcher":26,"roles":1723,"affiliations":1724,"properties":1736},"b882b433-ce67-4a57-a673-74a366c83f7e",[],[1725],{"id":1726,"sortIndex":36,"affiliation":1727,"properties":26},"2dc7b16d-d6a5-4215-a0b1-c0efc3ff3618",{"id":1728,"createTime":1729,"updateTime":1730,"relativeEntities":1731,"slug":1732,"properties":1733,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6e878906-eeac-4dbf-8809-5efbfd0274d0","2024-04-21T03:26:21.219+00:00","2024-09-21T23:52:20.334+00:00",[],"Paoli-Calmettes-Institute-Marseille-France",{"title":1734},{"EN":1735},"Paoli Calmettes Institute, Marseille, France",{"openalex":1737,"title":1739},{"VOID":1738},"A5047798037",{"EN":1740},"Valérie‐Jeanne Bardou",{"url":26,"publisher":1742,"properties":1769},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1743,"slug":663,"properties":1744,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1747,"manageAffiliations":1748,"indexDatabases":1749,"url":746,"thumbnailPath":26,"statistic":1764,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1745,"title":1746},{"VOID":666},{"EN":668},[],[],[1750,1757],{"id":727,"indexDatabase":1751,"url":740,"indexYears":741,"academicFieldIds":1756,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":1752,"label":1753,"description":1754,"key":737,"publicationTags":1755,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":1758,"url":723,"indexYears":26,"academicFieldIds":1763,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":1759,"label":1760,"description":1761,"key":719,"publicationTags":1762,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":1765,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":1766,"totalCitation":36,"totalCitationByYear":1767,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":1768,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},{"volume":1770,"issue":1772},{"VOID":1771},"6",{"VOID":1773},"3",726,{"total":1774,"publishYear":26,"statisticByYear":1776},{"2012":287,"2013":397,"2014":159,"2015":259,"2016":517,"2017":125,"2018":358,"2019":284,"2020":125,"2021":257,"2022":358,"2023":608,"2024":336},[1778,1782,1785,1789,1793,1797,1801,1805,1809,1813,1817,1820,1824,1828,1832,1836,1840,1844,1848,1852,1856,1859,1862,1866,1870,1874,1878,1882,1885,1889,1893,1897,1901,1904,1908,1911,1915,1919,1923,1927,1930,1933,1937,1940,1944,1948,1951,1955,1959,1963,1967,1971,1975,1977,1981],{"id":26,"text":1779,"url":26,"identifiers":1780},"Martinez V, Azzopardi JG: Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 1979, 3: 467-488.",{"doi":1781},"10.1111\u002Fj.1365-2559.1979.tb03029.x",{"id":26,"text":1783,"url":26,"identifiers":1784},"Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery. 1993, 114: 637-641. discussion 641–632",{},{"id":26,"text":1786,"url":26,"identifiers":1787},"Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE: Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000, 88: 2561-2569. 10.1002\u002F1097-0142(20000601)88:11\u003C2561::AID-CNCR19>3.3.CO;2-O.",{"doi":1788},"10.1002\u002F1097-0142(20000601)88:11\u003C2561::AID-CNCR19>3.0.CO;2-X",{"id":26,"text":1790,"url":26,"identifiers":1791},"Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975, 36: 1-85.",{"doi":1792},"10.1002\u002F1097-0142(197507)36:1\u003C1::AID-CNCR2820360102>3.0.CO;2-4",{"id":26,"text":1794,"url":26,"identifiers":1795},"Krecke KN, Gisvold JJ: Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol. 1993, 161: 957-960.",{"doi":1796},"10.2214\u002Fajr.161.5.8273634",{"id":26,"text":1798,"url":26,"identifiers":1799},"Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, Ku NN, Baekey PA, Cox CE: Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg. 1995, 222: 549-559. discussion 559–561",{"doi":1800},"10.1097\u002F00000658-199522240-00012",{"id":26,"text":1802,"url":26,"identifiers":1803},"Cornford EJ, Wilson AR, Athanassiou E, Galea M, Ellis IO, Elston CW, Blamey RW: Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. Br J Radiol. 1995, 68: 450-453.",{"doi":1804},"10.1259\u002F0007-1285-68-809-450",{"id":26,"text":1806,"url":26,"identifiers":1807},"Helvie MA, Paramagul C, Oberman HA, Adler DD: Invasive lobular carcinoma. Imaging features and clinical detection. Invest Radiol. 1993, 28: 202-207.",{"doi":1808},"10.1097\u002F00004424-199303000-00002",{"id":26,"text":1810,"url":26,"identifiers":1811},"Newstead GM, Baute PB, Toth HK: Invasive lobular and ductal carcinoma: mammographic findings and stage at diagnosis. Radiology. 1992, 184: 623-627.",{"doi":1812},"10.1148\u002Fradiology.184.3.1324506",{"id":26,"text":1814,"url":26,"identifiers":1815},"Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW, Stewart HJ: Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br J Surg. 1983, 70: 513-516.",{"doi":1816},"10.1002\u002Fbjs.1800700902",{"id":26,"text":1818,"url":26,"identifiers":1819},"Lesser ML, Rosen PP, Kinne DW: Multicentricity and bilaterality in invasive breast carcinoma. Surgery. 1982, 91: 234-240.",{},{"id":26,"text":1821,"url":26,"identifiers":1822},"du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW: Invasive lobular carcinomas of the breast – the prognosis of histopathological subtypes. Br J Cancer. 1989, 60: 605-609.",{"doi":1823},"10.1038\u002Fbjc.1989.323",{"id":26,"text":1825,"url":26,"identifiers":1826},"Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA: A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984, 50: 23-30.",{"doi":1827},"10.1038\u002Fbjc.1984.135",{"id":26,"text":1829,"url":26,"identifiers":1830},"Ashikari R, Huvos AG, Urban JA, Robbins GF: Infiltrating lobular carcinoma of the breast. Cancer. 1973, 31: 110-116.",{"doi":1831},"10.1002\u002F1097-0142(197301)31:1\u003C110::AID-CNCR2820310115>3.0.CO;2-V",{"id":26,"text":1833,"url":26,"identifiers":1834},"Mate TP, Carter D, Fischer DB, Hartman PV, McKhann C, Merino M, Prosnitz LR, Weissberg JB: A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer. 1986, 58: 1995-2002.",{"doi":1835},"10.1002\u002F1097-0142(19861101)58:9\u003C1995::AID-CNCR2820580907>3.0.CO;2-1",{"id":26,"text":1837,"url":26,"identifiers":1838},"Davis RP, Nora PF, Kooy RG, Hines JR: Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg. 1979, 114: 485-488.",{"doi":1839},"10.1001\u002Farchsurg.1979.01370280139021",{"id":26,"text":1841,"url":26,"identifiers":1842},"Smith DB, Howell A, Wagstaff J: Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol. 1987, 23: 979-982.",{"doi":1843},"10.1016\u002F0277-5379(87)90344-0",{"id":26,"text":1845,"url":26,"identifiers":1846},"Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P: Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?. Cancer. 1994, 73: 1673-1677.",{"doi":1847},"10.1002\u002F1097-0142(19940315)73:6\u003C1673::AID-CNCR2820730620>3.0.CO;2-B",{"id":26,"text":1849,"url":26,"identifiers":1850},"Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P: Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996, 77: 113-120. 10.1002\u002F(SICI)1097-0142(19960101)77:1\u003C113::AID-CNCR19>3.0.CO;2-8.",{"doi":1851},"10.1002\u002F(SICI)1097-0142(19960101)77:1\u003C113::AID-CNCR19>3.0.CO;2-8",{"id":26,"text":1853,"url":26,"identifiers":1854},"Toikkanen S, Pylkkanen L, Joensuu H: Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997, 76: 1234-1240.",{"doi":1855},"10.1038\u002Fbjc.1997.540",{"id":26,"text":1857,"url":26,"identifiers":1858},"McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res. 1977, 37: 637-639.",{},{"id":26,"text":1860,"url":26,"identifiers":1861},"Powell B, Garola RE, Chamness GC, McGuire WL: Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res. 1979, 39: 1678-1682.",{},{"id":26,"text":1863,"url":26,"identifiers":1864},"Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer. 1988, 61: 420-427.",{"doi":1865},"10.1002\u002F1097-0142(19880201)61:3\u003C420::AID-CNCR2820610303>3.0.CO;2-0",{"id":26,"text":1867,"url":26,"identifiers":1868},"Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, McGuire WL: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer. 1993, 71: 2157-2162.",{"doi":1869},"10.1002\u002F1097-0142(19930315)71:6+\u003C2157::AID-CNCR2820711606>3.0.CO;2-O",{"id":26,"text":1871,"url":26,"identifiers":1872},"Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989, 320: 627-633.",{"doi":1873},"10.1056\u002FNEJM198903093201003",{"id":26,"text":1875,"url":26,"identifiers":1876},"Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 1993, 28: 9-20.",{"doi":1877},"10.1007\u002FBF00666351",{"id":26,"text":1879,"url":26,"identifiers":1880},"Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, Pounds GW, Vendely P, Owens MA, Pandian MR: Correlation of HER-2\u002Fneu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992, 84: 1279-1282.",{"doi":1881},"10.1093\u002Fjnci\u002F84.16.1279",{"id":26,"text":1883,"url":26,"identifiers":1884},"Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992, 13: 3-17. 10.1210\u002Fer.13.1.3.",{},{"id":26,"text":1886,"url":26,"identifiers":1887},"Klijn JG, Berns PM, Bontenbal M, Foekens JA: Growth factors. Clinical implications in breast cancer. Ann N Y Acad Sci. 1993, 698: 85-101.",{"doi":1888},"10.1111\u002Fj.1749-6632.1993.tb17193.x",{"id":26,"text":1890,"url":26,"identifiers":1891},"Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993, 85: 200-206.",{"doi":1892},"10.1093\u002Fjnci\u002F85.3.200",{"id":26,"text":1894,"url":26,"identifiers":1895},"Henson D, Tarone R: A study of lobular carcinoma of the breast based on the Third National Cancer Survey in The United States of America. Tumori. 1979, 65: 133-142.",{"doi":1896},"10.1177\u002F030089167906500201",{"id":26,"text":1898,"url":26,"identifiers":1899},"Newman W: Lobular carcinoma of the female breast. Report of 73 cases. Ann Surg. 1966, 164: 305-314.",{"doi":1900},"10.1097\u002F00000658-196608000-00018",{"id":26,"text":1902,"url":26,"identifiers":1903},"Rosen P: The Pathology of Invasive Breast Carcinoma. 1991, Philadelphia: Lippincott, 2",{},{"id":26,"text":1905,"url":26,"identifiers":1906},"Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000, 92: 550-556. 10.1093\u002Fjnci\u002F92.7.550.",{"doi":1907},"10.1093\u002Fjnci\u002F92.7.550",{"id":26,"text":1909,"url":26,"identifiers":1910},"MacGrogan G, Jollet I, Huet S, Sierankowski G, Picot V, Bonichon F, Coindre JM: Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol. 1997, 10: 769-776.",{},{"id":26,"text":1912,"url":26,"identifiers":1913},"Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol. 1991, 48: 28-33.",{"doi":1914},"10.1002\u002Fjso.2930480106",{"id":26,"text":1916,"url":26,"identifiers":1917},"Harake MD, Maxwell AJ, Sukumar SA: Primary and metastatic lobular carcinoma of the breast. Clin Radiol. 2001, 56: 621-630. 10.1053\u002Fcrad.2001.0766.",{"doi":1918},"10.1053\u002Fcrad.2001.0766",{"id":26,"text":1920,"url":26,"identifiers":1921},"Winston CB, Hadar O, Teitcher JB, Caravelli JF, Sklarin NT, Panicek DM, Liberman L: Metastatic lobular carcinoma of the breast: patterns of spread in the chest, abdomen, and pelvis on CT. AJR Am J Roentgenol. 2000, 175: 795-800.",{"doi":1922},"10.2214\u002Fajr.175.3.1750795",{"id":26,"text":1924,"url":26,"identifiers":1925},"Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM: Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol. 2000, 114: 190-196.",{"doi":1926},"10.1309\u002FCPUX-KWEH-7B26-YE19",{"id":26,"text":1928,"url":26,"identifiers":1929},"Lamovec J, Zidar A: Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991, 115: 507-510.",{},{"id":26,"text":1931,"url":26,"identifiers":1932},"Wheeler JE, Enterline HT: Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu. 1976, 11: 161-188.",{},{"id":26,"text":1934,"url":26,"identifiers":1935},"Fechner RE: Infiltrating lobular carcinoma without lobular carcinoma in situ. Cancer. 1972, 29: 1539-1545.",{"doi":1936},"10.1002\u002F1097-0142(197206)29:6\u003C1539::AID-CNCR2820290618>3.0.CO;2-P",{"id":26,"text":1938,"url":26,"identifiers":1939},"Helin ML, Helle MJ, Helin HJ, Isola JJ: Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. Arch Pathol Lab Med. 1989, 113: 854-857.",{},{"id":26,"text":1941,"url":26,"identifiers":1942},"Poen JC, Tran L, Juillard G, Selch MT, Giuliano A, Silverstein M, Fingerhut A, Lewinsky B, Parker RG: Conservation therapy for invasive lobular carcinoma of the breast. Cancer. 1992, 69: 2789-2795.",{"doi":1943},"10.1002\u002F1097-0142(19920601)69:11\u003C2789::AID-CNCR2820691126>3.0.CO;2-J",{"id":26,"text":1945,"url":26,"identifiers":1946},"Soslow RA, Carlson DL, Horenstein MG, Osborne MP: A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Breast Cancer Res Treat. 2000, 61: 161-170. 10.1023\u002FA:1006479113769.",{"doi":1947},"10.1023\u002FA:1006479113769",{"id":26,"text":1949,"url":26,"identifiers":1950},"Chassevent A, Jourdan ML, Romain S, Descotes F, Colonna M, Martin PM, Bolla M, Spyratos F: S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res. 2001, 7: 909-917.",{},{"id":26,"text":1952,"url":26,"identifiers":1953},"Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M: Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol. 1993, 423: 497-502.",{"doi":1954},"10.1007\u002FBF01606541",{"id":26,"text":1956,"url":26,"identifiers":1957},"Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995, 13: 821-830.",{"doi":1958},"10.1200\u002FJCO.1995.13.4.821",{"id":26,"text":1960,"url":26,"identifiers":1961},"Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: Immunohistochemical detection of HER2\u002Fneu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995, 75: 1320-1326.",{"doi":1962},"10.1002\u002F1097-0142(19950315)75:6\u003C1320::AID-CNCR2820750614>3.0.CO;2-C",{"id":26,"text":1964,"url":26,"identifiers":1965},"Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast. Histopathology. 1982, 6: 149-161.",{"doi":1966},"10.1111\u002Fj.1365-2559.1982.tb02712.x",{"id":26,"text":1968,"url":26,"identifiers":1969},"DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M: Prognosis in infiltrating lobular carcinoma. An analysis of 'classical' and variant tumors. Am J Surg Pathol. 1990, 14: 12-23.",{"doi":1970},"10.1097\u002F00000478-199001000-00002",{"id":26,"text":1972,"url":26,"identifiers":1973},"Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992, 84: 1875-1887. 10.1093\u002Fjnci\u002F84.24.1875.",{"doi":1974},"10.1093\u002Fjnci\u002F84.24.1875",{"id":26,"text":1790,"url":26,"identifiers":1976},{"doi":1792},{"id":26,"text":1978,"url":26,"identifiers":1979},"Horn PL, Thompson WD: Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol. 1988, 128: 309-323.",{"doi":1980},"10.1093\u002Foxfordjournals.aje.a114971",{"id":26,"text":1982,"url":26,"identifiers":1983},"Frost AR, Terahata S, Yeh IT, Siegel RS, Overmoyer B, Silverberg SG: An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod Pathol. 1995, 8: 830-836.",{},{"id":1985,"createTime":1986,"updateTime":1987,"relativeEntities":1988,"slug":1989,"properties":1990,"entityType":778,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":2005,"translateLanguages":26,"viewCount":36,"primaryUrl":2006,"fullTextUrl":26,"authors":2007,"publicationType":849,"publisherRelationship":2097,"citationCount":2125,"citationInfo":2126,"publishDate":2130,"publishYear":2131,"citationAnalyzeStatus":886,"lastCitationAnalyze":1987,"indexDatabases":26,"openAccess":26,"references":2132,"isForceReanalyzing":1211},"247131c9-f713-4c29-bd44-a1820b07d4fe","2024-04-13T17:56:22.775+00:00","2024-04-14T04:03:03.720+00:00",[],"Tumor-associated-stromal-cells-as-key-contributors-to-the-tumor-microenvironment",{"mag":1991,"keywords":1993,"pmc":1994,"openalex":1996,"abstract":1998,"title":1999,"pm":2001,"doi":2003},{"VOID":1992},"2510046850",{},{"VOID":1995},"4982339",{"VOID":1997},"W2510046850",{},{"EN":2000},"Tumor-associated stromal cells as key contributors to the tumor microenvironment",{"VOID":2002},"27515302",{"VOID":2004},"10.1186\u002Fs13058-016-0740-2",[102],"https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13058-016-0740-2",[2008,2028,2048,2069,2083],{"id":2009,"sortIndex":114,"researcher":26,"roles":2010,"affiliations":2011,"properties":2021},"bf04bcd6-ca38-46fc-bea8-685c1a6a6477",[],[2012],{"id":26,"sortIndex":36,"affiliation":2013,"properties":26},{"id":2014,"createTime":2015,"updateTime":2015,"relativeEntities":2016,"slug":2017,"properties":2018,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"30504dfc-99e9-45b0-9b74-eceec3342927","2024-04-13T17:56:22.811+00:00",[],"Department-of-Regenerative-Medicine-Wake-Forest-University-Winston-Salem-NC-27157-USA",{"title":2019},{"EN":2020},"Department of Regenerative Medicine, Wake Forest University, Winston-Salem, NC, 27157, USA",{"openalex":2022,"orcid":2024,"title":2026},{"VOID":2023},"A5059485565",{"VOID":2025},"https:\u002F\u002Forcid.org\u002F0000-0002-3422-5959",{"EN":2027},"Kristina Stumpf",{"id":2029,"sortIndex":36,"researcher":26,"roles":2030,"affiliations":2031,"properties":2041},"840ee0dd-2275-42cc-86a2-ca2861b7bda8",[],[2032],{"id":26,"sortIndex":36,"affiliation":2033,"properties":26},{"id":2034,"createTime":2035,"updateTime":2035,"relativeEntities":2036,"slug":2037,"properties":2038,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4d6664f4-f8d1-4074-b89a-38c43bb168ca","2024-04-13T17:56:22.784+00:00",[],"Department-of-Cancer-Biology-Wake-Forest-Comprehensive-Cancer-Center-Winston-Salem-NC-27157-USA",{"title":2039},{"EN":2040},"Department of Cancer Biology, Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, 27157, USA",{"openalex":2042,"orcid":2044,"title":2046},{"VOID":2043},"A5061756900",{"VOID":2045},"https:\u002F\u002Forcid.org\u002F0000-0002-6519-9300",{"EN":2047},"Karen M. Bussard",{"id":2049,"sortIndex":59,"researcher":26,"roles":2050,"affiliations":2051,"properties":2062},"b9562302-1507-474e-82d2-d53126bd92d4",[],[2052],{"id":26,"sortIndex":36,"affiliation":2053,"properties":26},{"id":2054,"createTime":2055,"updateTime":2056,"relativeEntities":2057,"slug":2058,"properties":2059,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3aa70e93-196b-4ffc-a823-e3a83605e49d","2024-01-12T18:06:15.528+00:00","2024-10-09T01:41:55.282+00:00",[],"Department-of-Neuro-Oncology-The-University-of-Texas-MD-Anderson-Cancer-Center-Houston-TX-77030-USA",{"title":2060},{"VI":2061},"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA",{"openalex":2063,"orcid":2065,"title":2067},{"VOID":2064},"A5071050572",{"VOID":2066},"https:\u002F\u002Forcid.org\u002F0000-0002-1259-2133",{"EN":2068},"Candelaria Gomez‐Manzano",{"id":2070,"sortIndex":111,"researcher":26,"roles":2071,"affiliations":2072,"properties":2078},"83e04d19-b4e2-408c-90c5-d369c0f1e54f",[],[2073],{"id":26,"sortIndex":36,"affiliation":2074,"properties":26},{"id":2014,"createTime":2015,"updateTime":2015,"relativeEntities":2075,"slug":2017,"properties":2076,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2077},{"EN":2020},{"openalex":2079,"title":2081},{"VOID":2080},"A5090800488",{"EN":2082},"Frank C. Marini",{"id":2084,"sortIndex":115,"researcher":26,"roles":2085,"affiliations":2086,"properties":2092},"3bf67c8b-91ce-4d3a-a871-49af83fd6f00",[],[2087],{"id":26,"sortIndex":36,"affiliation":2088,"properties":26},{"id":2014,"createTime":2015,"updateTime":2015,"relativeEntities":2089,"slug":2017,"properties":2090,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2091},{"EN":2020},{"openalex":2093,"title":2095},{"VOID":2094},"A5028398735",{"EN":2096},"Lysette Mutkus",{"url":26,"publisher":2098,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2099,"slug":663,"properties":2100,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2103,"manageAffiliations":2104,"indexDatabases":2105,"url":746,"thumbnailPath":26,"statistic":2120,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2101,"title":2102},{"VOID":666},{"EN":668},[],[],[2106,2113],{"id":727,"indexDatabase":2107,"url":740,"indexYears":741,"academicFieldIds":2112,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":2108,"label":2109,"description":2110,"key":737,"publicationTags":2111,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":2114,"url":723,"indexYears":26,"academicFieldIds":2119,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":2115,"label":2116,"description":2117,"key":719,"publicationTags":2118,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":2121,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":2122,"totalCitation":36,"totalCitationByYear":2123,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2124,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},548,{"total":2125,"publishYear":26,"statisticByYear":2127},{"2016":114,"2017":252,"2018":569,"2019":534,"2020":1437,"2021":2128,"2022":2129,"2023":357,"2024":116},100,102,"2016-12-01",2016,[2133,2137,2141,2145,2149,2153,2157,2161,2165,2169,2173,2177,2181,2185,2189,2193,2196,2200,2203,2207,2211,2215,2219,2223,2227,2231,2235,2239,2243,2247,2251,2255,2259,2262,2266,2270,2274,2277,2281,2285,2289,2293,2297,2301,2304,2308,2312,2316,2320,2324,2328,2332,2336,2340,2344,2348,2352,2356],{"id":26,"text":2134,"url":26,"identifiers":2135},"Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M, Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One. 2012;7:e30563.",{"doi":2136},"10.1371\u002Fjournal.pone.0030563",{"id":26,"text":2138,"url":26,"identifiers":2139},"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–22.",{"doi":2140},"10.1016\u002Fj.ccr.2012.02.022",{"id":26,"text":2142,"url":26,"identifiers":2143},"Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.",{"doi":2144},"10.1056\u002FNEJM198612253152606",{"id":26,"text":2146,"url":26,"identifiers":2147},"Xiong Y, McDonald LT, Russell DL, Kelly RR, Wilson KR, Mehrotra M, Soloff AC, LaRue AC. Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment. World J Stem Cells. 2015;7:253–65.",{"doi":2148},"10.4252\u002Fwjsc.v7.i2.253",{"id":26,"text":2150,"url":26,"identifiers":2151},"Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010;107:20009–14.",{"doi":2152},"10.1073\u002Fpnas.1013805107",{"id":26,"text":2154,"url":26,"identifiers":2155},"Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009;4:e4992.",{"doi":2156},"10.1371\u002Fjournal.pone.0004992",{"id":26,"text":2158,"url":26,"identifiers":2159},"Medrek C, Ponten F, Jirstrom K, Leandersersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.",{"doi":2160},"10.1186\u002F1471-2407-12-306",{"id":26,"text":2162,"url":26,"identifiers":2163},"Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. 2013;91:411–29.",{"doi":2164},"10.1007\u002Fs00109-013-1021-5",{"id":26,"text":2166,"url":26,"identifiers":2167},"Midgley AC, Rogers M, Hallett MB, Clayton A, Bowen T, Phillips AO, Steadman R. Transforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J Biol Chem. 2013;288:14824–38.",{"doi":2168},"10.1074\u002Fjbc.M113.451336",{"id":26,"text":2170,"url":26,"identifiers":2171},"Untergasser G, Fander R, Lilg C, Lepperdinger G, Pla E, Berger P. Profiling molecular targets of TGF-β1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev. 2005;126:59–69.",{"doi":2172},"10.1016\u002Fj.mad.2004.09.023",{"id":26,"text":2174,"url":26,"identifiers":2175},"DeRuiter MC, Poelmann RE, VanMunsteren JC, Mironov V, Markwald RR, Gittenberger-de Groot AC. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res. 1997;80:444–51.",{"doi":2176},"10.1161\u002F01.RES.80.4.444",{"id":26,"text":2178,"url":26,"identifiers":2179},"Schully S, Francescone R, Faibish M, Bently B, Taylor SL, Oh D, Schapiro R, Moral L, Yan W, Shaeo R. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012;32:12950–60.",{"doi":2180},"10.1523\u002FJNEUROSCI.2017-12.2012",{"id":26,"text":2182,"url":26,"identifiers":2183},"Chen HF, Huang CH, Liu CJ, Hung JJ, Hsu CC, Teng SC, Wu KJ. Twist1 induces endothelial differentiation of tumour cells through the Jagged1-KLF4 axis. Nat Commun. 2014;22:4697.",{"doi":2184},"10.1038\u002Fncomms5697",{"id":26,"text":2186,"url":26,"identifiers":2187},"Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R, Mazzarella E, et al. Neuroendocrine transdifferentiation in human prostate cancer cells: an integrated approach. Cancer Res. 2015;75(15):2975–86.",{"doi":2188},"10.1158\u002F0008-5472.CAN-14-3830",{"id":26,"text":2190,"url":26,"identifiers":2191},"Spaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res. 2013;73:5347–59.",{"doi":2192},"10.1158\u002F0008-5472.CAN-13-0087",{"id":26,"text":2194,"url":26,"identifiers":2195},"Merriam-Webster. The Merriam-Webster dictionary. 11th ed. Springfield: Merriam-Webster, Inc; 2004.",{},{"id":26,"text":2197,"url":26,"identifiers":2198},"Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503–23.",{"doi":2199},"10.1084\u002Fjem.20140692",{"id":26,"text":2201,"url":26,"identifiers":2202},"Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1:482–97.",{},{"id":26,"text":2204,"url":26,"identifiers":2205},"Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–47.",{"doi":2206},"10.1016\u002Fj.ccr.2009.12.041",{"id":26,"text":2208,"url":26,"identifiers":2209},"Augsten M. Cancer-associated fibroblasts as anaother polarized cell type of the tumor microenvironment. Front Oncol. 2014;4:62–70.",{"doi":2210},"10.3389\u002Ffonc.2014.00062",{"id":26,"text":2212,"url":26,"identifiers":2213},"Wang C, Gao C, Men K, Qiao H, Wang Y. Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2. PLoS One. 2015;10:e0119348.",{"doi":2214},"10.1371\u002Fjournal.pone.0119348",{"id":26,"text":2216,"url":26,"identifiers":2217},"Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, Garrido I, Escourrou G, Valet P, Muller C. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71:2455–65.",{"doi":2218},"10.1158\u002F0008-5472.CAN-10-3323",{"id":26,"text":2220,"url":26,"identifiers":2221},"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbord R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–503.",{"doi":2222},"10.1038\u002Fnm.2492",{"id":26,"text":2224,"url":26,"identifiers":2225},"Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massague J. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2011;150:165–78.",{"doi":2226},"10.1016\u002Fj.cell.2012.04.042",{"id":26,"text":2228,"url":26,"identifiers":2229},"Yadav A, Kumar B, Yu J-G, Old M, Teknos TN, Kumar P. Tumor-associated endothelial cells promote tumor metastasis by chaperoning circulating tumor cells and protecting them from anoikis. PLoS One. 2015;10:e0141602.",{"doi":2230},"10.1371\u002Fjournal.pone.0141602",{"id":26,"text":2232,"url":26,"identifiers":2233},"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67.",{"doi":2234},"10.1158\u002F2159-8274.CD-10-0028",{"id":26,"text":2236,"url":26,"identifiers":2237},"Yu J, Du W, Wan F, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783–97.",{"doi":2238},"10.4049\u002Fjimmunol.1201449",{"id":26,"text":2240,"url":26,"identifiers":2241},"Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711.",{"doi":2242},"10.1146\u002Fannurev.immunol.21.120601.141040",{"id":26,"text":2244,"url":26,"identifiers":2245},"Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK\u002FTANKs: tumor-infiltrating\u002Ftumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst. 2014;106:dju200.",{"doi":2246},"10.1093\u002Fjnci\u002Fdju200",{"id":26,"text":2248,"url":26,"identifiers":2249},"Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G, Mortara L, Albini A, Noonan DM. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia. 2013;15:133–42.",{"doi":2250},"10.1593\u002Fneo.121758",{"id":26,"text":2252,"url":26,"identifiers":2253},"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.",{"doi":2254},"10.1038\u002Fnm1093",{"id":26,"text":2256,"url":26,"identifiers":2257},"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, Gimotty PA, Gilks CB, Lal P, Zhang P, Coulos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 2011;475:226–30.",{"doi":2258},"10.1038\u002Fnature10169",{"id":26,"text":2260,"url":26,"identifiers":2261},"Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, Yu BQ, Zhi QM, Li CL, Wang YQ, Tomei S, Cai Q, Ji J, Li JF, Chouchane L, Yu YY, Sun FZ, Xu ZH, Liu BY, Zhu ZG. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2\u002F interleukin-6 signaling in the tumor microenvironment. Cell Res. 2015;25:1138–48.",{},{"id":26,"text":2263,"url":26,"identifiers":2264},"Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Hattingly RR, Slane BF. IL-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer. 2015;15:584.",{"doi":2265},"10.1186\u002Fs12885-015-1576-3",{"id":26,"text":2267,"url":26,"identifiers":2268},"Lee KW, Yeo SY, Sung CO, Kim SH. Twist1 is a key regulator of cancer-associated fibroblasts. Cancer Res. 2015;75:73–85.",{"doi":2269},"10.1158\u002F0008-5472.CAN-14-0350",{"id":26,"text":2271,"url":26,"identifiers":2272},"Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70: 6945–6956.",{"doi":2273},"10.1158\u002F0008-5472.CAN-10-0785",{"id":26,"text":2275,"url":26,"identifiers":2276},"Yeh C-R, Hsu I, Song W, Chang H, Miyamoto H, Xiao G-Q, Li L, Yeh S. Fibroblast ER-alpha promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. Am J Cancer Res. 2015;5:1146–57.",{},{"id":26,"text":2278,"url":26,"identifiers":2279},"Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach F, Gayral M, Cordelier P, Delisle MB, Bousquet-Dubouch MP, Tomasini R, Schmid H, Mathonnet M, Pyronnet S, Martineau Y, Bousquet C. Pharmacological targeting of the protein synthesis mTOR\u002F4E-BP-1 pathway in cancer-associated fibroblasts aborgates pancreatic tumour chemoresistance. EMBO Mol Med. 2015;7:735–53.",{"doi":2280},"10.15252\u002Femmm.201404346",{"id":26,"text":2282,"url":26,"identifiers":2283},"Fang WB, Mafuvadze B, Yao M, Zou A, Portsche M, Cheng N. TGF-b negatively regulates CXCL1 chemokine expression in mammary fibroblasts through enhancement of Smad2\u002F3 and suppression of HGF\u002Fc-Met signaling mechanisms. PLoS One. 2015;10:e0135063.",{"doi":2284},"10.1371\u002Fjournal.pone.0135063",{"id":26,"text":2286,"url":26,"identifiers":2287},"Katanov C, Lerrer S, Liubomirski Y, Lieder-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D, Ben-Baruch A. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-a and the NF-kB pathway. Stem Cell Res Ther. 2015;6:87.",{"doi":2288},"10.1186\u002Fs13287-015-0080-7",{"id":26,"text":2290,"url":26,"identifiers":2291},"Taguchi A, Kawana K, Tomio K, Yamashita A, Isobe Y, Nagasaka K, Koga K, Inoue T, Hishida H, Kojima S, Adachi K, Matsumoto Y, Arimoto T, Wada-Hiraike O, Oda K, Kang JX, Arai H, Arita M, Osuga Y, Fujii T. Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. PLoS One. 2014;9:e89605.",{"doi":2292},"10.1371\u002Fjournal.pone.0089605",{"id":26,"text":2294,"url":26,"identifiers":2295},"Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol. 2009;10:116–25.",{"doi":2296},"10.1038\u002Fnrm2621",{"id":26,"text":2298,"url":26,"identifiers":2299},"Kadera BE, Li L, Poste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One. 2013;8:e71978.",{"doi":2300},"10.1371\u002Fjournal.pone.0071978",{"id":26,"text":2302,"url":26,"identifiers":2303},"Ali S, Suresh R, Banerjee S, Bao B, Xu Z, Wilson J, Philip PA, Apte M, Sarkar FH. Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. Am J Cancer Res. 2015;5:1251–64.",{},{"id":26,"text":2305,"url":26,"identifiers":2306},"Miller PC, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer. Clin Cancer Res. 2015;21:373–85.",{"doi":2307},"10.1158\u002F1078-0432.CCR-14-2053",{"id":26,"text":2309,"url":26,"identifiers":2310},"Shah SH, Miller P, Garcia-Contreras M, Ao Z, Machlin L, Issa E, El-Ashry D. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAKP-microRNAs to drive ER-negative breast cancer phenotype. Cancer Biol Ther. 2015;16:1671–81.",{"doi":2311},"10.1080\u002F15384047.2015.1071742",{"id":26,"text":2313,"url":26,"identifiers":2314},"Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L, Colarossi C, Francesangeli F, Biffoni M, Collura D, Giacobbe A, D’Urso L, Falchi M, Venneri MA, Muto G, De Maria R, Bonci D. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011;30:4231–42.",{"doi":2315},"10.1038\u002Fonc.2011.140",{"id":26,"text":2317,"url":26,"identifiers":2318},"Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6:567–78.",{"doi":2319},"10.1016\u002Fj.molonc.2012.07.007",{"id":26,"text":2321,"url":26,"identifiers":2322},"Pang W, Su J, Wang Y, Feng H, Dai X, Yuan Y, Chen X, Yao W. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Cancer Sci. 2015;106:1362–9.",{"doi":2323},"10.1111\u002Fcas.12747",{"id":26,"text":2325,"url":26,"identifiers":2326},"Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012;2:1100–8.",{"doi":2327},"10.1158\u002F2159-8290.CD-12-0206",{"id":26,"text":2329,"url":26,"identifiers":2330},"Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P. Senescent stroma promotes prostate cancer progression: the role of miR-210. Mol Oncol. 2014;8:1729–46.",{"doi":2331},"10.1016\u002Fj.molonc.2014.07.009",{"id":26,"text":2333,"url":26,"identifiers":2334},"Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013;15:284–94.",{"doi":2335},"10.1038\u002Fncb2690",{"id":26,"text":2337,"url":26,"identifiers":2338},"Luga V, Wrana JL. Tumor-stroma interaction: revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res. 2013;73:6843–7.",{"doi":2339},"10.1158\u002F0008-5472.CAN-13-1791",{"id":26,"text":2341,"url":26,"identifiers":2342},"Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151:1542–56.",{"doi":2343},"10.1016\u002Fj.cell.2012.11.024",{"id":26,"text":2345,"url":26,"identifiers":2346},"Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, Kim YJ, Adam J, Pichter P, Solary E, Berchem G, Moussay E. Exosomes released by chronic lymphocytic leukemia cells induced the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015;126:1106–17.",{"doi":2347},"10.1182\u002Fblood-2014-12-618025",{"id":26,"text":2349,"url":26,"identifiers":2350},"Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R, Deep G. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junctions molecules. Mol Carcinog. 2015;54:554–65.",{"doi":2351},"10.1002\u002Fmc.22124",{"id":26,"text":2353,"url":26,"identifiers":2354},"McKeown SR. Defining normoxia, physoxia and phyoxia in tumours--implications for treatment response. Br J Radiol. 2014;87:1035.",{"doi":2355},"10.1259\u002Fbjr.20130676",{"id":26,"text":2357,"url":26,"identifiers":2358},"Hu Y, Yan C, Mu L, Huang K, Li X, Tao D, Wu Y, Qin J. Fibroblast-derived exosomes contribute to chemoresistance through priming cancer stem cells in colorectal cancer. PLoS One. 2015;10:e0125625.",{"doi":2359},"10.1371\u002Fjournal.pone.0125625",{"id":2361,"createTime":2362,"updateTime":2363,"relativeEntities":2364,"slug":2365,"properties":2366,"entityType":778,"verifyStatus":25,"verifyTime":2381,"verifyNote":779,"syncStatus":28,"languages":2382,"translateLanguages":26,"viewCount":36,"primaryUrl":2383,"fullTextUrl":26,"authors":2384,"publicationType":849,"publisherRelationship":2419,"citationCount":2447,"citationInfo":2448,"publishDate":2450,"publishYear":2451,"citationAnalyzeStatus":886,"lastCitationAnalyze":2452,"indexDatabases":26,"openAccess":26,"references":2453,"isForceReanalyzing":1211},"5a19e53a-8d31-44b4-85dd-7f973447284c","2024-04-14T01:24:12.627+00:00","2024-12-09T23:56:36.951+00:00",[],"Hypoxia-and-oxidative-stress-in-breast-cancer-Oxidative-stress-its-effects-on-the-growth-metastatic-potential-and-response-to-therapy-of-breast-cancer",{"mag":2367,"keywords":2369,"pmc":2370,"openalex":2372,"abstract":2374,"title":2375,"pm":2377,"doi":2379},{"VOID":2368},"2171108478",{},{"VOID":2371},"138696",{"VOID":2373},"W2171108478",{},{"EN":2376},"Hypoxia and oxidative stress in breast cancer Oxidative stress - its effects on the growth, metastatic potential and response to therapy of breast cancer",{"VOID":2378},"11597322",{"VOID":2380},"10.1186\u002Fbcr315","2024-12-09T23:56:36.950+00:00",[102],"http:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr315",[2385,2405],{"id":2386,"sortIndex":36,"researcher":26,"roles":2387,"affiliations":2388,"properties":2398},"ff22953f-90bd-4d25-87a1-8ceab864b341",[],[2389],{"id":26,"sortIndex":36,"affiliation":2390,"properties":26},{"id":2391,"createTime":2392,"updateTime":2392,"relativeEntities":2393,"slug":2394,"properties":2395,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"261daa3b-688d-444b-b073-a8883898ead2","2024-04-14T01:24:12.644+00:00",[],"Molecular-Angiogenesis-Laboratory-Imperial-Cancer-Research-Fund-Weatherall-Institute-of-Molecular-Medicine-John-Radcliffe-Hospital-University-of-Oxford-Oxford-OX3-9DS-UK",{"title":2396},{"EN":2397},"Molecular Angiogenesis Laboratory, Imperial Cancer Research Fund, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK",{"openalex":2399,"orcid":2401,"title":2403},{"VOID":2400},"A5073709479",{"VOID":2402},"https:\u002F\u002Forcid.org\u002F0009-0006-3399-1308",{"EN":2404},"Nicholas Brown",{"id":2406,"sortIndex":115,"researcher":26,"roles":2407,"affiliations":2408,"properties":2414},"af26a920-b285-4251-9ee0-85dac3ef1589",[],[2409],{"id":26,"sortIndex":36,"affiliation":2410,"properties":26},{"id":2391,"createTime":2392,"updateTime":2392,"relativeEntities":2411,"slug":2394,"properties":2412,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2413},{"EN":2397},{"openalex":2415,"title":2417},{"VOID":2416},"A5034857234",{"EN":2418},"Roy Bicknell",{"url":26,"publisher":2420,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2421,"slug":663,"properties":2422,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2425,"manageAffiliations":2426,"indexDatabases":2427,"url":746,"thumbnailPath":26,"statistic":2442,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2423,"title":2424},{"VOID":666},{"EN":668},[],[],[2428,2435],{"id":727,"indexDatabase":2429,"url":740,"indexYears":741,"academicFieldIds":2434,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":2430,"label":2431,"description":2432,"key":737,"publicationTags":2433,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":2436,"url":723,"indexYears":26,"academicFieldIds":2441,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":2437,"label":2438,"description":2439,"key":719,"publicationTags":2440,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":2443,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":2444,"totalCitation":36,"totalCitationByYear":2445,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2446,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},433,{"total":2447,"publishYear":26,"statisticByYear":2449},{"2012":287,"2013":241,"2014":240,"2015":241,"2016":298,"2017":234,"2018":238,"2019":51,"2020":356,"2021":516,"2022":124,"2023":242,"2024":162},"2001-10-01",2001,"2024-04-14T12:44:03.281+00:00",[2454,2458,2461,2465,2469,2473,2476,2480,2484,2488,2492,2496,2499,2503,2507,2511,2515,2519,2523,2527,2531,2535,2539,2543,2547,2550,2554,2558,2562,2566,2570,2574],{"id":26,"text":2455,"url":26,"identifiers":2456},"Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996, 313: 17-29.",{"doi":2457},"10.1042\u002Fbj3130017",{"id":26,"text":2459,"url":26,"identifiers":2460},"Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51: 794-798.",{},{"id":26,"text":2462,"url":26,"identifiers":2463},"Toyokuni S, Okamoto K, Yodoi J, Hiai H: Persistent oxidative stress in cancer. FEBS Lett. 1995, 358: 1-3. 10.1016\u002F0014-5793(94)01368-B.",{"doi":2464},"10.1016\u002F0014-5793(94)01368-B",{"id":26,"text":2466,"url":26,"identifiers":2467},"Portakal O, Ozkaya O, Erden Inal M, Bozan B, Kosan M, Sayek I: Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000, 33: 279-284. 10.1016\u002FS0009-9120(00)00067-9.",{"doi":2468},"10.1016\u002FS0009-9120(00)00067-9",{"id":26,"text":2470,"url":26,"identifiers":2471},"Sundaresan M, Yu Z-X, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, Finkel T: Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J. 318: 379-382.",{"doi":2472},"10.1042\u002Fbj3180379",{"id":26,"text":2474,"url":26,"identifiers":2475},"Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R: Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000, 60: 6298-6302.",{},{"id":26,"text":2477,"url":26,"identifiers":2478},"Sipe HJ, Jordan SJ, Hanna PM, Mason RP: The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis. 1994, 15: 2637-2643.",{"doi":2479},"10.1093\u002Fcarcin\u002F15.11.2637",{"id":26,"text":2481,"url":26,"identifiers":2482},"Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ: Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Ann N Y Acad Sci. 2000, 899: 349-362.",{"doi":2483},"10.1111\u002Fj.1749-6632.2000.tb06199.x",{"id":26,"text":2485,"url":26,"identifiers":2486},"Lee YJ, Galoforo SS, Berns CM, Chen JC, Davis BH, Sim JE, Corry PM, Spitz DR: Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem. 1998, 273: 5294-5299. 10.1074\u002Fjbc.273.9.5294.",{"doi":2487},"10.1074\u002Fjbc.273.9.5294",{"id":26,"text":2489,"url":26,"identifiers":2490},"Kundu N, Zhang S, Fulton AM: Sublethal oxidative stress inhibits tumor cell adhesion and enhances experimental metastasis of murine mammary carcinoma. Clin Exp Metastasis. 1995, 13: 16-22.",{"doi":2491},"10.1007\u002FBF00144014",{"id":26,"text":2493,"url":26,"identifiers":2494},"Fulton AM, Chong YC: The role of macrophage-derived TNFα in the induction of sublethal tumor cell DNA damage. Carcinogenesis. 1992, 13: 77-81.",{"doi":2495},"10.1093\u002Fcarcin\u002F13.1.77",{"id":26,"text":2497,"url":26,"identifiers":2498},"Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 1995, 55: 4293-4296.",{},{"id":26,"text":2500,"url":26,"identifiers":2501},"Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti Panici P, Mancuso S: Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer. 1999, 79: 257-263.",{"doi":2502},"10.1038\u002Fsj.bjc.6690042",{"id":26,"text":2504,"url":26,"identifiers":2505},"Burdon RH: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995, 18: 775-794. 10.1016\u002F0891-5849(94)00198-S.",{"doi":2506},"10.1016\u002F0891-5849(94)00198-S",{"id":26,"text":2508,"url":26,"identifiers":2509},"Wang X, Martindale JL, Liu Y, Holbrook NJ: The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J. 1998, 333: 291-300.",{"doi":2510},"10.1042\u002Fbj3330291",{"id":26,"text":2512,"url":26,"identifiers":2513},"Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK: Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000, 92: 1926-1934. 10.1093\u002Fjnci\u002F92.23.1926.",{"doi":2514},"10.1093\u002Fjnci\u002F92.23.1926",{"id":26,"text":2516,"url":26,"identifiers":2517},"Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997, 275: 1649-1652. 10.1126\u002Fscience.275.5306.1649.",{"doi":2518},"10.1126\u002Fscience.275.5306.1649",{"id":26,"text":2520,"url":26,"identifiers":2521},"Yin Y, Solomon G, Deng C, Barrett JC: Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress. Mol Carcinog. 1999, 24: 15-24. 10.1002\u002F(SICI)1098-2744(199901)24:1\u003C15::AID-MC3>3.3.CO;2-P.",{"doi":2522},"10.1002\u002F(SICI)1098-2744(199901)24:1\u003C15::AID-MC3>3.0.CO;2-Y",{"id":26,"text":2524,"url":26,"identifiers":2525},"Lazo JS, Kuo SM, Woo ES, Pitt BR: The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem Biol Interact. 1998, 111-112: 255-262. 10.1016\u002FS0009-2797(97)00165-8.",{"doi":2526},"10.1016\u002FS0009-2797(97)00165-8",{"id":26,"text":2528,"url":26,"identifiers":2529},"O'Donnell-Tormey J, DeBoer CJ, Nathan CF: Resistance of human tumor cells in vitro to oxidative cytolysis. J Clin Invest. 1985, 76: 80-86.",{"doi":2530},"10.1172\u002FJCI111981",{"id":26,"text":2532,"url":26,"identifiers":2533},"Shaw M, Cohen P, Alessi DR: The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Biochem J. 1998, 336: 241-246.",{"doi":2534},"10.1042\u002Fbj3360241",{"id":26,"text":2536,"url":26,"identifiers":2537},"Ziemann C, Burkle A, Kahl GF, Hirsch-Ernst KI: Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein over-expression in primary rat hepatocyte cultures. Carcinogenesis. 1999, 20: 407-414. 10.1093\u002Fcarcin\u002F20.3.407.",{"doi":2538},"10.1093\u002Fcarcin\u002F20.3.407",{"id":26,"text":2540,"url":26,"identifiers":2541},"Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT: Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000, 275: 25130-25138. 10.1074\u002Fjbc.M001914200.",{"doi":2542},"10.1074\u002Fjbc.M001914200",{"id":26,"text":2544,"url":26,"identifiers":2545},"Richard DE, Berra E, Pouyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem. 2000, 275: 26765-26771.",{"doi":2546},"10.1016\u002FS0021-9258(19)61441-9",{"id":26,"text":2548,"url":26,"identifiers":2549},"Milligan SA, Owens MW, Grisham MB: Augmentation of cytokine-induced nitric oxide synthesis by hydrogen peroxide. Am J Physiol. 1996, 271: L114-L120.",{},{"id":26,"text":2551,"url":26,"identifiers":2552},"Huot J, Houle F, Marceau F, Landry J: Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase\u002Fheat shock protein 27 pathway in vascular endothelial cells. Circ Res. 1997, 80: 383-392.",{"doi":2553},"10.1161\u002F01.RES.80.3.383",{"id":26,"text":2555,"url":26,"identifiers":2556},"Rust W, Kingsley K, Petnicki T, Padmanabhan S, Carper SW, Plopper GE: Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on laminin-5. Mol Cell Biol Res Commun. 1999, 1: 196-202. 10.1006\u002Fmcbr.1999.0130.",{"doi":2557},"10.1006\u002Fmcbr.1999.0130",{"id":26,"text":2559,"url":26,"identifiers":2560},"Moldovan L, Irani K, Moldovan NI, Finkel T, Goldschmidt-Clermont PJ: The actin cytoskeleton reorganization induced by Rac1 requires the production of superoxide. Antiox Redox Signal. 1999, 1: 29-43.",{"doi":2561},"10.1089\u002Fars.1999.1.1-29",{"id":26,"text":2563,"url":26,"identifiers":2564},"Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2: 252-257. 10.1186\u002Fbcr65.",{"doi":2565},"10.1186\u002Fbcr65",{"id":26,"text":2567,"url":26,"identifiers":2568},"Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996, 98: 2572-2579.",{"doi":2569},"10.1172\u002FJCI119076",{"id":26,"text":2571,"url":26,"identifiers":2572},"Swaim MW, Pizzo SV: Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol. 1988, 43: 365-379.",{"doi":2573},"10.1002\u002Fjlb.43.4.365",{"id":26,"text":2575,"url":26,"identifiers":2576},"Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, Trent JM: Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci USA. 1993, 90: 3113-3117.",{"doi":2577},"10.1073\u002Fpnas.90.7.3113",{"id":2579,"createTime":2580,"updateTime":2581,"relativeEntities":2582,"slug":2583,"properties":2584,"entityType":778,"verifyStatus":25,"verifyTime":2581,"verifyNote":779,"syncStatus":28,"languages":2599,"translateLanguages":26,"viewCount":36,"primaryUrl":2600,"fullTextUrl":26,"authors":2601,"publicationType":849,"publisherRelationship":2636,"citationCount":2664,"citationInfo":2665,"publishDate":2667,"publishYear":1439,"citationAnalyzeStatus":886,"lastCitationAnalyze":2668,"indexDatabases":26,"openAccess":26,"references":2669,"isForceReanalyzing":1211},"ee8d9607-7f7d-42a4-9d93-079e0fce6517","2024-04-12T02:14:27.317+00:00","2025-01-18T07:26:52.562+00:00",[],"HER2-therapy-Molecular-mechanisms-of-trastuzumab-resistance",{"mag":2585,"keywords":2587,"pmc":2588,"openalex":2590,"abstract":2592,"title":2593,"pm":2595,"doi":2597},{"VOID":2586},"1644299043",{},{"VOID":2589},"1797036",{"VOID":2591},"W1644299043",{},{"EN":2594},"HER2 therapy: Molecular mechanisms of trastuzumab resistance",{"VOID":2596},"17096862",{"VOID":2598},"10.1186\u002Fbcr1612",[102],"http:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr1612",[2602,2620],{"id":2603,"sortIndex":36,"researcher":26,"roles":2604,"affiliations":2605,"properties":2615},"0be1a94b-a58d-42b1-921b-dca8f08d194e",[],[2606],{"id":26,"sortIndex":36,"affiliation":2607,"properties":26},{"id":2608,"createTime":2609,"updateTime":2609,"relativeEntities":2610,"slug":2611,"properties":2612,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6f860c09-1bc4-40ee-8983-ecfb370650a4","2024-04-12T02:14:27.336+00:00",[],"Department-of-Breast-Medical-Oncology-Breast-Cancer-Translational-Research-Laboratory-The-University-of-Texas-MD-Anderson-Cancer-Center-Holcombe-Blvd-Houston-Texas-77030-4009-USA",{"title":2613},{"EN":2614},"Department of Breast Medical Oncology, Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas, 77030-4009, USA",{"openalex":2616,"title":2618},{"VOID":2617},"A5042383028",{"EN":2619},"Rita Nahta",{"id":2621,"sortIndex":115,"researcher":26,"roles":2622,"affiliations":2623,"properties":2629},"b96c9f02-6695-4cc2-874f-ac4841d2b206",[],[2624],{"id":26,"sortIndex":36,"affiliation":2625,"properties":26},{"id":2608,"createTime":2609,"updateTime":2609,"relativeEntities":2626,"slug":2611,"properties":2627,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2628},{"EN":2614},{"openalex":2630,"orcid":2632,"title":2634},{"VOID":2631},"A5087724207",{"VOID":2633},"https:\u002F\u002Forcid.org\u002F0000-0003-2437-3920",{"EN":2635},"Francisco J. Esteva",{"url":26,"publisher":2637,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2638,"slug":663,"properties":2639,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2642,"manageAffiliations":2643,"indexDatabases":2644,"url":746,"thumbnailPath":26,"statistic":2659,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2640,"title":2641},{"VOID":666},{"EN":668},[],[],[2645,2652],{"id":727,"indexDatabase":2646,"url":740,"indexYears":741,"academicFieldIds":2651,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":2647,"label":2648,"description":2649,"key":737,"publicationTags":2650,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":2653,"url":723,"indexYears":26,"academicFieldIds":2658,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":2654,"label":2655,"description":2656,"key":719,"publicationTags":2657,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":2660,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":2661,"totalCitation":36,"totalCitationByYear":2662,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":2663,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},381,{"total":2664,"publishYear":26,"statisticByYear":2666},{"2012":255,"2013":285,"2014":398,"2015":260,"2016":260,"2017":234,"2018":298,"2019":53,"2020":124,"2021":51,"2022":298,"2023":116,"2024":111},"2006-12-01","2024-04-13T10:10:59.173+00:00",[2670,2674,2678,2682,2686,2690,2694,2698,2702,2706,2709,2713,2717,2721,2725,2729,2733,2737,2740,2744,2748,2752,2756,2760,2764,2768,2772,2776,2780,2784,2788,2792,2796,2800,2803,2807,2811,2815,2818,2821,2825,2828,2832,2836,2839,2842,2845,2848,2851,2855,2859,2863,2867,2871,2875,2879,2883,2887,2891,2895,2899,2903,2907,2910,2913,2916,2920,2924,2928,2932,2935,2939],{"id":26,"text":2671,"url":26,"identifiers":2672},"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2\u002Fneu oncogene. Science. 1987, 235: 177-182. 10.1126\u002Fscience.3798106.",{"doi":2673},"10.1126\u002Fscience.3798106",{"id":26,"text":2675,"url":26,"identifiers":2676},"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2\u002Fneu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712. 10.1126\u002Fscience.2470152.",{"doi":2677},"10.1126\u002Fscience.2470152",{"id":26,"text":2679,"url":26,"identifiers":2680},"Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, et al: HER-2\u002Fneu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997, 15: 2894-2904.",{"doi":2681},"10.1200\u002FJCO.1997.15.8.2894",{"id":26,"text":2683,"url":26,"identifiers":2684},"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185her2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992, 89: 4285-4289. 10.1073\u002Fpnas.89.10.4285.",{"doi":2685},"10.1073\u002Fpnas.89.10.4285",{"id":26,"text":2687,"url":26,"identifiers":2688},"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353: 1673-1684. 10.1056\u002FNEJMoa052122.",{"doi":2689},"10.1056\u002FNEJMoa052122",{"id":26,"text":2691,"url":26,"identifiers":2692},"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353: 1659-1672. 10.1056\u002FNEJMoa052306.",{"doi":2693},"10.1056\u002FNEJMoa052306",{"id":26,"text":2695,"url":26,"identifiers":2696},"Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005, 23: 3676-3685. 10.1200\u002FJCO.2005.07.032.",{"doi":2697},"10.1200\u002FJCO.2005.07.032",{"id":26,"text":2699,"url":26,"identifiers":2700},"Nahta R, Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232: 123-138. 10.1016\u002Fj.canlet.2005.01.041.",{"doi":2701},"10.1016\u002Fj.canlet.2005.01.041",{"id":26,"text":2703,"url":26,"identifiers":2704},"Baselga J, Albanell J, Molina MA, Arribas J: Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001, 28 (Suppl 16): 4-11. 10.1016\u002FS0093-7754(01)90276-3.",{"doi":2705},"10.1016\u002FS0093-7754(01)90276-3",{"id":26,"text":2707,"url":26,"identifiers":2708},"Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999, 26 (Suppl 12): 60-70.",{},{"id":26,"text":2710,"url":26,"identifiers":2711},"Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004, 6: 117-127. 10.1016\u002Fj.ccr.2004.06.022.",{"doi":2712},"10.1016\u002Fj.ccr.2004.06.022",{"id":26,"text":2714,"url":26,"identifiers":2715},"Cooley S, Burns LJ, Repka T, Miller JS: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2\u002Fneu. Exp Hematol. 1999, 27: 1533-1541. 10.1016\u002FS0301-472X(99)00089-2.",{"doi":2716},"10.1016\u002FS0301-472X(99)00089-2",{"id":26,"text":2718,"url":26,"identifiers":2719},"Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000, 6: 443-446. 10.1038\u002F74704.",{"doi":2720},"10.1038\u002F74704",{"id":26,"text":2722,"url":26,"identifiers":2723},"Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, et al: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004, 10: 5650-5655. 10.1158\u002F1078-0432.CCR-04-0225.",{"doi":2724},"10.1158\u002F1078-0432.CCR-04-0225",{"id":26,"text":2726,"url":26,"identifiers":2727},"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, et al: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006, 94: 259-267. 10.1038\u002Fsj.bjc.6602930.",{"doi":2728},"10.1038\u002Fsj.bjc.6602930",{"id":26,"text":2730,"url":26,"identifiers":2731},"Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature. 2002, 416: 279-280. 10.1038\u002F416279b.",{"doi":2732},"10.1038\u002F416279b",{"id":26,"text":2734,"url":26,"identifiers":2735},"Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D: Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 2003, 98: 1377-1385. 10.1002\u002Fcncr.11656.",{"doi":2736},"10.1002\u002Fcncr.11656",{"id":26,"text":2738,"url":26,"identifiers":2739},"Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006. [E-pubahead of print]",{},{"id":26,"text":2741,"url":26,"identifiers":2742},"Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\u002Fneu-overexpressing metastatic breast cancer. J Clin Oncol. 1996, 14: 737-744.",{"doi":2743},"10.1200\u002FJCO.1996.14.3.737",{"id":26,"text":2745,"url":26,"identifiers":2746},"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17: 2639-2648.",{"doi":2747},"10.1200\u002FJCO.1999.17.9.2639",{"id":26,"text":2749,"url":26,"identifiers":2750},"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20: 719-726. 10.1200\u002FJCO.20.3.719.",{"doi":2751},"10.1200\u002FJCO.20.3.719",{"id":26,"text":2753,"url":26,"identifiers":2754},"Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001, 19: 2587-2595.",{"doi":2755},"10.1200\u002FJCO.2001.19.10.2587",{"id":26,"text":2757,"url":26,"identifiers":2758},"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056\u002FNEJM200103153441101.",{"doi":2759},"10.1056\u002FNEJM200103153441101",{"id":26,"text":2761,"url":26,"identifiers":2762},"Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20: 1800-1808. 10.1200\u002FJCO.2002.07.058.",{"doi":2763},"10.1200\u002FJCO.2002.07.058",{"id":26,"text":2765,"url":26,"identifiers":2766},"Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006, 3: 269-280. 10.1038\u002Fncponc0509.",{"doi":2767},"10.1038\u002Fncponc0509",{"id":26,"text":2769,"url":26,"identifiers":2770},"Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL: Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002, 99: 783-791. 10.1002\u002Fijc.10410.",{"doi":2771},"10.1002\u002Fijc.10410",{"id":26,"text":2773,"url":26,"identifiers":2774},"Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65: 473-482.",{"doi":2775},"10.1158\u002F0008-5472.473.65.2",{"id":26,"text":2777,"url":26,"identifiers":2778},"Carraway KL, Price-Schiavi SA, Komatsu M, Jepson S, Perez A, Carraway CA: Muc4\u002Fsialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2001, 6: 323-337. 10.1023\u002FA:1011327708973.",{"doi":2779},"10.1023\u002FA:1011327708973",{"id":26,"text":2781,"url":26,"identifiers":2782},"Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T: The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol. 1991, 11: 833-842.",{"doi":2783},"10.1128\u002FMCB.11.2.833",{"id":26,"text":2785,"url":26,"identifiers":2786},"Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J: Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2004, 3: 1585-1592.",{"doi":2787},"10.1158\u002F1535-7163.1585.3.12",{"id":26,"text":2789,"url":26,"identifiers":2790},"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001, 93: 1852-1857. 10.1093\u002Fjnci\u002F93.24.1852.",{"doi":2791},"10.1093\u002Fjnci\u002F93.24.1852",{"id":26,"text":2793,"url":26,"identifiers":2794},"Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor\u002Fhuman epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65: 11118-11128. 10.1158\u002F0008-5472.CAN-04-3841.",{"doi":2795},"10.1158\u002F0008-5472.CAN-04-3841",{"id":26,"text":2797,"url":26,"identifiers":2798},"Lu Y, Zi X, Pollak M: Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer. 2004, 108: 334-341. 10.1002\u002Fijc.11445.",{"doi":2799},"10.1002\u002Fijc.11445",{"id":26,"text":2801,"url":26,"identifiers":2802},"Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62: 4132-4141.",{},{"id":26,"text":2804,"url":26,"identifiers":2805},"Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC: The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem. 2003, 278: 23441-23450. 10.1074\u002Fjbc.M300848200.",{"doi":2806},"10.1074\u002Fjbc.M300848200",{"id":26,"text":2808,"url":26,"identifiers":2809},"Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ: P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004, 64: 3981-3986. 10.1158\u002F0008-5472.CAN-03-3900.",{"doi":2810},"10.1158\u002F0008-5472.CAN-03-3900",{"id":26,"text":2812,"url":26,"identifiers":2813},"Chan CT, Metz MZ, Kane SE: Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat. 2005, 91: 187-201. 10.1007\u002Fs10549-004-7715-1.",{"doi":2814},"10.1007\u002Fs10549-004-7715-1",{"id":26,"text":2816,"url":26,"identifiers":2817},"Lin YZ, Clinton GM: A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene. 1991, 6: 639-643.",{},{"id":26,"text":2819,"url":26,"identifiers":2820},"Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene. 1993, 8: 2917-2923.",{},{"id":26,"text":2822,"url":26,"identifiers":2823},"Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p185\u002Fneu is released from the surface of human breast carcinoma cells, sk-br-3. J Biol Chem. 1991, 266: 1716-1720.",{"doi":2824},"10.1016\u002FS0021-9258(18)52354-1",{"id":26,"text":2826,"url":26,"identifiers":2827},"Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveras B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000, 6: 2356-2362.",{},{"id":26,"text":2829,"url":26,"identifiers":2830},"Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995, 13: 1129-1135.",{"doi":2831},"10.1200\u002FJCO.1995.13.5.1129",{"id":26,"text":2833,"url":26,"identifiers":2834},"Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2\u002Fc-neu protein. J Clin Oncol. 1997, 15: 2518-2525.",{"doi":2835},"10.1200\u002FJCO.1997.15.7.2518",{"id":26,"text":2837,"url":26,"identifiers":2838},"Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Cancer and Leukemia Group B, et al: Circulating HER-2\u002FerbB-2\u002Fc-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001, 7: 2703-2711.",{},{"id":26,"text":2840,"url":26,"identifiers":2841},"Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, Clinton GM: NH2-terminally truncated HER-2\u002Fneu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998, 58: 5123-5129.",{},{"id":26,"text":2843,"url":26,"identifiers":2844},"Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J, et al: NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002, 8: 347-353.",{},{"id":26,"text":2846,"url":26,"identifiers":2847},"Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61: 4744-4749.",{},{"id":26,"text":2849,"url":26,"identifiers":2850},"Esteva FJ, Cheli C, Fritsche HA, Fornier M, Slamon DJ, Thiel RP, Luftner D, Ghani F: Clinical utility of circulating HER-2\u002Fneu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy. Breast Can Res Treat. 2004, 88: 6001-",{},{"id":26,"text":2852,"url":26,"identifiers":2853},"Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG: Monitoring of serum Her-2\u002Fneu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004, 10: 1618-1624. 10.1158\u002F1078-0432.CCR-0385-3.",{"doi":2854},"10.1158\u002F1078-0432.CCR-0385-3",{"id":26,"text":2856,"url":26,"identifiers":2857},"Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C: Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005, 16: 234-239. 10.1093\u002Fannonc\u002Fmdi059.",{"doi":2858},"10.1093\u002Fannonc\u002Fmdi059",{"id":26,"text":2860,"url":26,"identifiers":2861},"Ali SM, Esteva FJ, Fornier M, Gligorov J, Harris L, Kostler WJ, Luftner D, Pichon MF, Tse C, Lipton A: Serum HER-2\u002Fneu change predicts clinical outcome to trastuzumab-based therapy. J Clin Oncol. 2006, 24 (Suppl): 500-",{"doi":2862},"10.1200\u002Fjco.2006.24.18_suppl.500",{"id":26,"text":2864,"url":26,"identifiers":2865},"Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 2006, 25: 3234-3244. 10.1038\u002Fsj.emboj.7601191.",{"doi":2866},"10.1038\u002Fsj.emboj.7601191",{"id":26,"text":2868,"url":26,"identifiers":2869},"Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002, 2: 127-137. 10.1016\u002FS1535-6108(02)00097-1.",{"doi":2870},"10.1016\u002FS1535-6108(02)00097-1",{"id":26,"text":2872,"url":26,"identifiers":2873},"Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003, 421: 756-760. 10.1038\u002Fnature01392.",{"doi":2874},"10.1038\u002Fnature01392",{"id":26,"text":2876,"url":26,"identifiers":2877},"Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004, 5: 317-328. 10.1016\u002FS1535-6108(04)00083-2.",{"doi":2878},"10.1016\u002FS1535-6108(04)00083-2",{"id":26,"text":2880,"url":26,"identifiers":2881},"Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64: 2343-2346. 10.1158\u002F0008-5472.CAN-03-3856.",{"doi":2882},"10.1158\u002F0008-5472.CAN-03-3856",{"id":26,"text":2884,"url":26,"identifiers":2885},"Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64: 6652-6659. 10.1158\u002F0008-5472.CAN-04-1168.",{"doi":2886},"10.1158\u002F0008-5472.CAN-04-1168",{"id":26,"text":2888,"url":26,"identifiers":2889},"Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\u002FerbB2 and downstream Erk1\u002F2 and AKT pathways. Oncogene. 2002, 21: 6255-6263. 10.1038\u002Fsj.onc.1205794.",{"doi":2890},"10.1038\u002Fsj.onc.1205794",{"id":26,"text":2892,"url":26,"identifiers":2893},"Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005, 24: 6213-6221. 10.1038\u002Fsj.onc.1208774.",{"doi":2894},"10.1038\u002Fsj.onc.1208774",{"id":26,"text":2896,"url":26,"identifiers":2897},"Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, et al: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA. 2006, 103: 7795-7800. 10.1073\u002Fpnas.0602468103.",{"doi":2898},"10.1073\u002Fpnas.0602468103",{"id":26,"text":2900,"url":26,"identifiers":2901},"Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66: 1630-1639. 10.1158\u002F0008-5472.CAN-05-1182.",{"doi":2902},"10.1158\u002F0008-5472.CAN-05-1182",{"id":26,"text":2904,"url":26,"identifiers":2905},"Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005, 23: 5305-5313. 10.1200\u002FJCO.2005.16.584.",{"doi":2906},"10.1200\u002FJCO.2005.16.584",{"id":26,"text":2908,"url":26,"identifiers":2909},"Geyer CE, Cameron D, Lindquist D, Chan S, Pienkowski T, Romieu CG, Jagiello-Gruszfeld A, Crown J, Kaufman B, Chan A, et al: A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Presentation at Scientific Special Session, \"Lapatinib in Trastuzumab-Resistant Breast Cancer\". J Clin Oncol. 2006, 24 (18S):",{},{"id":26,"text":2911,"url":26,"identifiers":2912},"Camirand A, Lu Y, Pollak M: Co-targeting HER2\u002FErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit. 2002, 8: BR521-BR526.",{},{"id":26,"text":2914,"url":26,"identifiers":2915},"DiGiovanna MP, Chakraborty A: Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells. Proc Am Assoc Cancer Res. 2006, 47: 1226-",{},{"id":26,"text":2917,"url":26,"identifiers":2918},"Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW: Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer. 2002, 38: 1615-1621. 10.1016\u002FS0959-8049(02)00127-2.",{"doi":2919},"10.1016\u002FS0959-8049(02)00127-2",{"id":26,"text":2921,"url":26,"identifiers":2922},"Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G: A phase I trial of perifosine (NSC 639966) on a loading dose\u002Fmaintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 2004, 10: 7450-7456. 10.1158\u002F1078-0432.CCR-03-0406.",{"doi":2923},"10.1158\u002F1078-0432.CCR-03-0406",{"id":26,"text":2925,"url":26,"identifiers":2926},"Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000, 19: 6680-6686. 10.1038\u002Fsj.onc.1204091.",{"doi":2927},"10.1038\u002Fsj.onc.1204091",{"id":26,"text":2929,"url":26,"identifiers":2930},"Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005, 23: 5314-5322. 10.1200\u002FJCO.2005.66.130.",{"doi":2931},"10.1200\u002FJCO.2005.66.130",{"id":26,"text":2933,"url":26,"identifiers":2934},"Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003, 2: 971-984.",{},{"id":26,"text":2936,"url":26,"identifiers":2937},"Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K: Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005, 11: 6382-6389. 10.1158\u002F1078-0432.CCR-05-0344.",{"doi":2938},"10.1158\u002F1078-0432.CCR-05-0344",{"id":26,"text":2940,"url":26,"identifiers":2941},"Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002, 62: 3151-3158.",{},{"id":2943,"createTime":2944,"updateTime":2944,"relativeEntities":2945,"slug":2946,"properties":2947,"entityType":778,"verifyStatus":25,"verifyTime":2944,"verifyNote":779,"syncStatus":28,"languages":2962,"translateLanguages":26,"viewCount":36,"primaryUrl":2963,"fullTextUrl":26,"authors":2964,"publicationType":849,"publisherRelationship":2987,"citationCount":3020,"citationInfo":3021,"publishDate":3023,"publishYear":3024,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":3025,"isForceReanalyzing":1211},"8e538420-db54-4e09-8a9a-20931a514666","2024-10-04T10:33:36.642+00:00",[],"Key-stages-in-mammary-gland-development-The-cues-that-regulate-ductal-branching-morphogenesis",{"mag":2948,"keywords":2950,"pmc":2951,"openalex":2953,"abstract":2955,"title":2956,"pm":2958,"doi":2960},{"VOID":2949},"1523335221",{},{"VOID":2952},"1413974",{"VOID":2954},"W1523335221",{},{"EN":2957},"Key stages in mammary gland development: The cues that regulate ductal branching morphogenesis",{"VOID":2959},"16524451",{"VOID":2961},"10.1186\u002Fbcr1368",[102],"http:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr1368",[2965],{"id":2966,"sortIndex":36,"researcher":26,"roles":2967,"affiliations":2968,"properties":2980},"e3ebc36c-e78e-4b50-9d68-220754d30ed8",[],[2969],{"id":2970,"sortIndex":36,"affiliation":2971,"properties":26},"2ff477c3-b5d7-42db-a716-84b60cfbced3",{"id":2972,"createTime":2973,"updateTime":2974,"relativeEntities":2975,"slug":2976,"properties":2977,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5479ca55-690e-4bfe-b924-77fb54569a3c","2024-09-22T07:47:01.123+00:00","2024-10-04T10:33:36.656+00:00",[],"Dept-of-Anatomy-University-of-California-San-Francisco-USA",{"title":2978},{"EN":2979},"Dept. of Anatomy, University of California, San Francisco, USA",{"openalex":2981,"orcid":2983,"title":2985},{"VOID":2982},"A5014951457",{"VOID":2984},"https:\u002F\u002Forcid.org\u002F0000-0002-3644-3861",{"EN":2986},"Mark D. Sternlicht",{"url":26,"publisher":2988,"properties":3015},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2989,"slug":663,"properties":2990,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2993,"manageAffiliations":2994,"indexDatabases":2995,"url":746,"thumbnailPath":26,"statistic":3010,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2991,"title":2992},{"VOID":666},{"EN":668},[],[],[2996,3003],{"id":727,"indexDatabase":2997,"url":740,"indexYears":741,"academicFieldIds":3002,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":2998,"label":2999,"description":3000,"key":737,"publicationTags":3001,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":3004,"url":723,"indexYears":26,"academicFieldIds":3009,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":3005,"label":3006,"description":3007,"key":719,"publicationTags":3008,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":3011,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":3012,"totalCitation":36,"totalCitationByYear":3013,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":3014,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},{"volume":3016,"issue":3018},{"VOID":3017},"8",{"VOID":3019},"1",378,{"total":3020,"publishYear":26,"statisticByYear":3022},{"2012":260,"2013":222,"2014":244,"2015":173,"2016":234,"2017":79,"2018":516,"2019":242,"2020":336,"2021":124,"2022":239,"2023":124,"2024":116},"2005-02-01",2005,[3026,3030,3034,3038,3042,3046,3050,3054,3058,3062,3066,3070,3074,3077,3081,3085,3089,3093,3097,3101,3105,3109,3113,3117,3121,3125,3129,3133,3137,3140,3144,3148,3152,3156,3159,3163,3167,3171,3175,3179,3183,3187,3191,3195,3199,3203,3207,3211,3215,3219,3223,3227,3230,3234,3238],{"id":26,"text":3027,"url":26,"identifiers":3028},"Affolter M, Bellusci S, Itoh N, Shilo B, Thiery JP, Werb Z: Tube or not tube: remodeling epithelial tissues by branching morphogenesis. Dev Cell. 2003, 4: 11-18. 10.1016\u002FS1534-5807(02)00410-0.",{"doi":3029},"10.1016\u002FS1534-5807(02)00410-0",{"id":26,"text":3031,"url":26,"identifiers":3032},"Davies JA: Watching tubules glow and branch. Curr Opin Genet Dev. 2005, 15: 364-370. 10.1016\u002Fj.gde.2005.06.003.",{"doi":3033},"10.1016\u002Fj.gde.2005.06.003",{"id":26,"text":3035,"url":26,"identifiers":3036},"Lubarsky B, Krasnow MA: Tube morphogenesis: making and shaping biological tubes. Cell. 2003, 112: 19-28. 10.1016\u002FS0092-8674(02)01283-7.",{"doi":3037},"10.1016\u002FS0092-8674(02)01283-7",{"id":26,"text":3039,"url":26,"identifiers":3040},"O'Brien LE, Zegers MMP, Mostov KE: Building epithelial architecture: insights from three-dimensional culture models. Nat Rev Mol Cell Biol. 2002, 3: 531-537. 10.1038\u002Fnrm859.",{"doi":3041},"10.1038\u002Fnrm859",{"id":26,"text":3043,"url":26,"identifiers":3044},"Hens JR, Wysolmerski JJ: Key stages of mammary gland development: molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Res. 2005, 7: 220-224. 10.1186\u002Fbcr1306.",{"doi":3045},"10.1186\u002Fbcr1306",{"id":26,"text":3047,"url":26,"identifiers":3048},"Hinck L, Silberstein GB: Key stages of mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res. 2005, 7: 245-251. 10.1186\u002Fbcr1331.",{"doi":3049},"10.1186\u002Fbcr1331",{"id":26,"text":3051,"url":26,"identifiers":3052},"Howard BA, Gusterson BA: Human breast development. J Mammary Gland Biol Neoplasia. 2000, 5: 119-137. 10.1023\u002FA:1026487120779.",{"doi":3053},"10.1023\u002FA:1026487120779",{"id":26,"text":3055,"url":26,"identifiers":3056},"Curtis Hewitt S, Couse JF, Korach KS: Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2000, 2: 345-352. 10.1186\u002Fbcr79.",{"doi":3057},"10.1186\u002Fbcr79",{"id":26,"text":3059,"url":26,"identifiers":3060},"Bocchinfuso WP, Lindzey JK, Hewitt SC, Clark JA, Myers PH, Cooper R, Korach KS: Induction of mammary gland development in estrogen receptor-alpha knockout mice. Endocrinology. 2000, 141: 2982-2994. 10.1210\u002Fen.141.8.2982.",{"doi":3061},"10.1210\u002Fendo.141.8.7609",{"id":26,"text":3063,"url":26,"identifiers":3064},"Sakakura T, Nishizuka Y, Dawe CJ: Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science. 1976, 194: 1439-1441.",{"doi":3065},"10.1126\u002Fscience.827022",{"id":26,"text":3067,"url":26,"identifiers":3068},"Cunha GR, Young P, Christov K, Guzman R, Nandi S, Talamantes F, Thordarson G: Mammary phenotypic expression induced in epidermal cells by embryonic mammary mesenchyme. Acta Anat (Basel). 1995, 152: 195-204.",{"doi":3069},"10.1159\u002F000147698",{"id":26,"text":3071,"url":26,"identifiers":3072},"Naylor MJ, Ormandy CJ: Mouse strain-specific patterns of mammary epithelial ductal side branching are elicited by stromal factors. Dev Dyn. 2002, 225: 100-105. 10.1002\u002Fdvdy.10133.",{"doi":3073},"10.1002\u002Fdvdy.10133",{"id":26,"text":3075,"url":26,"identifiers":3076},"Daniel CW, Silberstein GB, Strickland P: Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res. 1987, 47: 6052-6057.",{},{"id":26,"text":3078,"url":26,"identifiers":3079},"Kleinberg DL, Feldman M, Ruan W: IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neoplasia. 2000, 5: 7-17. 10.1023\u002FA:1009507030633.",{"doi":3080},"10.1023\u002FA:1009507030633",{"id":26,"text":3082,"url":26,"identifiers":3083},"Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L: Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol. 2001, 229: 163-175. 10.1006\u002Fdbio.2000.9961.",{"doi":3084},"10.1006\u002Fdbio.2000.9961",{"id":26,"text":3086,"url":26,"identifiers":3087},"Fisher CR, Graves KH, Parlow AF, Simpson ER: Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA. 1998, 95: 6965-6970. 10.1073\u002Fpnas.95.12.6965.",{"doi":3088},"10.1073\u002Fpnas.95.12.6965",{"id":26,"text":3090,"url":26,"identifiers":3091},"Richards RG, Klotz DM, Walker MP, Diaugustine RP: Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. Endocrinology. 2004, 145: 3106-3110. 10.1210\u002Fen.2003-1112.",{"doi":3092},"10.1210\u002Fen.2003-1112",{"id":26,"text":3094,"url":26,"identifiers":3095},"Bonnette SG, Hadsell DL: Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology. 2001, 142: 4937-4945. 10.1210\u002Fen.142.11.4937.",{"doi":3096},"10.1210\u002Fendo.142.11.8500",{"id":26,"text":3098,"url":26,"identifiers":3099},"Mueller SO, Clark JA, Myers PH, Korach KS: Mammary gland development in adult mice requires epithelial and stromal estrogen receptor alpha. Endocrinology. 2002, 143: 2357-2365. 10.1210\u002Fen.143.6.2357.",{"doi":3100},"10.1210\u002Fendo.143.6.8836",{"id":26,"text":3102,"url":26,"identifiers":3103},"Ruan W, Monaco ME, Kleinberg DL: Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology. 2005, 146: 1170-1178. 10.1210\u002Fen.2004-1360.",{"doi":3104},"10.1210\u002Fen.2004-1360",{"id":26,"text":3106,"url":26,"identifiers":3107},"Soyal S, Ismail PM, Li J, Mulac-Jericevic B, Conneely OM, Lydon JP: Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics. Breast Cancer Res. 2002, 4: 191-196. 10.1186\u002Fbcr451.",{"doi":3108},"10.1186\u002Fbcr451",{"id":26,"text":3110,"url":26,"identifiers":3111},"Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA: A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci USA. 1998, 95: 5076-5081. 10.1073\u002Fpnas.95.9.5076.",{"doi":3112},"10.1073\u002Fpnas.95.9.5076",{"id":26,"text":3114,"url":26,"identifiers":3115},"Humphreys RC, Lydon J, O'Malley BW, Rosen JM: Mammary gland development is mediated by both stromal and epithelial progesterone receptors. Mol Endocrinol. 1997, 11: 801-811. 10.1210\u002Fme.11.6.801.",{"doi":3116},"10.1210\u002Fmend.11.6.9891",{"id":26,"text":3118,"url":26,"identifiers":3119},"Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA: Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000, 14: 650-654.",{"doi":3120},"10.1101\u002Fgad.14.6.650",{"id":26,"text":3122,"url":26,"identifiers":3123},"Conneely OM, Jericevic BM, Lydon JP: Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2003, 8: 205-214. 10.1023\u002FA:1025952924864.",{"doi":3124},"10.1023\u002FA:1025952924864",{"id":26,"text":3126,"url":26,"identifiers":3127},"Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, et al: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000, 103: 41-50. 10.1016\u002FS0092-8674(00)00103-3.",{"doi":3128},"10.1016\u002FS0092-8674(00)00103-3",{"id":26,"text":3130,"url":26,"identifiers":3131},"Coleman S, Silberstein GB, Daniel CW: Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor. Dev Biol. 1988, 127: 304-315. 10.1016\u002F0012-1606(88)90317-X.",{"doi":3132},"10.1016\u002F0012-1606(88)90317-X",{"id":26,"text":3134,"url":26,"identifiers":3135},"Kenney NJ, Bowman A, Korach KS, Barrett JC, Salomon DS: Effect of exogenous epidermal-like growth factors on mammary gland development and differentiation in the estrogen receptor-alpha knockout (ERKO) mouse. Breast Cancer Res Treat. 2003, 79: 161-173. 10.1023\u002FA:1023938510508.",{"doi":3136},"10.1023\u002FA:1023938510508",{"id":26,"text":3138,"url":26,"identifiers":3139},"Sebastian J, Richards RG, Walker MP, Wiesen JF, Werb Z, Derynck R, Hom YK, Cunha GR, DiAugustine RP: Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ. 1998, 9: 777-785.",{},{"id":26,"text":3141,"url":26,"identifiers":3142},"Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC: Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 1999, 126: 2739-2750.",{"doi":3143},"10.1242\u002Fdev.126.12.2739",{"id":26,"text":3145,"url":26,"identifiers":3146},"Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z: Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development. 2005, 132: 3923-3933. 10.1242\u002Fdev.01966.",{"doi":3147},"10.1242\u002Fdev.01966",{"id":26,"text":3149,"url":26,"identifiers":3150},"Wiseman BS, Sternlicht MD, Lund LR, Alexander CM, Mott J, Bissell MJ, Soloway P, Itohara S, Werb Z: Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol. 2003, 162: 1123-1133. 10.1083\u002Fjcb.200302090.",{"doi":3151},"10.1083\u002Fjcb.200302090",{"id":26,"text":3153,"url":26,"identifiers":3154},"Kheradmand F, Rishi K, Werb Z: Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A\u002FMMP2. J Cell Sci. 2002, 115: 839-848.",{"doi":3155},"10.1242\u002Fjcs.115.4.839",{"id":26,"text":3157,"url":26,"identifiers":3158},"Lu P, Ewald A, Martin G, Werb Z: Essential function of FGF signaling pathway during branching morphogenesis of mammary gland (abstract #515). Dev Biol. 2005, 283: 680-681.",{},{"id":26,"text":3160,"url":26,"identifiers":3161},"Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF: ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA. 2004, 101: 17138-17143. 10.1073\u002Fpnas.0407057101.",{"doi":3162},"10.1073\u002Fpnas.0407057101",{"id":26,"text":3164,"url":26,"identifiers":3165},"Andrechek ER, White D, Muller WJ: Targeted disruption of ErbB2\u002FNeu in the mammary epithelium results in impaired ductal outgrowth. Oncogene. 2005, 24: 932-937. 10.1038\u002Fsj.onc.1208230.",{"doi":3166},"10.1038\u002Fsj.onc.1208230",{"id":26,"text":3168,"url":26,"identifiers":3169},"Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP: Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci USA. 2003, 100: 8281-8286. 10.1073\u002Fpnas.1436402100.",{"doi":3170},"10.1073\u002Fpnas.1436402100",{"id":26,"text":3172,"url":26,"identifiers":3173},"Dunbar ME, Dann P, Brown CW, Van Houton J, Dreyer B, Philbrick WP, Wysolmerski JJ: Temporally regulated overexpression of parathyroid hormone-related protein in the mammary gland reveals distinct fetal and pubertal phenotypes. J Endocrinol. 2001, 171: 403-416. 10.1677\u002Fjoe.0.1710403.",{"doi":3174},"10.1677\u002Fjoe.0.1710403",{"id":26,"text":3176,"url":26,"identifiers":3177},"Srinivasan K, Strickland P, Valdes A, Shin GC, Hinck L: Netrin-1\u002Fneogenin interaction stabilizes multipotent progenitor cap cells during mammary gland morphogenesis. Dev Cell. 2003, 4: 371-382. 10.1016\u002FS1534-5807(03)00054-6.",{"doi":3178},"10.1016\u002FS1534-5807(03)00054-6",{"id":26,"text":3180,"url":26,"identifiers":3181},"Lewis MT: Hedgehog signaling in mouse mammary gland development and neoplasia. J Mammary Gland Biol Neoplasia. 2001, 6: 53-66. 10.1023\u002FA:1009516515338.",{"doi":3182},"10.1023\u002FA:1009516515338",{"id":26,"text":3184,"url":26,"identifiers":3185},"Radisky DC, Hirai Y, Bissell MJ: Delivering the message: epimorphin and mammary epithelial morphogenesis. Trends Cell Biol. 2003, 13: 426-434. 10.1016\u002FS0962-8924(03)00146-6.",{"doi":3186},"10.1016\u002FS0962-8924(03)00146-6",{"id":26,"text":3188,"url":26,"identifiers":3189},"Gouon-Evans V, Lin EY, Pollard JW: Requirement of macrophages and eosinophils and their cytokines\u002Fchemokines for mammary gland development. Breast Cancer Res. 2002, 4: 155-164. 10.1186\u002Fbcr441.",{"doi":3190},"10.1186\u002Fbcr441",{"id":26,"text":3192,"url":26,"identifiers":3193},"Daniel CW, Robinson S, Silberstein GB: The role of TGF-β in patterning and growth of the mammary ductal tree. J Mammary Gland Biol Neoplasia. 1996, 1: 331-341. 10.1007\u002FBF02017389.",{"doi":3194},"10.1007\u002FBF02017389",{"id":26,"text":3196,"url":26,"identifiers":3197},"Ewan KB, Shyamala G, Ravani SA, Tang Y, Akhurst R, Wakefield L, Barcellos-Hoff MH: Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am J Pathol. 2002, 160: 2081-2093.",{"doi":3198},"10.1016\u002FS0002-9440(10)61158-3",{"id":26,"text":3200,"url":26,"identifiers":3201},"Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146\u002Fannurev.cellbio.17.1.463.",{"doi":3202},"10.1146\u002Fannurev.cellbio.17.1.463",{"id":26,"text":3204,"url":26,"identifiers":3205},"Fata JE, Werb Z, Bissell MJ: Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res. 2004, 6: 1-11.",{"doi":3206},"10.1186\u002Fbcr634",{"id":26,"text":3208,"url":26,"identifiers":3209},"Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM: The α2 integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol. 2002, 161: 337-344.",{"doi":3210},"10.1016\u002FS0002-9440(10)64185-5",{"id":26,"text":3212,"url":26,"identifiers":3213},"Klinowska TC, Soriano JV, Edwards GM, Oliver JM, Valentijn AJ, Montesano R, Streuli CH: Laminin and β1 integrins are crucial for normal mammary gland development in the mouse. Dev Biol. 1999, 215: 13-32. 10.1006\u002Fdbio.1999.9435.",{"doi":3214},"10.1006\u002Fdbio.1999.9435",{"id":26,"text":3216,"url":26,"identifiers":3217},"Klinowska TC, Alexander CM, Georges-Labouesse E, Van der Neut R, Kreidberg JA, Jones CJ, Sonnenberg A, Streuli CH: Epithelial development and differentiation in the mammary gland is not dependent on α3 or α6 integrin subunits. Dev Biol. 2001, 233: 449-467. 10.1006\u002Fdbio.2001.0204.",{"doi":3218},"10.1006\u002Fdbio.2001.0204",{"id":26,"text":3220,"url":26,"identifiers":3221},"Vogel WF, Aszodi A, Alves F, Pawson T: Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol. 2001, 21: 2906-2917. 10.1128\u002FMCB.21.8.2906-2917.2001.",{"doi":3222},"10.1128\u002FMCB.21.8.2906-2917.2001",{"id":26,"text":3224,"url":26,"identifiers":3225},"Hathaway HJ, Shur BD: Mammary gland morphogenesis is inhibited in transgenic mice that overexpress cell surface β1,4-galactosyltransferase. Development. 1996, 122: 2859-2872.",{"doi":3226},"10.1242\u002Fdev.122.9.2859",{"id":26,"text":3228,"url":26,"identifiers":3229},"Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ: A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res. 2002, 62: 7102-7109.",{},{"id":26,"text":3231,"url":26,"identifiers":3232},"Sakai T, Larsen M, Yamada KM: Fibronectin requirement in branching morphogenesis. Nature. 2003, 423: 876-881. 10.1038\u002Fnature01712.",{"doi":3233},"10.1038\u002Fnature01712",{"id":26,"text":3235,"url":26,"identifiers":3236},"Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW: Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci. 2002, 115: 39-50.",{"doi":3237},"10.1242\u002Fjcs.115.1.39",{"id":26,"text":3239,"url":26,"identifiers":3240},"Runswick SK, O'Hare MJ, Jones L, Streuli CH, Garrod DR: Desmosomal adhesion regulates epithelial morphogenesis and cell positioning. Nat Cell Biol. 2001, 3: 823-830. 10.1038\u002Fncb0901-823.",{"doi":3241},"10.1038\u002Fncb0901-823",{"id":3243,"createTime":3244,"updateTime":3245,"relativeEntities":3246,"slug":3247,"properties":3248,"entityType":778,"verifyStatus":25,"verifyTime":3245,"verifyNote":779,"syncStatus":28,"languages":3263,"translateLanguages":26,"viewCount":36,"primaryUrl":3264,"fullTextUrl":26,"authors":3265,"publicationType":849,"publisherRelationship":3435,"citationCount":3463,"citationInfo":3464,"publishDate":3466,"publishYear":3467,"citationAnalyzeStatus":886,"lastCitationAnalyze":3468,"indexDatabases":26,"openAccess":26,"references":3469,"isForceReanalyzing":1211},"6808addd-0514-4b83-aaa8-3765a1429e98","2024-04-14T08:14:43.661+00:00","2025-02-09T07:06:44.178+00:00",[],"Transcriptome-analyses-of-mouse-and-human-mammary-cell-subpopulations-reveal-multiple-conserved-genes-and-pathways",{"mag":3249,"keywords":3251,"pmc":3252,"openalex":3254,"abstract":3256,"title":3257,"pm":3259,"doi":3261},{"VOID":3250},"2160779973",{},{"VOID":3253},"2879567",{"VOID":3255},"W2160779973",{},{"EN":3258},"Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways",{"VOID":3260},"20346151",{"VOID":3262},"10.1186\u002Fbcr2560",[102],"http:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr2560",[3266,3287,3308,3322,3336,3352,3368,3384,3405,3419],{"id":3267,"sortIndex":50,"researcher":26,"roles":3268,"affiliations":3269,"properties":3280},"324a30c0-77f1-428e-a13c-9ed04398f830",[],[3270],{"id":26,"sortIndex":36,"affiliation":3271,"properties":26},{"id":3272,"createTime":3273,"updateTime":3274,"relativeEntities":3275,"slug":3276,"properties":3277,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"279c111b-4cc3-4373-94d1-35cb0807a807","2024-01-05T14:07:05.095+00:00","2024-09-29T17:33:15.244+00:00",[],"Department-of-Medical-Biology-The-University-of-Melbourne-Parkville-VIC-3010-Australia",{"title":3278},{"VI":3279},"Department of Medical Biology, The University of Melbourne, Parkville, VIC, 3010, Australia",{"openalex":3281,"orcid":3283,"title":3285},{"VOID":3282},"A5053608981",{"VOID":3284},"https:\u002F\u002Forcid.org\u002F0000-0001-9221-2892",{"EN":3286},"Gordon K. Smyth",{"id":3288,"sortIndex":158,"researcher":26,"roles":3289,"affiliations":3290,"properties":3301},"9cd6e2bf-58fe-4473-90fd-95c1291b456f",[],[3291],{"id":26,"sortIndex":36,"affiliation":3292,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3296,"slug":3297,"properties":3298,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"2e3de4b2-2204-4502-a962-f9a0032f45f5","2024-01-01T16:34:03.099+00:00","2025-02-04T09:18:14.630+00:00",[],"The-Walter-and-Eliza-Hall-Institute-of-Medical-Research-1G-Royal-Parade-Parkville-VIC-3052-Australia",{"title":3299},{"VI":3300},"The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia",{"openalex":3302,"orcid":3304,"title":3306},{"VOID":3303},"A5079753000",{"VOID":3305},"https:\u002F\u002Forcid.org\u002F0000-0001-9386-2416",{"EN":3307},"Geoffrey J. Lindeman",{"id":3309,"sortIndex":111,"researcher":26,"roles":3310,"affiliations":3311,"properties":3317},"bd7569b3-bebe-4d34-b183-5ced0c892c8f",[],[3312],{"id":26,"sortIndex":36,"affiliation":3313,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3314,"slug":3297,"properties":3315,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3316},{"VI":3300},{"openalex":3318,"title":3320},{"VOID":3319},"A5019239188",{"EN":3321},"Marie Liesse Asselin-Labat",{"id":3323,"sortIndex":162,"researcher":26,"roles":3324,"affiliations":3325,"properties":3331},"7cc13e40-8865-4fe1-83df-4432cadaa8a2",[],[3326],{"id":26,"sortIndex":36,"affiliation":3327,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3328,"slug":3297,"properties":3329,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3330},{"VI":3300},{"openalex":3332,"title":3334},{"VOID":3333},"A5064405368",{"EN":3335},"François Vaillant",{"id":3337,"sortIndex":36,"researcher":26,"roles":3338,"affiliations":3339,"properties":3345},"459735f6-4491-4bc1-a365-560b7a37c506",[],[3340],{"id":26,"sortIndex":36,"affiliation":3341,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3342,"slug":3297,"properties":3343,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3344},{"VI":3300},{"openalex":3346,"orcid":3348,"title":3350},{"VOID":3347},"A5088828593",{"VOID":3349},"https:\u002F\u002Forcid.org\u002F0000-0001-8065-8838",{"EN":3351},"Elgene Lim",{"id":3353,"sortIndex":115,"researcher":26,"roles":3354,"affiliations":3355,"properties":3361},"5f4db0d6-bfb5-4fb9-82ed-6285fbce6ea1",[],[3356],{"id":26,"sortIndex":36,"affiliation":3357,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3358,"slug":3297,"properties":3359,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3360},{"VI":3300},{"openalex":3362,"orcid":3364,"title":3366},{"VOID":3363},"A5008365894",{"VOID":3365},"https:\u002F\u002Forcid.org\u002F0000-0002-6701-9545",{"EN":3367},"Di Wu",{"id":3369,"sortIndex":114,"researcher":26,"roles":3370,"affiliations":3371,"properties":3377},"676d3422-72b5-4a68-a153-1f79291190e1",[],[3372],{"id":26,"sortIndex":36,"affiliation":3373,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3374,"slug":3297,"properties":3375,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3376},{"VI":3300},{"openalex":3378,"orcid":3380,"title":3382},{"VOID":3379},"A5076938587",{"VOID":3381},"https:\u002F\u002Forcid.org\u002F0000-0002-3684-4331",{"EN":3383},"Bhupinder Pal",{"id":3385,"sortIndex":135,"researcher":26,"roles":3386,"affiliations":3387,"properties":3398},"86b83e9f-7c5e-4461-b1aa-fa7fe0ba7d9f",[],[3388],{"id":26,"sortIndex":36,"affiliation":3389,"properties":26},{"id":3390,"createTime":3391,"updateTime":3392,"relativeEntities":3393,"slug":3394,"properties":3395,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1e2712e5-56c4-49a3-96f1-c0160b54f2b5","2023-12-05T06:52:40.107+00:00","2024-10-15T10:54:22.279+00:00",[],"Department-of-Immunology-Juntendo-University-School-of-Medicine-2-1-1-Hongo-Bunkyo-ku-Tokyo-113-8421-Japan",{"title":3396},{"VI":3397},"Department of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan",{"openalex":3399,"orcid":3401,"title":3403},{"VOID":3400},"A5070494006",{"VOID":3402},"https:\u002F\u002Forcid.org\u002F0000-0003-4279-9343",{"EN":3404},"Hideo Yagita",{"id":3406,"sortIndex":59,"researcher":26,"roles":3407,"affiliations":3408,"properties":3414},"2afc588f-e0a0-4f96-a305-3e5057008317",[],[3409],{"id":26,"sortIndex":36,"affiliation":3410,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3411,"slug":3297,"properties":3412,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3413},{"VI":3300},{"openalex":3415,"title":3417},{"VOID":3416},"A5071690501",{"EN":3418},"Toula Bouras",{"id":3420,"sortIndex":52,"researcher":26,"roles":3421,"affiliations":3422,"properties":3428},"a5603a3c-c605-4ced-8c50-c250041c8814",[],[3423],{"id":26,"sortIndex":36,"affiliation":3424,"properties":26},{"id":3293,"createTime":3294,"updateTime":3295,"relativeEntities":3425,"slug":3297,"properties":3426,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3427},{"VI":3300},{"openalex":3429,"orcid":3431,"title":3433},{"VOID":3430},"A5013309333",{"VOID":3432},"https:\u002F\u002Forcid.org\u002F0000-0001-9173-6977",{"EN":3434},"Jane E. Visvader",{"url":26,"publisher":3436,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3437,"slug":663,"properties":3438,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3441,"manageAffiliations":3442,"indexDatabases":3443,"url":746,"thumbnailPath":26,"statistic":3458,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":3439,"title":3440},{"VOID":666},{"EN":668},[],[],[3444,3451],{"id":727,"indexDatabase":3445,"url":740,"indexYears":741,"academicFieldIds":3450,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":3446,"label":3447,"description":3448,"key":737,"publicationTags":3449,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":3452,"url":723,"indexYears":26,"academicFieldIds":3457,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":3453,"label":3454,"description":3455,"key":719,"publicationTags":3456,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":3459,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":3460,"totalCitation":36,"totalCitationByYear":3461,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":3462,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},366,{"total":3463,"publishYear":26,"statisticByYear":3465},{"2012":240,"2013":241,"2014":287,"2015":285,"2016":287,"2017":239,"2018":241,"2019":255,"2020":244,"2021":241,"2022":260,"2023":336,"2024":114},"2010-04-01",2010,"2024-04-14T20:12:42.774+00:00",[3470,3474,3478,3480,3482,3486,3490,3494,3498,3502,3506,3510,3514,3518,3522,3526,3530,3533,3537,3540,3544,3547,3551,3555,3559,3562,3565,3569,3573,3577,3581,3585,3589,3593,3597,3601,3605,3609,3613,3617,3621,3625,3629],{"id":26,"text":3471,"url":26,"identifiers":3472},"Visvader JE: Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009, 23: 2563-2577. 10.1101\u002Fgad.1849509.",{"doi":3473},"10.1101\u002Fgad.1849509",{"id":26,"text":3475,"url":26,"identifiers":3476},"Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, Wees van der J, Lindeman GJ, Visvader JE: Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007, 9: 201-209. 10.1038\u002Fncb1530.",{"doi":3477},"10.1038\u002Fncb1530",{"id":26,"text":1630,"url":26,"identifiers":3479},{"doi":1632},{"id":26,"text":1626,"url":26,"identifiers":3481},{"doi":1628},{"id":26,"text":3483,"url":26,"identifiers":3484},"Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ: Purification and unique properties of mammary epithelial stem cells. Nature. 2006, 439: 993-997.",{"doi":3485},"10.1038\u002Fnature04496",{"id":26,"text":3487,"url":26,"identifiers":3488},"Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT, Eaves CJ: A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med. 2008, 14: 1384-1389. 10.1038\u002Fnm.1791.",{"doi":3489},"10.1038\u002Fnm.1791",{"id":26,"text":3491,"url":26,"identifiers":3492},"Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009, 15: 907-913. 10.1038\u002Fnm.2000.",{"doi":3493},"10.1038\u002Fnm.2000",{"id":26,"text":3495,"url":26,"identifiers":3496},"Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007, 11: 259-273. 10.1016\u002Fj.ccr.2007.01.013.",{"doi":3497},"10.1016\u002Fj.ccr.2007.01.013",{"id":26,"text":3499,"url":26,"identifiers":3500},"Stingl J, Eaves CJ, Zandieh I, Emerman JT: Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat. 2001, 67: 93-109. 10.1023\u002FA:1010615124301.",{"doi":3501},"10.1023\u002FA:1010615124301",{"id":26,"text":3503,"url":26,"identifiers":3504},"Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, Bissell MJ, Petersen OW: Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol. 2007, 177: 87-101. 10.1083\u002Fjcb.200611114.",{"doi":3505},"10.1083\u002Fjcb.200611114",{"id":26,"text":3507,"url":26,"identifiers":3508},"Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, Iscove N, Jones S, McKinney S, Emerman J, Aparicio S, Marra M, Eaves C: Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell. 2008, 3: 109-118. 10.1016\u002Fj.stem.2008.05.018.",{"doi":3509},"10.1016\u002Fj.stem.2008.05.018",{"id":26,"text":3511,"url":26,"identifiers":3512},"Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ: Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006, 98: 1011-1014. 10.1093\u002Fjnci\u002Fdjj267.",{"doi":3513},"10.1093\u002Fjnci\u002Fdjj267",{"id":26,"text":3515,"url":26,"identifiers":3516},"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13: 2329-2334. 10.1158\u002F1078-0432.CCR-06-1109.",{"doi":3517},"10.1158\u002F1078-0432.CCR-06-1109",{"id":26,"text":3519,"url":26,"identifiers":3520},"Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8: R76-10.1186\u002Fgb-2007-8-5-r76.",{"doi":3521},"10.1186\u002Fgb-2007-8-5-r76",{"id":26,"text":3523,"url":26,"identifiers":3524},"Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M, Smalley MJ: Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics. 2008, 9: 591-10.1186\u002F1471-2164-9-591.",{"doi":3525},"10.1186\u002F1471-2164-9-591",{"id":26,"text":3527,"url":26,"identifiers":3528},"Noto K, Kato K, Okumura K, Yagita H: Identification and functional characterization of mouse CD29 with a mAb. Int Immunol. 1995, 7: 835-842. 10.1093\u002Fintimm\u002F7.5.835.",{"doi":3529},"10.1093\u002Fintimm\u002F7.5.835",{"id":26,"text":3531,"url":26,"identifiers":3532},"WEASEL for Flow Cytometry Data Analysis. [ http:\u002F\u002Fwww.wehi.edu.au\u002Ffaculty\u002Fadvanced_research_technologies\u002Fflow_cytometry\u002Fweasel_for_flow_cytometry_data_analysis\u002F ]",{},{"id":26,"text":3534,"url":26,"identifiers":3535},"Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80-10.1186\u002Fgb-2004-5-10-r80.",{"doi":3536},"10.1186\u002Fgb-2004-5-10-r80",{"id":26,"text":3538,"url":26,"identifiers":3539},"Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article 3",{},{"id":26,"text":3541,"url":26,"identifiers":3542},"Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK: A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007, 23: 2700-2707. 10.1093\u002Fbioinformatics\u002Fbtm412.",{"doi":3543},"10.1093\u002Fbioinformatics\u002Fbtm412",{"id":26,"text":3545,"url":26,"identifiers":3546},"Gene Expression Omnibus. [ http:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fgeo ]",{},{"id":26,"text":3548,"url":26,"identifiers":3549},"Smyth GK, Speed T: Normalization of cDNA microarray data. Methods. 2003, 31: 265-273. 10.1016\u002FS1046-2023(03)00155-5.",{"doi":3550},"10.1016\u002FS1046-2023(03)00155-5",{"id":26,"text":3552,"url":26,"identifiers":3553},"Ritchie ME, Diyagama D, Neilson J, van Laar R, Dobrovic A, Holloway A, Smyth GK: Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics. 2006, 7: 261-10.1186\u002F1471-2105-7-261.",{"doi":3554},"10.1186\u002F1471-2105-7-261",{"id":26,"text":3556,"url":26,"identifiers":3557},"Smyth GK, Michaud J, Scott HS: Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005, 21: 2067-2075. 10.1093\u002Fbioinformatics\u002Fbti270.",{"doi":3558},"10.1093\u002Fbioinformatics\u002Fbti270",{"id":26,"text":3560,"url":26,"identifiers":3561},"Mouse Genomics Informatics - Mammalian Orthology. [ http:\u002F\u002Fwww.informatics.jax.org\u002Forthology.shtml ]",{},{"id":26,"text":3563,"url":26,"identifiers":3564},"Ingenuity Systems. [ http:\u002F\u002Fwww.ingenuity.com ]",{},{"id":26,"text":3566,"url":26,"identifiers":3567},"Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000, 19: 968-988. 10.1038\u002Fsj.onc.1203277.",{"doi":3568},"10.1038\u002Fsj.onc.1203277",{"id":26,"text":3570,"url":26,"identifiers":3571},"Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ, Visvader JE: Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell. 2008, 3: 429-441. 10.1016\u002Fj.stem.2008.08.001.",{"doi":3572},"10.1016\u002Fj.stem.2008.08.001",{"id":26,"text":3574,"url":26,"identifiers":3575},"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016\u002Fj.stem.2007.08.014.",{"doi":3576},"10.1016\u002Fj.stem.2007.08.014",{"id":26,"text":3578,"url":26,"identifiers":3579},"Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69: 1302-1313. 10.1158\u002F0008-5472.CAN-08-2741.",{"doi":3580},"10.1158\u002F0008-5472.CAN-08-2741",{"id":26,"text":3582,"url":26,"identifiers":3583},"Hsu SY, Kudo M, Chen T, Nakabayashi K, Bhalla A, Spek van der PJ, van Duin M, Hsueh AJ: The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol. 2000, 14: 1257-1271. 10.1210\u002Fme.14.8.1257.",{"doi":3584},"10.1210\u002Fmend.14.8.0510",{"id":26,"text":3586,"url":26,"identifiers":3587},"Barker N, van Es JH, Kuipers J, Kujala P, Born van den M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007, 449: 1003-1007. 10.1038\u002Fnature06196.",{"doi":3588},"10.1038\u002Fnature06196",{"id":26,"text":3590,"url":26,"identifiers":3591},"Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-890. 10.1016\u002Fj.cell.2009.11.007.",{"doi":3592},"10.1016\u002Fj.cell.2009.11.007",{"id":26,"text":3594,"url":26,"identifiers":3595},"DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C: A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69: 5364-5373. 10.1158\u002F0008-5472.CAN-08-4135.",{"doi":3596},"10.1158\u002F0008-5472.CAN-08-4135",{"id":26,"text":3598,"url":26,"identifiers":3599},"Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14: 8010-8018. 10.1158\u002F1078-0432.CCR-08-1208.",{"doi":3600},"10.1158\u002F1078-0432.CCR-08-1208",{"id":26,"text":3602,"url":26,"identifiers":3603},"Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ: The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev. 2008, 22: 581-586. 10.1101\u002Fgad.1614608.",{"doi":3604},"10.1101\u002Fgad.1614608",{"id":26,"text":3606,"url":26,"identifiers":3607},"Holick MF: Vitamin D deficiency. N Engl J Med. 2007, 357: 266-281. 10.1056\u002FNEJMra070553.",{"doi":3608},"10.1056\u002FNEJMra070553",{"id":26,"text":3610,"url":26,"identifiers":3611},"Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\u002FCXCL12 secretion. Cell. 2005, 121: 335-348. 10.1016\u002Fj.cell.2005.02.034.",{"doi":3612},"10.1016\u002Fj.cell.2005.02.034",{"id":26,"text":3614,"url":26,"identifiers":3615},"Sum EY, Segara D, Duscio B, Bath ML, Field AS, Sutherland RL, Lindeman GJ, Visvader JE: Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci USA. 2005, 102: 7659-7664. 10.1073\u002Fpnas.0502990102.",{"doi":3616},"10.1073\u002Fpnas.0502990102",{"id":26,"text":3618,"url":26,"identifiers":3619},"Visvader JE, Venter D, Hahm K, Santamaria M, Sum EY, O'Reilly L, White D, Williams R, Armes J, Lindeman GJ: The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci USA. 2001, 98: 14452-14457. 10.1073\u002Fpnas.251547698.",{"doi":3620},"10.1073\u002Fpnas.251547698",{"id":26,"text":3622,"url":26,"identifiers":3623},"Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF: Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells. 2008, 26: 364-371. 10.1634\u002Fstemcells.2007-0440.",{"doi":3624},"10.1634\u002Fstemcells.2007-0440",{"id":26,"text":3626,"url":26,"identifiers":3627},"Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE: The mammary progenitor marker CD61\u002Fbeta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68: 7711-7717. 10.1158\u002F0008-5472.CAN-08-1949.",{"doi":3628},"10.1158\u002F0008-5472.CAN-08-1949",{"id":26,"text":3630,"url":26,"identifiers":3631},"Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM: Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008, 68: 4674-4682. 10.1158\u002F0008-5472.CAN-07-6353.",{"doi":3632},"10.1158\u002F0008-5472.CAN-07-6353",{"id":3634,"createTime":3635,"updateTime":3635,"relativeEntities":3636,"slug":3637,"properties":3638,"entityType":778,"verifyStatus":25,"verifyTime":3635,"verifyNote":779,"syncStatus":28,"languages":3653,"translateLanguages":26,"viewCount":36,"primaryUrl":3654,"fullTextUrl":26,"authors":3655,"publicationType":849,"publisherRelationship":3830,"citationCount":3862,"citationInfo":3863,"publishDate":26,"publishYear":26,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":3865,"isForceReanalyzing":1211},"a830cf47-fb22-4f76-9c4d-6e158a8e748c","2024-10-04T10:33:35.674+00:00",[],"Involution-of-the-mouse-mammary-gland-is-associated-with-an-immune-cascade-and-an-acute-phase-response-involving-LBP-CD14-and-STAT3",{"mag":3639,"keywords":3641,"pmc":3642,"openalex":3644,"abstract":3646,"title":3647,"pm":3649,"doi":3651},{"VOID":3640},"1828930947",{},{"VOID":3643},"400652",{"VOID":3645},"W1828930947",{},{"EN":3648},"Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3",{"VOID":3650},"14979920",{"VOID":3652},"10.1186\u002Fbcr753",[102],"https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr753",[3656,3678,3693,3710,3729,3744,3761,3778,3798,3815],{"id":3657,"sortIndex":135,"researcher":26,"roles":3658,"affiliations":3659,"properties":3671},"6a159fd2-96e3-49eb-9033-2e74a212b0ca",[],[3660],{"id":3661,"sortIndex":36,"affiliation":3662,"properties":26},"7145577c-d745-45cf-9d8f-e930f6092d38",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3666,"slug":3667,"properties":3668,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1d8f5bf8-7668-4222-9be6-d289b490c9ae","2023-12-22T03:11:36.052+00:00","2024-10-04T10:33:35.684+00:00",[],"Division-of-Cancer-Sciences-and-Molecular-Pathology-Western-Infirmary-University-of-Glasgow-Glasgow-UK",{"title":3669},{"VI":3670},"Division of Cancer Sciences and Molecular Pathology, Western Infirmary, University of Glasgow, Glasgow, UK",{"openalex":3672,"orcid":3674,"title":3676},{"VOID":3673},"A5002664251",{"VOID":3675},"https:\u002F\u002Forcid.org\u002F0000-0001-8933-8494",{"EN":3677},"Alison M. Bell",{"id":3679,"sortIndex":162,"researcher":26,"roles":3680,"affiliations":3681,"properties":3688},"03c5d43d-2e13-4dde-9614-ca21408803dc",[],[3682],{"id":3683,"sortIndex":36,"affiliation":3684,"properties":26},"7b6e9de2-5abc-4c8f-afad-c2ff2da15e60",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3685,"slug":3667,"properties":3686,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3687},{"VI":3670},{"openalex":3689,"title":3691},{"VOID":3690},"A5008206855",{"EN":3692},"Victoria J. Heath",{"id":3694,"sortIndex":115,"researcher":26,"roles":3695,"affiliations":3696,"properties":3703},"3bf53f3a-cbfb-461d-bedd-a89fca62a0d9",[],[3697],{"id":3698,"sortIndex":36,"affiliation":3699,"properties":26},"b61b5990-a2be-415d-94c0-7ca6243d0b67",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3700,"slug":3667,"properties":3701,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3702},{"VI":3670},{"openalex":3704,"orcid":3706,"title":3708},{"VOID":3705},"A5063125795",{"VOID":3707},"https:\u002F\u002Forcid.org\u002F0000-0001-5975-2475",{"EN":3709},"Joanna S. Morris",{"id":3711,"sortIndex":59,"researcher":26,"roles":3712,"affiliations":3713,"properties":3724},"48288cb2-cccd-4a85-8424-4189f0ff6ed1",[],[3714],{"id":3715,"sortIndex":36,"affiliation":3716,"properties":26},"db23e9a1-4540-4c6f-86e5-0cf2b4db2242",{"id":3717,"createTime":3718,"updateTime":3718,"relativeEntities":3719,"slug":3720,"properties":3721,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"80e0901d-34b4-4c51-a7cb-7f6dd15685d6","2024-10-04T10:33:35.699+00:00",[],"Abbott-Laboratories-Limited-Diagnostic-Division-Maidenhead-UK",{"title":3722},{"EN":3723},"Abbott Laboratories Limited, Diagnostic Division, Maidenhead, UK",{"openalex":3725,"title":3727},{"VOID":3726},"A5060028034",{"EN":3728},"Stephen J. Weber-Hall",{"id":3730,"sortIndex":52,"researcher":26,"roles":3731,"affiliations":3732,"properties":3739},"7eae1b8a-aac6-4a99-a038-d9a77386fcb0",[],[3733],{"id":3734,"sortIndex":36,"affiliation":3735,"properties":26},"4ec057fe-a73c-44cc-aad7-e0ca78ade95f",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3736,"slug":3667,"properties":3737,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3738},{"VI":3670},{"openalex":3740,"title":3742},{"VOID":3741},"A5013318026",{"EN":3743},"Barry A. Gusterson",{"id":3745,"sortIndex":111,"researcher":26,"roles":3746,"affiliations":3747,"properties":3754},"d8e9ef73-129b-4aab-84d0-32835f6f2500",[],[3748],{"id":3749,"sortIndex":36,"affiliation":3750,"properties":26},"3bf94ca6-0adc-4ae3-a8b8-e6be955a492e",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3751,"slug":3667,"properties":3752,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3753},{"VI":3670},{"openalex":3755,"orcid":3757,"title":3759},{"VOID":3756},"A5026223610",{"VOID":3758},"https:\u002F\u002Forcid.org\u002F0000-0002-1358-4610",{"EN":3760},"Marie Anne Pringle",{"id":3762,"sortIndex":36,"researcher":26,"roles":3763,"affiliations":3764,"properties":3771},"31ee59a9-7616-434e-a0af-48fe8b990833",[],[3765],{"id":3766,"sortIndex":36,"affiliation":3767,"properties":26},"26693106-4528-40cb-8e95-79794bac3907",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3768,"slug":3667,"properties":3769,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3770},{"VI":3670},{"openalex":3772,"orcid":3774,"title":3776},{"VOID":3773},"A5042322496",{"VOID":3775},"https:\u002F\u002Forcid.org\u002F0000-0002-9946-1549",{"EN":3777},"Torsten Stein",{"id":3779,"sortIndex":50,"researcher":26,"roles":3780,"affiliations":3781,"properties":3793},"3a4cb01c-57ba-4cf8-9c00-fa92fba5fc36",[],[3782],{"id":3783,"sortIndex":36,"affiliation":3784,"properties":26},"66f33b85-1adf-4b9a-9786-2449454c8588",{"id":3785,"createTime":3786,"updateTime":3787,"relativeEntities":3788,"slug":3789,"properties":3790,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"bd3a902d-1066-418a-b0e9-6e884ae3d873","2024-01-17T11:07:02.199+00:00","2024-10-04T10:33:35.723+00:00",[],"Department-of-Pathology-Western-Infirmary-Glasgow-UK",{"title":3791},{"VI":3792},"Department of Pathology, Western Infirmary, Glasgow, UK",{"openalex":3794,"title":3796},{"VOID":3795},"A5010348036",{"EN":3797},"G. P. Sandilands",{"id":3799,"sortIndex":114,"researcher":26,"roles":3800,"affiliations":3801,"properties":3808},"88b7b498-ffc1-4c08-80ba-e3f51118c4b4",[],[3802],{"id":3803,"sortIndex":36,"affiliation":3804,"properties":26},"8cc9f29d-2f8e-4ab8-a3f1-a258380eabcb",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3805,"slug":3667,"properties":3806,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3807},{"VI":3670},{"openalex":3809,"orcid":3811,"title":3813},{"VOID":3810},"A5102728673",{"VOID":3812},"https:\u002F\u002Forcid.org\u002F0000-0001-8498-4593",{"EN":3814},"Claire Davies",{"id":3816,"sortIndex":158,"researcher":26,"roles":3817,"affiliations":3818,"properties":3825},"e1985ecb-540f-42a1-a241-ed47660c8314",[],[3819],{"id":3820,"sortIndex":36,"affiliation":3821,"properties":26},"18bc0231-b3bb-4eaa-b504-547261c1c7e1",{"id":3663,"createTime":3664,"updateTime":3665,"relativeEntities":3822,"slug":3667,"properties":3823,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":3824},{"VI":3670},{"openalex":3826,"title":3828},{"VOID":3827},"A5059394861",{"EN":3829},"Roderick K. Ferrier",{"url":26,"publisher":3831,"properties":3858},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3832,"slug":663,"properties":3833,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3836,"manageAffiliations":3837,"indexDatabases":3838,"url":746,"thumbnailPath":26,"statistic":3853,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":3834,"title":3835},{"VOID":666},{"EN":668},[],[],[3839,3846],{"id":727,"indexDatabase":3840,"url":740,"indexYears":741,"academicFieldIds":3845,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":3841,"label":3842,"description":3843,"key":737,"publicationTags":3844,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":3847,"url":723,"indexYears":26,"academicFieldIds":3852,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":3848,"label":3849,"description":3850,"key":719,"publicationTags":3851,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":3854,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":3855,"totalCitation":36,"totalCitationByYear":3856,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":3857,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},{"volume":3859,"issue":3860},{"VOID":1771},{"VOID":3861},"2",358,{"total":3862,"publishYear":26,"statisticByYear":3864},{"2012":234,"2013":336,"2014":516,"2015":173,"2016":124,"2017":336,"2018":242,"2019":51,"2020":51,"2021":336,"2022":356,"2023":50,"2024":53},[3866,3870,3874,3878,3882,3886,3890,3894,3897,3901,3905,3909,3913,3917,3921,3925,3929,3933,3937,3941,3945,3949,3953,3957,3960,3964,3968,3972,3976,3980,3984,3988,3992,3996,4000,4004,4008,4012,4015,4019,4023,4027,4031,4035,4039,4043,4047,4051,4055,4058,4062,4066,4070,4074,4078,4082,4086,4090,4094,4098,4102,4106,4109,4113,4117],{"id":26,"text":3867,"url":26,"identifiers":3868},"Richert MM, Schwertfeger KL, Ryder JW, Anderson SM: An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia. 2000, 5: 227-241. 10.1023\u002FA:1026499523505.",{"doi":3869},"10.1023\u002FA:1026499523505",{"id":26,"text":3871,"url":26,"identifiers":3872},"Masso-Welch PA, Darcy KM, Stangle-Castor NC, Ip MM: A developmental atlas of rat mammary gland histology. J Mammary Gland Biol Neoplasia. 2000, 5: 165-185. 10.1023\u002FA:1026491221687.",{"doi":3873},"10.1023\u002FA:1026491221687",{"id":26,"text":3875,"url":26,"identifiers":3876},"Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z: Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development. 1996, 122: 181-193.",{"doi":3877},"10.1242\u002Fdev.122.1.181",{"id":26,"text":3879,"url":26,"identifiers":3880},"Li M, Liu X, Robinson G, Bar-Paled U, Wagner K-U, Young WS, Hennighausen L, Furth PA: Mammary derived signals activate programmed cell during the involuting mammary gland. Proc Natl Acad Sci USA. 1997, 94: 3425-3430. 10.1073\u002Fpnas.94.7.3425.",{"doi":3881},"10.1073\u002Fpnas.94.7.3425",{"id":26,"text":3883,"url":26,"identifiers":3884},"Marti A, Lazar H, Ritter P, Jaggi R: Transcription factor activities and gene expression during mouse mammary gland involution. J Mammary Gland Biol Neoplasia. 1999, 4: 145-152. 10.1023\u002FA:1018721107061.",{"doi":3885},"10.1023\u002FA:1018721107061",{"id":26,"text":3887,"url":26,"identifiers":3888},"Master SR, Hartman JL, D'Cruz CM, Moody SE, Keiper EA, Ha SI, Cox JD, Belka GK, Chodosh LA: Functional microarray analysis of mammary organogenesis reveals a developmental role in adaptive thermogenesis. Mol Endocrinol. 2000, 16: 1185-1203. 10.1210\u002Fme.16.6.1185.",{"doi":3889},"10.1210\u002Fmend.16.6.0865",{"id":26,"text":3891,"url":26,"identifiers":3892},"Clarkson RWE, Wayland MT, Lee J, Freeman T, Watson CJ: Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004, 6: R92-R109. 10.1186\u002Fbcr754.",{"doi":3893},"10.1186\u002Fbcr754",{"id":26,"text":3895,"url":26,"identifiers":3896},"Eckersall PD: Recent advances and future prospects for the use of acute phase proteins as markers of disease in animals. Revue Méd Vét. 2000, 151: 577-584.",{},{"id":26,"text":3898,"url":26,"identifiers":3899},"Dinarello CA: Interleukin-1 and the pathogenesis of the acute phase response. New Engl J Med. 1984, 311: 1413-1418.",{"doi":3900},"10.1056\u002FNEJM198411293112205",{"id":26,"text":3902,"url":26,"identifiers":3903},"Heinrich PC, Castell JC, Andus T: Interleukin-6 and the acute phase response. Biochem J. 1990, 265: 621-636.",{"doi":3904},"10.1042\u002Fbj2650621",{"id":26,"text":3906,"url":26,"identifiers":3907},"Beutler B, Cerami A: Cachectin\u002Ftumor necrosis factor: an endogenous mediator of shock and inflammation. Immunol Res. 1986, 5: 281-293.",{"doi":3908},"10.1007\u002FBF02935501",{"id":26,"text":3910,"url":26,"identifiers":3911},"Anderson JC: The increased resistance of mice to experimental staphylococcal mastitis following inoculation of endotoxin. Res Vet Sci. 1976, 21: 64-68.",{"doi":3912},"10.1016\u002FS0034-5288(18)33395-2",{"id":26,"text":3914,"url":26,"identifiers":3915},"Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ: Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999, 13: 2604-2616. 10.1101\u002Fgad.13.19.2604.",{"doi":3916},"10.1101\u002Fgad.13.19.2604",{"id":26,"text":3918,"url":26,"identifiers":3919},"Humphreys RC, Bierie B, Zhao L, Raz R, Levy D, Hennighausen L: Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology. 2002, 143: 3641-3650. 10.1210\u002Fen.2002-220224.",{"doi":3920},"10.1210\u002Fen.2002-220224",{"id":26,"text":3922,"url":26,"identifiers":3923},"Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruta M, Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994, 77: 63-71.",{"doi":3924},"10.1016\u002F0092-8674(94)90235-6",{"id":26,"text":3926,"url":26,"identifiers":3927},"Zhong Z, Wen Z, Darnell JE: Stat3: a new family member that is activated through tyrosine phosphorylation in response to EGF and IL-6. Science. 1994, 264: 95-98.",{"doi":3928},"10.1126\u002Fscience.8140422",{"id":26,"text":3930,"url":26,"identifiers":3931},"Trautwein C, Rakemann T, Niehof M, Rose-John S, Manns MP: Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology. 1996, 110: 1854-1862.",{"doi":3932},"10.1053\u002Fgast.1996.v110.pm8964411",{"id":26,"text":3934,"url":26,"identifiers":3935},"Schumann RR, Kirschning CJ, Unbehaun A, Aberle HP, Knope HP, Lamping N, Ulevitch RJ, Herrmann F: The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF\u002FSTAT-3 and other cytokine-inducible nuclear proteins. Mol Cell Biol. 1996, 16: 3490-3503.",{"doi":3936},"10.1128\u002FMCB.16.7.3490",{"id":26,"text":3938,"url":26,"identifiers":3939},"Cantwell CA, Sterneck E, Johnson PF: Interleukin-6-specific activation of the C\u002FEBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol. 1998, 18: 2108-2117.",{"doi":3940},"10.1128\u002FMCB.18.4.2108",{"id":26,"text":3942,"url":26,"identifiers":3943},"Boudreau F, Yu SJ, Asselin C: CCAAT\u002Fenhancer binding proteins beta and delta regulate alpha1-acid glycoprotein gene expression in rat intestinal epithelial cells. DNA Cell Biol. 1998, 17: 669-677.",{"doi":3944},"10.1089\u002Fdna.1998.17.669",{"id":26,"text":3946,"url":26,"identifiers":3947},"Alam T, An MR, Papaconstantinou J: Differential expression of three C\u002FEBP isoforms in multiple tissues during the acute phase response. J Biol Chem. 1992, 267: 5021-5024.",{"doi":3948},"10.1016\u002FS0021-9258(18)42720-2",{"id":26,"text":3950,"url":26,"identifiers":3951},"Pan Z, Hetherington CJ, Zhang DE: CCAAT\u002Fenhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development. J Biol Chem. 1999, 274: 23242-23248. 10.1074\u002Fjbc.274.33.23242.",{"doi":3952},"10.1074\u002Fjbc.274.33.23242",{"id":26,"text":3954,"url":26,"identifiers":3955},"Devitt A, Moffa OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD: Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature. 1998, 392: 505-509. 10.1038\u002F33169.",{"doi":3956},"10.1038\u002F33169",{"id":26,"text":3958,"url":26,"identifiers":3959},"Wright SD: CD14: a leukocyte membrane protein that functions in the response to endotoxin [abstract]. FASEB J. 1990, 4: A1848-",{},{"id":26,"text":3961,"url":26,"identifiers":3962},"Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990, 249: 1431-1433.",{"doi":3963},"10.1126\u002Fscience.1698311",{"id":26,"text":3965,"url":26,"identifiers":3966},"Paape MJ, Lillius EM, Wiitanen PA, Kontio MP: Intramammary defense against infections induced by Escherichia coli in cows. Am J Vet Res. 1996, 57: 477-482.",{"doi":3967},"10.2460\u002Fajvr.1996.57.04.477",{"id":26,"text":3969,"url":26,"identifiers":3970},"Labeta MO, Vidal K, Nores JE, Arias M, Vita N, Morgan BP, Guillemot JC, Loyaux D, Ferrara P, Schmid D, Affolter M, Borysiewicz LK, Donnet-Hughes A, Schiffrin EJ: Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med. 2000, 191: 1807-1812. 10.1084\u002Fjem.191.10.1807.",{"doi":3971},"10.1084\u002Fjem.191.10.1807",{"id":26,"text":3973,"url":26,"identifiers":3974},"Walker NI, Bennett RE, Kerr JFR: Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat. 1989, 185: 19-32.",{"doi":3975},"10.1002\u002Faja.1001850104",{"id":26,"text":3977,"url":26,"identifiers":3978},"Fadok VA: Clearance: the last and often forgotten stage of apoptosis. J Mammary Gland Biol Neoplasia. 1999, 4: 203-211. 10.1023\u002FA:1011384009787.",{"doi":3979},"10.1023\u002FA:1011384009787",{"id":26,"text":3981,"url":26,"identifiers":3982},"Monks J, Geske FJ, Lehman L, Fadok VA: Do inflammatory cells participate in mammary gland involution?. J Mammary Gland Biol Neoplasia. 2002, 7: 163-176. 10.1023\u002FA:1020351919634.",{"doi":3983},"10.1023\u002FA:1020351919634",{"id":26,"text":3985,"url":26,"identifiers":3986},"Gregory CD: CD14-dependent clearance of apoptotic cells: relevance to the immune system. Curr Opin Immunol. 2000, 12: 27-34. 10.1016\u002FS0952-7915(99)00047-3.",{"doi":3987},"10.1016\u002FS0952-7915(99)00047-3",{"id":26,"text":3989,"url":26,"identifiers":3990},"Old LJ: Tumor necrosis factor. Sci Am. 1988, 258: 59-75.",{"doi":3991},"10.1038\u002Fscientificamerican0588-59",{"id":26,"text":3993,"url":26,"identifiers":3994},"Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\u002Fparacrinemechanisms involving TGF β, PGE2, and PAF. J Clin Invest. 1998, 1001: 890-898.",{"doi":3995},"10.1172\u002FJCI1112",{"id":26,"text":3997,"url":26,"identifiers":3998},"Laurent PE: Clinical measurement of acute phase proteins to detect and monitor infectious disease. In Acute Phase Proteins in the Acute Phase Response. Edited by: Pepys MB. 1989, New York: Springer-Verlag, 151-159.",{"doi":3999},"10.1007\u002F978-1-4471-1739-1_12",{"id":26,"text":4001,"url":26,"identifiers":4002},"Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997, 88: 417-426.",{"doi":4003},"10.1016\u002FS0092-8674(00)81880-2",{"id":26,"text":4005,"url":26,"identifiers":4006},"Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A: Conversion of proepithelin to epithelins. Roles of SLPI and elastase in host defense and wound repair. Cell. 2002, 111: 867-878.",{"doi":4007},"10.1016\u002FS0092-8674(02)01141-8",{"id":26,"text":4009,"url":26,"identifiers":4010},"Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T: Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 1994, 263: 89-92.",{"doi":4011},"10.1126\u002Fscience.8272872",{"id":26,"text":4013,"url":26,"identifiers":4014},"Hutt JA, DeWille JW: Oncostatin M induces growth arrest of mammary epithelium via a CCAAT\u002Fenhancer-binding protein delta-dependent pathway. Mol Cancer Ther. 2002, 1: 601-610.",{},{"id":26,"text":4016,"url":26,"identifiers":4017},"Grant SL, Douglas AM, Goss GA, Begley CG: Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors. 2001, 19: 153-162.",{"doi":4018},"10.3109\u002F08977190109001083",{"id":26,"text":4020,"url":26,"identifiers":4021},"Schere-Levy C, Buggiano V, Quaglino A, Gattelli A, Cirio MC, Piazzon I, Vanzulli S, Kordon EC: Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse mammary gland involution. Exp Cell Res. 2003, 282: 35-47. 10.1006\u002Fexcr.2002.5666.",{"doi":4022},"10.1006\u002Fexcr.2002.5666",{"id":26,"text":4024,"url":26,"identifiers":4025},"Kritikou EA, Sharkey A, Abell K, Came PJ, Anderson E, Clarkson RWE, Watson CJ: A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development. 2003, 130: 3459-3468. 10.1242\u002Fdev.00578.",{"doi":4026},"10.1242\u002Fdev.00578",{"id":26,"text":4028,"url":26,"identifiers":4029},"Lee CS, McDowell GH, Lascelles AK: The importance of macrophages in the removal of fat from the involuting mammary gland. Res Vet Sci. 1969, 10: 34-38.",{"doi":4030},"10.1016\u002FS0034-5288(18)34484-9",{"id":26,"text":4032,"url":26,"identifiers":4033},"Nordin W, Lee CS: Cytology of milk in guinea pigs. Acta Anat. 1982, 113: 135-144.",{"doi":4034},"10.1159\u002F000145548",{"id":26,"text":4036,"url":26,"identifiers":4037},"Lee CS, McCauley I, Hartmann PE: Light and electron microscopy of cells in pig colostrum, milk and involution secretion. Acta Anat. 1983, 116: 126-135.",{"doi":4038},"10.1159\u002F000145734",{"id":26,"text":4040,"url":26,"identifiers":4041},"Colditz IG: Studies on the inflammatory response during involution of the ovine mammary gland. Q J Exp Physiol. 1988, 73: 363-368.",{"doi":4042},"10.1113\u002Fexpphysiol.1988.sp003152",{"id":26,"text":4044,"url":26,"identifiers":4045},"O'Donnell LC, Druhan LJ, Avalos BR: Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol. 2002, 72: 478-485.",{"doi":4046},"10.1189\u002Fjlb.72.3.478",{"id":26,"text":4048,"url":26,"identifiers":4049},"Engelhardt E, Toksoy A, Goebeler M, Debus S, Brocker EB, Gillitzer R: Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol. 1998, 153: 1849-1860.",{"doi":4050},"10.1016\u002FS0002-9440(10)65699-4",{"id":26,"text":4052,"url":26,"identifiers":4053},"Wiekowski MT, Chen SC, Zalamea P, Wilburn BP, Kinsley DJ, Sharif WW, Jensen KK, Hedrick JA, Manfra D, Lira SA: Disruption of neutrophil migration in a conditional transgenic model: evidence for CXCR2 desensitization in vivo. J Immunol. 2001, 167: 7102-7110.",{"doi":4054},"10.4049\u002Fjimmunol.167.12.7102",{"id":26,"text":4056,"url":26,"identifiers":4057},"Aubry F, Habasque C, Satie AP, Jegou B, Samson M: Expression and regulation of the CXC-chemokines, GRO\u002FKC and IP-10\u002F mob-1 in rat seminiferous tubules. Eur Cytokine Netw. 2000, 11: 690-698.",{},{"id":26,"text":4059,"url":26,"identifiers":4060},"Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T: Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest. 1997, 100: 2810-2815.",{"doi":4061},"10.1172\u002FJCI119828",{"id":26,"text":4063,"url":26,"identifiers":4064},"Jones CE, Chan K: Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol. 2002, 26: 748-753.",{"doi":4065},"10.1165\u002Fajrcmb.26.6.4757",{"id":26,"text":4067,"url":26,"identifiers":4068},"Mehrad B, Strieter RM, Moore TA, Tsai WC, Lira SA, Standiford TJ: CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol. 1999, 163: 6086-6094.",{"doi":4069},"10.4049\u002Fjimmunol.163.11.6086",{"id":26,"text":4071,"url":26,"identifiers":4072},"Endlich B, Armstrong D, Brodsky J, Novotny M, Hamilton TA: Distinct temporal patterns of macrophage-inflammatory protein-2 and KC chemokine gene expression in surgical injury. J Immunol. 2002, 168: 3586-3594.",{"doi":4073},"10.4049\u002Fjimmunol.168.7.3586",{"id":26,"text":4075,"url":26,"identifiers":4076},"Rovai LE, Herschman HR, Smith JB: The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukoc Biol. 1998, 64: 494-502.",{"doi":4077},"10.1002\u002Fjlb.64.4.494",{"id":26,"text":4079,"url":26,"identifiers":4080},"Anisowicz A, Zajchowski D, Stenman G, Sager R: Functional diversity of GRO gene expression in human fibroblasts and mammary epithelial cells. Proc Nat Acad Sci USA. 1988, 85: 9645-9649.",{"doi":4081},"10.1073\u002Fpnas.85.24.9645",{"id":26,"text":4083,"url":26,"identifiers":4084},"Paape M, Mehrzad J, Zhao J, Detilleux J, Burvenich C: Defense of the bovine mammary gland by polymorphonuclear neutrophil leukocytes. J Mammary Gland Biol Neoplasia. 2002, 7: 109-121. 10.1023\u002FA:1020343717817.",{"doi":4085},"10.1023\u002FA:1020343717817",{"id":26,"text":4087,"url":26,"identifiers":4088},"Gouon-Evans V, Rothenberg ME, Pollard JW: Postnatal mammary gland development requires macrophages and eosinophils. Development. 2000, 127: 2269-2282.",{"doi":4089},"10.1242\u002Fdev.127.11.2269",{"id":26,"text":4091,"url":26,"identifiers":4092},"Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, Watson JD, Kumble KD: B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol. 2000, 12: 677-689. 10.1093\u002Fintimm\u002F12.5.677.",{"doi":4093},"10.1093\u002Fintimm\u002F12.5.677",{"id":26,"text":4095,"url":26,"identifiers":4096},"Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B: Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001, 194: 855-861. 10.1084\u002Fjem.194.6.855.",{"doi":4097},"10.1084\u002Fjem.194.6.855",{"id":26,"text":4099,"url":26,"identifiers":4100},"Nickerson SC: Immunological aspects of mammary involution. J Dairy Sci. 1989, 72: 1665-1678.",{"doi":4101},"10.3168\u002Fjds.S0022-0302(89)79278-X",{"id":26,"text":4103,"url":26,"identifiers":4104},"Myokai F, Takashiba S, Lebo R, Amar S: A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor α gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci USA. 1999, 96: 4518-4523. 10.1073\u002Fpnas.96.8.4518.",{"doi":4105},"10.1073\u002Fpnas.96.8.4518",{"id":26,"text":4107,"url":26,"identifiers":4108},"Kushner I, Mackiewicz A: Acute phase proteins as disease markers. Dis Markers. 1987, 5: 1-11.",{},{"id":26,"text":4110,"url":26,"identifiers":4111},"Hochepied T, Berger FG, Baumann H, Libert C: α1-acid glycoprotein: and acute phase protein with inflammatory and immunomodulating properties. Cyt Growth Factor Rev. 2003, 14: 25-34. 10.1016\u002FS1359-6101(02)00054-0.",{"doi":4112},"10.1016\u002FS1359-6101(02)00054-0",{"id":26,"text":4114,"url":26,"identifiers":4115},"Gitlin JD: Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem. 1988, 263: 6281-6287.",{"doi":4116},"10.1016\u002FS0021-9258(18)68783-6",{"id":26,"text":4118,"url":26,"identifiers":4119},"Pietzsch A, Buchler C, Aslanidis C, Schmitz G: Identification and characterization of a novel monocyte\u002Fmacrophage differentiation-dependent gene that is responsive to lipopolysaccharide, ceramide, and lysophosphatidylcholine. Biochem Biophys Res Commun. 1997, 235: 4-9. 10.1006\u002Fbbrc.1997.6715.",{"doi":4120},"10.1006\u002Fbbrc.1997.6715",{"id":4122,"createTime":4123,"updateTime":4124,"relativeEntities":4125,"slug":4126,"properties":4127,"entityType":778,"verifyStatus":25,"verifyTime":4138,"verifyNote":779,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":4139,"fullTextUrl":26,"authors":4140,"publicationType":849,"publisherRelationship":4231,"citationCount":4264,"citationInfo":4265,"publishDate":4268,"publishYear":4266,"citationAnalyzeStatus":4269,"lastCitationAnalyze":4270,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":1211},"a8ddfa0d-77b1-41c1-80be-2046ee85e796","2024-01-30T03:34:37.198+00:00","2026-05-25T07:59:51.900+00:00",[],"Dysregulation-of-microRNAs-in-breast-cancer-and-their-potential-role-as-prognostic-and-predictive-biomarkers-in-patient-management",{"references":4128,"abstract":4130,"title":4132,"doi":4134,"gsPaper":4136},{"VOID":4129},"Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223:308–18.\nCurtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.\nHe L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.\nDvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497:378–82.\nPillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11:1753–61.\nLu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.\nVolinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.\nTang J, Ahmad A, Sarkar FH. The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci. 2012;13:13414–37.\nChen L, Bourguignon LY. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer. 2014;13:52.\nAhmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, et al. Phosphoglucose isomerase\u002Fautocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011;71:3400–9.\nBaffa R, Fassan M, Volinia S, OHara B, Liu C, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009;219:214–21.\nO’Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12:201.\nCalin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999-3004.\nIorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E. Breast cancer and microRNAs: therapeutic impact. Breast. 2011;20:S63–70.\nCorcoran C, Friel AM, Duffy MJ, Crown J, O’Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem. 2011;57:18–32.\nMa L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.\nGabriely G, Teplyuk NM, Krichevsky AM. Context effect: microRNA-10b in cancer cell proliferation, spread and death. Autophagy. 2011;7:1384–6.\nHuang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, et al. Up-regulation of miR-21 by HER2\u002Fneu signaling promotes cell invasion. J Biol Chem. 2009;284:18515–24.\nHan M, Wang Y, Liu M, Bi X, Bao J, Zeng N, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012;103:1058–64.\nQi L, Bart J, Tan LP, Platteel I, Sluis T, Huitema S, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.\nSong B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010;29:29.\nLu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27:4373–9.\nJiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70:3119–27.\nZhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci. 2013;20:79.\nKong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285:17869–79.\nHuang GQ, Gumireddy K, Schrier M, le Sage C, Nagel R, Coukos G, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10:202–10.\nYan GR, Xu SH, Tan ZL, Liu L, He QY. Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. Proteomics. 2011;11:912–20.\nZhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.\nFerracin M, Bassi C, Pedriali M, Pagotto S, D’Abundo L, Zagatti B, et al. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2\u002FHER2 expression. Mol Cancer. 2013;12:130.\nFeliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernández-Losa J, et al. miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. PLoS One. 2013;8:e76247.\nScott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007;282:1479–86.\nLiu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res. 2013;25:46–54.\nElgamal OA, Park JK, Gusev Y, Azevedo-Pouly AC, Jiang J, Roopra A, et al. Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One. 2013;8:e76402.\nJiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, et al. Restoration of miR17\u002F20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2. Cancer Immunol Res. 2014;2:789–99.\nFan M, Sethuraman A, Brown M, Sun W, Pfeffer LM. Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. Breast Cancer Res Treat. 2014;146:487–502.\nLi Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival. J Int Med Res. 2013;41:596–602.\nFu Y, Jiang BQ, Wu Y, Li ZD, Zhuang ZG. Hsa-miR-206 inhibits the migration and invasion of breast cancer by targeting Cx43. Zhonghua Yi XueZaZhi. 2013;93:2890–4.\nZhang HF, Xu LY, Li E. A family of pleiotropically acting microRNAs in cancer progression, miR-200: potential cancer therapeutic targets. Curr Pharm Des. 2014;20:1896–903.\nRoy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, et al. Significance of PELP1\u002FHDAC2\u002FmiR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene. 2014;33:3707–16.\nCastilla MÁ, Díaz-Martín J, Sarrió D, Romero-Pérez L, López-García MÁ, Vieites B, et al. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One. 2012;7:e47709.\nXiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. 2014;7:ra11.\nBhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008;27:5643–7.\nPng KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2012;481:190–4.\nTavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52.\nZhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, et al. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther. 2012;11:108–18.\nValastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032–46.\nAugoff K, McCue B, Plow EF, Sossey-Alaoui K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer. 2012;11:5.\nSossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R, Plow EF. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer. 2011;129:1331–43.\nKasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.\nGarcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3:279–90.\nJiang H, Zhang G, Wu JH, Jiang CP. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014;31:1509–16.\nKeklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, et al. MicroRNA-520\u002F373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-b signaling pathways. Oncogene. 2012;31:4150–63.\nVárallyay É, Burgyan J, Havelda J. MicroRNA detection by northern blotting using locked nucleic acid probes. Nat Protoc. 2008;3:190–6.\nHammond SM. microRNA detection comes of age. Nat Methods. 2006;3:12–3.\nBalcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol. 2011;11:70.\nLi W, Ruan K. MicroRNA detection by microarray. Anal Bioanal Chem. 2009;394:1117–24.\nWu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10:42.\nCreighton CJ, Reid JG, Gunaratne PH. Expression profiling of microRNAs by deep sequencing. Brief Bioinform. 2009;10:490–7.\nVandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:1–12.\nvan Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012;14:R34.\nMestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10:R64.\nKodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol. 2014;8:874–83.\nWang F, Hou J, Jin W, Li J, Yue Y, Jin H, et al. Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. Molecules. 2014;19:6282–93.\nChan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013;19:4477–87.\nCuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132:1602–12.\nNg EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8:e53141.\nGodfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, DeRoo LA, et al. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 2013;15:R42.\nVan der Auwera I, Yu W, Suo L, Van Neste L, Van Dam P, Van Marck EA, et al. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One. 2010;5:e12616.\nBlenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin S-F, Dunning MJ, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8:R214.\nSerpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev. 2014;40:595–604.\nde Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics. 2013;14:643.\nLowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2\u002Fneu receptor status in breast cancer. Breast Cancer Res. 2009;11:R27.\nCrippa E, Lusa L, De Cecco L, Marchesi E, Calin GA, Radice P, et al. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS One. 2014;9:e87039.\nHe YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R, et al. miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer. Exp Ther Med. 2013;5:813–8.\nVolinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012;109:1–6.\nGiricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, et al. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol. 2012;226:108–19.\nVan der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer. 2010;103:532–41.\nLerebours F, Cizeron-Clairac G, Susini A, Vacher S, Mouret-Fourme E, Belichard C, et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer. 2013;133:1614–23.\nMasri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 2010;124:89–99.\nWard A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2013;32:1173–82.\nCittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010;9:317.\nZhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221\u002F222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008;283:31079–86.\nWei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, et al. Exosomal miR-221\u002F222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014;147:423–31.\nGan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221\u002F222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 2014;21:290–6.\nRao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221\u002F222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30:1082–97.\nShibahara Y, Miki Y, Onodera Y, Hata S, Chan MS, Yiu CC, et al. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol. 2012;227:357–66.\nJung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118:2603–14.\nZhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285:21496–507.\nWang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012;7:e34210.\nCliment J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 2007;67:818–26.\nBockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013;4:1393.\nFang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, et al. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res. 2014;47:60–9.\nMei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. 2010;9:77–86.\nDong J, Zhao YP, Zhou L, Zhang TP, Chen G. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res. 2011;42:8–14.\nKato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 2009;28:2419–24.\nStankevicins L, da Silva AP A, Ventura Dos Passos F, Dos Santos Ferreira E, Menks Ribeiro MC, G David M, et al. MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells. Radiat Oncol. 2013;8:231.\nQuesne JL, Jones J, Warren J, Dawson S-J, Ali HR, Bardwell H, et al. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol. 2012;227:306–14.\nSempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612–20.\nDangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009;28:347–58.\nYu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131:1109–23.\nMa L, Li GZ, Wu ZS, Meng G. Prognostic significance of let-7b expression in breast cancer and correlation to its target gene of BSG expression. Med Oncol. 2014;31:1–5.\nMarkou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem. 2014;60:197–205.\nXu Y, Jin J, Liu Y, Huang Z, Deng Y, You T, et al. Snail-regulated miR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2. PLoS One. 2014;9:e99516.\nCheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, et al. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat. 2012;134:1081–93.\nAgrawal R, Tran U, Wessely O. The miR-30 miRNA family regulates xenopus pronephros development and targets the transcription factor Xlim1\u002FLhx1. Development. 2009;136:3927–36.\nMartinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci U S A. 2011;108:522–7.\nXia Z, Zhang N, Jin H, Yu Z, Xu G, Huang Z. Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas. Clin Neurol Neurosurg. 2010;112:413–9.\nZhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, et al. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene. 2014;33:3119–28.\nLeivonen S-K, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale A-L, et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 2014;8:93–104.\nShen L, Li J, Xu L, Ma J, Li H, Xiao X, et al. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med. 2012;3:475–80.\nWang S, Li H, Wang J, Wang D. Expression of microRNA-497 and its prognostic significance in human breast cancer. Diagn Pathol. 2013;8:172.\nGuttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204–16.\nShen S, Sun Q, Liang Z, Cui X, Ren X, Chen H, et al. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One. 2014;9:e100664.\nSi ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007;26:2799–803.\nLee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer. 2011;14:269.\nLi M, Ma X, Li M, Zhang B, Huang J, Liu L, et al. Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis. Dis Markers. 2014;2014:106197.\nWang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, et al. Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9:e89223.\nYuva-Aydemir Y, Simkin A, Gascon E, Gao FB. MicroRNA-9: functional evolution of a conserved small regulatory RNA. RNA Biol. 2011;8:557–64.\nMa L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC\u002FMYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12:247–56.\nZhou X, Marian C, Makambi KH, Kosti O, Kallakury BVS, Loffredo CA, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One. 2012;7:e39011.\nMulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, et al. miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res. 2012;18:6702–13.\nSong CG, Wu XY, Wang C, Fu FM, Shao ZM. Correlation of miR-155 on formalin-fixed paraffin embedded tissues with invasiveness and prognosis of breast cancer. Zhonghua Wai Ke Za Zhi. 2012;50:1011–4.\nKong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33:679–89.\nGrelier G, Voirin N, Ay A-S, Cox DG, Chabaud S, Treilleux I, et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101:673–83.\nKhoshnaw SM, Rakha EA, Abdel-Fatah T, Nolan CC, Hodi Z, Macmillan RD, et al. The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. Breast Cancer Res Treat. 2013;137:139–53.\nLeaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, et al. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2011;2:9–18.\nSung H, Jeon S, Lee K-M, Han S, Song M, Choi J-Y, et al. Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival. BMC Cancer. 2012;12:1–12.\nLee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415–20.\nLund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004;303:95–8.\nBernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:364–6.\nChendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005;436:740–4.\nKok KH, Ng MH, Ching YP, Jin DY. Human TRBP and PACT directly interact with each other and associate with Dicer to facilitate the production of small interfering RNA. J Biol Chem. 2007;282:17649–57.\nSchwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115:199–208.",{"EN":4131},"MicroRNAs (miRNAs) are an emerging class of gene expression modulators with relevant roles in several biological processes, including cell differentiation, development, apoptosis, and regulation of the cell cycle. Deregulation of those tiny RNA molecules has been described frequently as a major determinant for the initiation and progression of diseases, including cancer. Not only miRNAs but also the enzymes responsible for miRNA processing could be deregulated in cancer. In this review, we address the role of miRNAs in the pathogenesis of breast cancer, since there are oncogenic, tumor-suppressive, and metastatic-influencing miRNAs. Additionally, the different detection platforms and normalization strategies for miRNAs will be discussed. The major part of this review, however, will focus on the capability of miRNAs to act as diagnostic, predictive, or prognostic biomarkers. We will give an overview of their potential to correlate with response to or benefit from a given treatment and we will consider their ability to give information on prognosis in breast cancer. We will focus on miRNAs validated by more than one study or verified in independent cohorts or where results rely on preclinical as well as clinical evidence. As such, we will discuss their potential use in the personalized management of breast cancer.",{"EN":4133},"Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management",{"VOID":4135},"10.1186\u002Fs13058-015-0526-y",{"VOID":4137},"[\"7043898668857911759\"]","2024-05-13T04:08:18.784+00:00","https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13058-015-0526-y",[4141,4157,4169,4186,4198,4217],{"id":4142,"sortIndex":111,"researcher":26,"roles":4143,"affiliations":4145,"properties":4154},"e72d2e77-39c7-4ecb-8a22-fd187372018b",[4144],"AUTHOR",[4146],{"id":26,"sortIndex":36,"affiliation":4147,"properties":26},{"id":4148,"createTime":4149,"updateTime":4149,"relativeEntities":4150,"slug":26,"properties":4151,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"7b47c22e-e858-40ee-81c9-3ae35513a0ef","2024-01-30T03:34:37.270+00:00",[],{"title":4152},{"VI":4153},"CORE, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium",{"title":4155},{"VI":4156},"Luc Y Dirix",{"id":4158,"sortIndex":59,"researcher":26,"roles":4159,"affiliations":4160,"properties":4166},"6b3c5e2b-0174-4dbe-b5a9-2d276fd132b1",[4144],[4161],{"id":26,"sortIndex":36,"affiliation":4162,"properties":26},{"id":4148,"createTime":4149,"updateTime":4149,"relativeEntities":4163,"slug":26,"properties":4164,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4165},{"VI":4153},{"title":4167},{"VI":4168},"Peter B Vermeulen",{"id":4170,"sortIndex":115,"researcher":26,"roles":4171,"affiliations":4172,"properties":4181},"199fac7d-59c5-4182-86c0-bc0eedae113b",[4144],[4173],{"id":26,"sortIndex":36,"affiliation":4174,"properties":26},{"id":4175,"createTime":4176,"updateTime":4176,"relativeEntities":4177,"slug":26,"properties":4178,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"c87f000c-d2a8-442f-8db1-f0ebc07b9900","2024-01-30T03:34:37.230+00:00",[],{"title":4179},{"VI":4180},"Department of Oncology, University Hospitals Leuven and Catholic University Leuven, Leuven, Belgium",{"title":4182,"gsAuthor":4184},{"VI":4183},"Hans Wildiers",{"VOID":4185},"[\"wRCqNikAAAAJ\"]",{"id":4187,"sortIndex":36,"researcher":26,"roles":4188,"affiliations":4189,"properties":4195},"8f1688d1-b1c0-47e3-ae31-a6766e1b853c",[4144],[4190],{"id":26,"sortIndex":36,"affiliation":4191,"properties":26},{"id":4175,"createTime":4176,"updateTime":4176,"relativeEntities":4192,"slug":26,"properties":4193,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4194},{"VI":4180},{"title":4196},{"VI":4197},"Eleni van Schooneveld",{"id":4199,"sortIndex":162,"researcher":26,"roles":4200,"affiliations":4201,"properties":4214},"e0d92c3d-dfd5-4eef-a164-d399fb611f33",[4144],[4202,4209],{"id":4203,"sortIndex":115,"affiliation":4204,"properties":4208},"d3a35712-13c3-4f5c-8378-d9bf815bba80",{"id":4148,"createTime":4149,"updateTime":4149,"relativeEntities":4205,"slug":26,"properties":4206,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4207},{"VI":4153},{},{"id":26,"sortIndex":36,"affiliation":4210,"properties":26},{"id":4175,"createTime":4176,"updateTime":4176,"relativeEntities":4211,"slug":26,"properties":4212,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4213},{"VI":4180},{"title":4215},{"VI":4216},"Steven J Van Laere",{"id":4218,"sortIndex":114,"researcher":26,"roles":4219,"affiliations":4220,"properties":4226},"14edfbcc-d402-41ea-9205-b013cc7856b7",[4144],[4221],{"id":26,"sortIndex":36,"affiliation":4222,"properties":26},{"id":4175,"createTime":4176,"updateTime":4176,"relativeEntities":4223,"slug":26,"properties":4224,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":4225},{"VI":4180},{"title":4227,"gsAuthor":4229},{"VI":4228},"Ignace Vergote",{"VOID":4230},"[\"EtAWDp8AAAAJ\"]",{"url":4139,"publisher":4232,"properties":4259},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4233,"slug":663,"properties":4234,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4237,"manageAffiliations":4238,"indexDatabases":4239,"url":746,"thumbnailPath":26,"statistic":4254,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":4235,"title":4236},{"VOID":666},{"EN":668},[],[],[4240,4247],{"id":727,"indexDatabase":4241,"url":740,"indexYears":741,"academicFieldIds":4246,"indexDatabaseRanking":745},{"id":729,"createTime":730,"updateTime":731,"relativeEntities":4242,"label":4243,"description":4244,"key":737,"publicationTags":4245,"standard":26},[],{"EN":734,"VI":734},{"EN":734,"VI":736},[739],[743,744],{"id":708,"indexDatabase":4248,"url":723,"indexYears":26,"academicFieldIds":4253,"indexDatabaseRanking":26},{"id":710,"createTime":711,"updateTime":712,"relativeEntities":4249,"label":4250,"description":4251,"key":719,"publicationTags":4252,"standard":26},[],{"EN":715,"VI":715},{"VI":717,"EN":718},[721,722],[725],{"impactFactor":36,"impactFactorByYear":4255,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":29,"totalPublicationByYear":4256,"totalCitation":36,"totalCitationByYear":4257,"totalCitationPerPublication":36,"totalCitationPerPublicationByYear":4258,"hindexLast5Year":36,"hindex":36},{},{"2000":59,"2001":115,"2003":115,"2004":162,"2005":59,"2006":114,"2007":59,"2008":111,"2009":59,"2010":59,"2011":59,"2012":114,"2014":115,"2015":114,"2016":115,"2017":111,"2018":115,"2019":115,"2020":115,"2021":114,"2022":114,"2023":115,"2024":114},{},{},{"volume":4260,"pages":4262},{"VOID":4261},"17",{"VOID":4263},"1-15",356,{"total":4264,"publishYear":4266,"statisticByYear":4267},2015,{"2015":356,"2016":159,"2017":257,"2018":252,"2019":222,"2020":516,"2021":103,"2022":238,"2023":298,"2024":111,"2025":356,"2026":158},"2015-02-18","DONE_ANALYZE_CITATION","2026-05-25T07:59:51.899+00:00"]